#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Neural Mechanisms of Risky Decision Making in Adolescents Reporting Frequent Alcohol and/or Marijuana Use
#Text=Because adolescence is a period of heightened exploration of new behaviors, there is a natural increase in risk taking including initial use of alcohol and marijuana.
1-1	0-6	Neural	_	
1-2	7-17	Mechanisms	_	
1-3	18-20	of	_	
1-4	21-26	Risky	_	
1-5	27-35	Decision	_	
1-6	36-42	Making	_	
1-7	43-45	in	_	
1-8	46-57	Adolescents	_	
1-9	58-67	Reporting	_	
1-10	68-76	Frequent	_	
1-11	77-84	Alcohol	_	
1-12	85-88	and	_	
1-13	88-89	/	_	
1-14	89-91	or	_	
1-15	92-101	Marijuana	_	
1-16	102-105	Use	_	
1-17	106-113	Because	_	
1-18	114-125	adolescence	_	
1-19	126-128	is	_	
1-20	129-130	a	_	
1-21	131-137	period	_	
1-22	138-140	of	_	
1-23	141-151	heightened	_	
1-24	152-163	exploration	_	
1-25	164-166	of	_	
1-26	167-170	new	_	
1-27	171-180	behaviors	_	
1-28	180-181	,	_	
1-29	182-187	there	_	
1-30	188-190	is	_	
1-31	191-192	a	_	
1-32	193-200	natural	_	
1-33	201-209	increase	_	
1-34	210-212	in	_	
1-35	213-217	risk	_	
1-36	218-224	taking	_	
1-37	225-234	including	_	
1-38	235-242	initial	_	
1-39	243-246	use	_	
1-40	247-249	of	_	
1-41	250-257	alcohol	_	
1-42	258-261	and	_	
1-43	262-271	marijuana	_	
1-44	271-272	.	_	

#Text=In order to better understand potential differences in neurocognitive functioning among adolescents who use drugs, the current study aimed to identify the neural substrates of risky decision making that differ among adolescents who primary users of alcohol or marijuana, primary users of both alcohol and marijuana, and controls who report primary use of neither drug.
2-1	273-275	In	_	
2-2	276-281	order	_	
2-3	282-284	to	_	
2-4	285-291	better	_	
2-5	292-302	understand	_	
2-6	303-312	potential	_	
2-7	313-324	differences	_	
2-8	325-327	in	_	
2-9	328-342	neurocognitive	_	
2-10	343-354	functioning	_	
2-11	355-360	among	_	
2-12	361-372	adolescents	_	
2-13	373-376	who	_	
2-14	377-380	use	_	
2-15	381-386	drugs	_	
2-16	386-387	,	_	
2-17	388-391	the	_	
2-18	392-399	current	_	
2-19	400-405	study	_	
2-20	406-411	aimed	_	
2-21	412-414	to	_	
2-22	415-423	identify	_	
2-23	424-427	the	_	
2-24	428-434	neural	_	
2-25	435-445	substrates	_	
2-26	446-448	of	_	
2-27	449-454	risky	_	
2-28	455-463	decision	_	
2-29	464-470	making	_	
2-30	471-475	that	_	
2-31	476-482	differ	_	
2-32	483-488	among	_	
2-33	489-500	adolescents	_	
2-34	501-504	who	_	
2-35	505-512	primary	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[1]	
2-36	513-518	users	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[1]	
2-37	519-521	of	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[1]	
2-38	522-529	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[1]	
2-39	530-532	or	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[1]	
2-40	533-542	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#DrugDependence[1]	
2-41	542-543	,	_	
2-42	544-551	primary	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[2]	
2-43	552-557	users	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[2]	
2-44	558-560	of	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[2]	
2-45	561-565	both	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[2]	
2-46	566-573	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[2]	
2-47	574-577	and	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[2]	
2-48	578-587	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[2]	
2-49	587-588	,	_	
2-50	589-592	and	_	
2-51	593-601	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
2-52	602-605	who	_	
2-53	606-612	report	_	
2-54	613-620	primary	_	
2-55	621-624	use	_	
2-56	625-627	of	_	
2-57	628-635	neither	_	
2-58	636-640	drug	_	
2-59	640-641	.	_	

#Text=Participants completed the Balloon Analogue Risk Task (BART) while undergoing functional magnetic resonance imaging.
3-1	642-654	Participants	_	
3-2	655-664	completed	_	
3-3	665-668	the	_	
3-4	669-676	Balloon	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[3]	
3-5	677-685	Analogue	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[3]	
3-6	686-690	Risk	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[3]	
3-7	691-695	Task	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[3]	
3-8	696-697	(	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[3]	
3-9	697-701	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[3]	
3-10	701-702	)	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[3]	
3-11	703-708	while	_	
3-12	709-719	undergoing	_	
3-13	720-730	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
3-14	731-739	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
3-15	740-749	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
3-16	750-757	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
3-17	757-758	.	_	

#Text=Comparison of brain activation during risky decisions versus non-risky decisions across all subjects revealed greater response to risky decisions in dorsal anterior cinguate cortex (dACC), anterior insula, ventral striatum, and lateral prefrontal cortex.
4-1	759-769	Comparison	_	
4-2	770-772	of	_	
4-3	773-778	brain	_	
4-4	779-789	activation	_	
4-5	790-796	during	_	
4-6	797-802	risky	_	
4-7	803-812	decisions	_	
4-8	813-819	versus	_	
4-9	820-829	non-risky	_	
4-10	830-839	decisions	_	
4-11	840-846	across	_	
4-12	847-850	all	_	
4-13	851-859	subjects	_	
4-14	860-868	revealed	_	
4-15	869-876	greater	_	
4-16	877-885	response	_	
4-17	886-888	to	_	
4-18	889-894	risky	_	
4-19	895-904	decisions	_	
4-20	905-907	in	_	
4-21	908-914	dorsal	_	
4-22	915-923	anterior	_	
4-23	924-932	cinguate	_	
4-24	933-939	cortex	_	
4-25	940-941	(	_	
4-26	941-945	dACC	_	
4-27	945-946	)	_	
4-28	946-947	,	_	
4-29	948-956	anterior	_	
4-30	957-963	insula	_	
4-31	963-964	,	_	
4-32	965-972	ventral	_	
4-33	973-981	striatum	_	
4-34	981-982	,	_	
4-35	983-986	and	_	
4-36	987-994	lateral	_	
4-37	995-1005	prefrontal	_	
4-38	1006-1012	cortex	_	
4-39	1012-1013	.	_	

#Text=Group comparisons across non-using controls, primary marijuana, primary alcohol, and alcohol and marijuana users revealed several notable differences in the recruitment of brain regions.
5-1	1014-1019	Group	_	
5-2	1020-1031	comparisons	_	
5-3	1032-1038	across	_	
5-4	1039-1048	non-using	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
5-5	1049-1057	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[5]	
5-6	1057-1058	,	_	
5-7	1059-1066	primary	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[6]	
5-8	1067-1076	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[6]	
5-9	1076-1077	,	_	
5-10	1078-1085	primary	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]	
5-11	1086-1093	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[7]	
5-12	1093-1094	,	_	
5-13	1095-1098	and	_	
5-14	1099-1106	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[8]	
5-15	1107-1110	and	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[8]	
5-16	1111-1120	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[8]	
5-17	1121-1126	users	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[8]	
5-18	1127-1135	revealed	_	
5-19	1136-1143	several	_	
5-20	1144-1151	notable	_	
5-21	1152-1163	differences	_	
5-22	1164-1166	in	_	
5-23	1167-1170	the	_	
5-24	1171-1182	recruitment	_	
5-25	1183-1185	of	_	
5-26	1186-1191	brain	_	
5-27	1192-1199	regions	_	
5-28	1199-1200	.	_	

#Text=Adolescents who use both alcohol and marijauna show decreased response during risky decision making compared to controls in insula, striatum, and thalamus, and reduced differentiation of increasing risk in dACC, insula, striatum, and superior parietal lobe compared to controls.
6-1	1201-1212	Adolescents	_	
6-2	1213-1216	who	_	
6-3	1217-1220	use	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[9]	
6-4	1221-1225	both	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[9]	
6-5	1226-1233	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[9]	
6-6	1234-1237	and	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[9]	
6-7	1238-1247	marijauna	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[9]	
6-8	1248-1252	show	_	
6-9	1253-1262	decreased	_	
6-10	1263-1271	response	_	
6-11	1272-1278	during	_	
6-12	1279-1284	risky	_	
6-13	1285-1293	decision	_	
6-14	1294-1300	making	_	
6-15	1301-1309	compared	_	
6-16	1310-1312	to	_	
6-17	1313-1321	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
6-18	1322-1324	in	_	
6-19	1325-1331	insula	_	
6-20	1331-1332	,	_	
6-21	1333-1341	striatum	_	
6-22	1341-1342	,	_	
6-23	1343-1346	and	_	
6-24	1347-1355	thalamus	_	
6-25	1355-1356	,	_	
6-26	1357-1360	and	_	
6-27	1361-1368	reduced	_	
6-28	1369-1384	differentiation	_	
6-29	1385-1387	of	_	
6-30	1388-1398	increasing	_	
6-31	1399-1403	risk	_	
6-32	1404-1406	in	_	
6-33	1407-1411	dACC	_	
6-34	1411-1412	,	_	
6-35	1413-1419	insula	_	
6-36	1419-1420	,	_	
6-37	1421-1429	striatum	_	
6-38	1429-1430	,	_	
6-39	1431-1434	and	_	
6-40	1435-1443	superior	_	
6-41	1444-1452	parietal	_	
6-42	1453-1457	lobe	_	
6-43	1458-1466	compared	_	
6-44	1467-1469	to	_	
6-45	1470-1478	controls	_	
6-46	1478-1479	.	_	

#Text=These results provide evidence of differential engagement of risky decision making circuits among adolescents with varying levels of alcohol and marijuana use, and may provide useful targets for longitudinal studies that explicitly address causality of these differences.
7-1	1480-1485	These	_	
7-2	1486-1493	results	_	
7-3	1494-1501	provide	_	
7-4	1502-1510	evidence	_	
7-5	1511-1513	of	_	
7-6	1514-1526	differential	_	
7-7	1527-1537	engagement	_	
7-8	1538-1540	of	_	
7-9	1541-1546	risky	_	
7-10	1547-1555	decision	_	
7-11	1556-1562	making	_	
7-12	1563-1571	circuits	_	
7-13	1572-1577	among	_	
7-14	1578-1589	adolescents	_	
7-15	1590-1594	with	_	
7-16	1595-1602	varying	_	
7-17	1603-1609	levels	_	
7-18	1610-1612	of	_	
7-19	1613-1620	alcohol	_	
7-20	1621-1624	and	_	
7-21	1625-1634	marijuana	_	
7-22	1635-1638	use	_	
7-23	1638-1639	,	_	
7-24	1640-1643	and	_	
7-25	1644-1647	may	_	
7-26	1648-1655	provide	_	
7-27	1656-1662	useful	_	
7-28	1663-1670	targets	_	
7-29	1671-1674	for	_	
7-30	1675-1687	longitudinal	_	
7-31	1688-1695	studies	_	
7-32	1696-1700	that	_	
7-33	1701-1711	explicitly	_	
7-34	1712-1719	address	_	
7-35	1720-1729	causality	_	
7-36	1730-1732	of	_	
7-37	1733-1738	these	_	
7-38	1739-1750	differences	_	
7-39	1750-1751	.	_	

#Text=Introduction
#Text=Initial exploration of substance use often occurs during adolescence, with 75.6% of all teens trying alcohol and 48.6% trying marijuana by the age of 18, with 46.8% and 27.7%, respectively, using each on a regular basis by the end of high school.
8-1	1752-1764	Introduction	_	
8-2	1765-1772	Initial	_	
8-3	1773-1784	exploration	_	
8-4	1785-1787	of	_	
8-5	1788-1797	substance	_	
8-6	1798-1801	use	_	
8-7	1802-1807	often	_	
8-8	1808-1814	occurs	_	
8-9	1815-1821	during	_	
8-10	1822-1833	adolescence	_	
8-11	1833-1834	,	_	
8-12	1835-1839	with	_	
8-13	1840-1845	75.6%	_	
8-14	1846-1848	of	_	
8-15	1849-1852	all	_	
8-16	1853-1858	teens	_	
8-17	1859-1865	trying	_	
8-18	1866-1873	alcohol	_	
8-19	1874-1877	and	_	
8-20	1878-1883	48.6%	_	
8-21	1884-1890	trying	_	
8-22	1891-1900	marijuana	_	
8-23	1901-1903	by	_	
8-24	1904-1907	the	_	
8-25	1908-1911	age	_	
8-26	1912-1914	of	_	
8-27	1915-1917	18	_	
8-28	1917-1918	,	_	
8-29	1919-1923	with	_	
8-30	1924-1929	46.8%	_	
8-31	1930-1933	and	_	
8-32	1934-1939	27.7%	_	
8-33	1939-1940	,	_	
8-34	1941-1953	respectively	_	
8-35	1953-1954	,	_	
8-36	1955-1960	using	_	
8-37	1961-1965	each	_	
8-38	1966-1968	on	_	
8-39	1969-1970	a	_	
8-40	1971-1978	regular	_	
8-41	1979-1984	basis	_	
8-42	1985-1987	by	_	
8-43	1988-1991	the	_	
8-44	1992-1995	end	_	
8-45	1996-1998	of	_	
8-46	1999-2003	high	_	
8-47	2004-2010	school	_	
8-48	2010-2011	.	_	

#Text=While some argue for the normative nature of this exploration, others suggest that substance use during adolescence is associated with numerous harmful sequelae.
9-1	2012-2017	While	_	
9-2	2018-2022	some	_	
9-3	2023-2028	argue	_	
9-4	2029-2032	for	_	
9-5	2033-2036	the	_	
9-6	2037-2046	normative	_	
9-7	2047-2053	nature	_	
9-8	2054-2056	of	_	
9-9	2057-2061	this	_	
9-10	2062-2073	exploration	_	
9-11	2073-2074	,	_	
9-12	2075-2081	others	_	
9-13	2082-2089	suggest	_	
9-14	2090-2094	that	_	
9-15	2095-2104	substance	_	
9-16	2105-2108	use	_	
9-17	2109-2115	during	_	
9-18	2116-2127	adolescence	_	
9-19	2128-2130	is	_	
9-20	2131-2141	associated	_	
9-21	2142-2146	with	_	
9-22	2147-2155	numerous	_	
9-23	2156-2163	harmful	_	
9-24	2164-2172	sequelae	_	
9-25	2172-2173	.	_	

#Text=Data from cross-sectional and longitudinal studies suggest that alcohol and marijuana use during adolescence is associated with changes in neural development and neurocognitive functioning.
10-1	2174-2178	Data	_	
10-2	2179-2183	from	_	
10-3	2184-2199	cross-sectional	_	
10-4	2200-2203	and	_	
10-5	2204-2216	longitudinal	_	
10-6	2217-2224	studies	_	
10-7	2225-2232	suggest	_	
10-8	2233-2237	that	_	
10-9	2238-2245	alcohol	_	
10-10	2246-2249	and	_	
10-11	2250-2259	marijuana	_	
10-12	2260-2263	use	_	
10-13	2264-2270	during	_	
10-14	2271-2282	adolescence	_	
10-15	2283-2285	is	_	
10-16	2286-2296	associated	_	
10-17	2297-2301	with	_	
10-18	2302-2309	changes	_	
10-19	2310-2312	in	_	
10-20	2313-2319	neural	_	
10-21	2320-2331	development	_	
10-22	2332-2335	and	_	
10-23	2336-2350	neurocognitive	_	
10-24	2351-2362	functioning	_	
10-25	2362-2363	.	_	

#Text=Differential rates of development of neural systems may be one reason for increased exploration of drugs during adolescence.
11-1	2364-2376	Differential	_	
11-2	2377-2382	rates	_	
11-3	2383-2385	of	_	
11-4	2386-2397	development	_	
11-5	2398-2400	of	_	
11-6	2401-2407	neural	_	
11-7	2408-2415	systems	_	
11-8	2416-2419	may	_	
11-9	2420-2422	be	_	
11-10	2423-2426	one	_	
11-11	2427-2433	reason	_	
11-12	2434-2437	for	_	
11-13	2438-2447	increased	_	
11-14	2448-2459	exploration	_	
11-15	2460-2462	of	_	
11-16	2463-2468	drugs	_	
11-17	2469-2475	during	_	
11-18	2476-2487	adolescence	_	
11-19	2487-2488	.	_	

#Text=While recruitment of frontal-based cognitive control systems increases linearly throughout development, reward based systems follow a quadratic increase with the peak occuring during adolescence, resulting in an imbalance between the two systems during the critical age period when drug use increases.
12-1	2489-2494	While	_	
12-2	2495-2506	recruitment	_	
12-3	2507-2509	of	_	
12-4	2510-2523	frontal-based	_	
12-5	2524-2533	cognitive	_	
12-6	2534-2541	control	_	
12-7	2542-2549	systems	_	
12-8	2550-2559	increases	_	
12-9	2560-2568	linearly	_	
12-10	2569-2579	throughout	_	
12-11	2580-2591	development	_	
12-12	2591-2592	,	_	
12-13	2593-2599	reward	_	
12-14	2600-2605	based	_	
12-15	2606-2613	systems	_	
12-16	2614-2620	follow	_	
12-17	2621-2622	a	_	
12-18	2623-2632	quadratic	_	
12-19	2633-2641	increase	_	
12-20	2642-2646	with	_	
12-21	2647-2650	the	_	
12-22	2651-2655	peak	_	
12-23	2656-2664	occuring	_	
12-24	2665-2671	during	_	
12-25	2672-2683	adolescence	_	
12-26	2683-2684	,	_	
12-27	2685-2694	resulting	_	
12-28	2695-2697	in	_	
12-29	2698-2700	an	_	
12-30	2701-2710	imbalance	_	
12-31	2711-2718	between	_	
12-32	2719-2722	the	_	
12-33	2723-2726	two	_	
12-34	2727-2734	systems	_	
12-35	2735-2741	during	_	
12-36	2742-2745	the	_	
12-37	2746-2754	critical	_	
12-38	2755-2758	age	_	
12-39	2759-2765	period	_	
12-40	2766-2770	when	_	
12-41	2771-2775	drug	_	
12-42	2776-2779	use	_	
12-43	2780-2789	increases	_	
12-44	2789-2790	.	_	

#Text=Studies have demonstrated reduced lateral frontal engagement during response inhibition among high-risk adolescents (i.e. those with a positive family history positive for substance use disorder) and among current alcohol/marijuana users compared to controls, as well as differential response in ventral striatal regions in current alcohol/marijuana users compared to non-using controls.
13-1	2791-2798	Studies	_	
13-2	2799-2803	have	_	
13-3	2804-2816	demonstrated	_	
13-4	2817-2824	reduced	_	
13-5	2825-2832	lateral	_	
13-6	2833-2840	frontal	_	
13-7	2841-2851	engagement	_	
13-8	2852-2858	during	_	
13-9	2859-2867	response	_	
13-10	2868-2878	inhibition	_	
13-11	2879-2884	among	_	
13-12	2885-2894	high-risk	_	
13-13	2895-2906	adolescents	_	
13-14	2907-2908	(	_	
13-15	2908-2911	i.e	_	
13-16	2911-2912	.	_	
13-17	2913-2918	those	_	
13-18	2919-2923	with	_	
13-19	2924-2925	a	_	
13-20	2926-2934	positive	_	
13-21	2935-2941	family	_	
13-22	2942-2949	history	_	
13-23	2950-2958	positive	_	
13-24	2959-2962	for	_	
13-25	2963-2972	substance	_	
13-26	2973-2976	use	_	
13-27	2977-2985	disorder	_	
13-28	2985-2986	)	_	
13-29	2987-2990	and	_	
13-30	2991-2996	among	_	
13-31	2997-3004	current	_	
13-32	3005-3012	alcohol	_	
13-33	3012-3013	/	_	
13-34	3013-3022	marijuana	_	
13-35	3023-3028	users	_	
13-36	3029-3037	compared	_	
13-37	3038-3040	to	_	
13-38	3041-3049	controls	_	
13-39	3049-3050	,	_	
13-40	3051-3053	as	_	
13-41	3054-3058	well	_	
13-42	3059-3061	as	_	
13-43	3062-3074	differential	_	
13-44	3075-3083	response	_	
13-45	3084-3086	in	_	
13-46	3087-3094	ventral	_	
13-47	3095-3103	striatal	_	
13-48	3104-3111	regions	_	
13-49	3112-3114	in	_	
13-50	3115-3122	current	_	
13-51	3123-3130	alcohol	_	
13-52	3130-3131	/	_	
13-53	3131-3140	marijuana	_	
13-54	3141-3146	users	_	
13-55	3147-3155	compared	_	
13-56	3156-3158	to	_	
13-57	3159-3168	non-using	_	
13-58	3169-3177	controls	_	
13-59	3177-3178	.	_	

#Text=While the above studies have examined the neural differences in cognitive and emotional functioning, they have not addressed potential competition between regions implicated in cognitive/emotional functioning.
14-1	3179-3184	While	_	
14-2	3185-3188	the	_	
14-3	3189-3194	above	_	
14-4	3195-3202	studies	_	
14-5	3203-3207	have	_	
14-6	3208-3216	examined	_	
14-7	3217-3220	the	_	
14-8	3221-3227	neural	_	
14-9	3228-3239	differences	_	
14-10	3240-3242	in	_	
14-11	3243-3252	cognitive	_	
14-12	3253-3256	and	_	
14-13	3257-3266	emotional	_	
14-14	3267-3278	functioning	_	
14-15	3278-3279	,	_	
14-16	3280-3284	they	_	
14-17	3285-3289	have	_	
14-18	3290-3293	not	_	
14-19	3294-3303	addressed	_	
14-20	3304-3313	potential	_	
14-21	3314-3325	competition	_	
14-22	3326-3333	between	_	
14-23	3334-3341	regions	_	
14-24	3342-3352	implicated	_	
14-25	3353-3355	in	_	
14-26	3356-3365	cognitive	_	
14-27	3365-3366	/	_	
14-28	3366-3375	emotional	_	
14-29	3376-3387	functioning	_	
14-30	3387-3388	.	_	

#Text=Examination of potential competition between cognitive and emotional functioning may be key for understanding drug use during adolescence.
15-1	3389-3400	Examination	_	
15-2	3401-3403	of	_	
15-3	3404-3413	potential	_	
15-4	3414-3425	competition	_	
15-5	3426-3433	between	_	
15-6	3434-3443	cognitive	_	
15-7	3444-3447	and	_	
15-8	3448-3457	emotional	_	
15-9	3458-3469	functioning	_	
15-10	3470-3473	may	_	
15-11	3474-3476	be	_	
15-12	3477-3480	key	_	
15-13	3481-3484	for	_	
15-14	3485-3498	understanding	_	
15-15	3499-3503	drug	_	
15-16	3504-3507	use	_	
15-17	3508-3514	during	_	
15-18	3515-3526	adolescence	_	
15-19	3526-3527	.	_	

#Text=Decision making tasks are an ideal context in which to probe these interactions given that these tasks often involve trading off risks and rewards, requiring regions implicated in both cognitive and emotional processing.
16-1	3528-3536	Decision	_	
16-2	3537-3543	making	_	
16-3	3544-3549	tasks	_	
16-4	3550-3553	are	_	
16-5	3554-3556	an	_	
16-6	3557-3562	ideal	_	
16-7	3563-3570	context	_	
16-8	3571-3573	in	_	
16-9	3574-3579	which	_	
16-10	3580-3582	to	_	
16-11	3583-3588	probe	_	
16-12	3589-3594	these	_	
16-13	3595-3607	interactions	_	
16-14	3608-3613	given	_	
16-15	3614-3618	that	_	
16-16	3619-3624	these	_	
16-17	3625-3630	tasks	_	
16-18	3631-3636	often	_	
16-19	3637-3644	involve	_	
16-20	3645-3652	trading	_	
16-21	3653-3656	off	_	
16-22	3657-3662	risks	_	
16-23	3663-3666	and	_	
16-24	3667-3674	rewards	_	
16-25	3674-3675	,	_	
16-26	3676-3685	requiring	_	
16-27	3686-3693	regions	_	
16-28	3694-3704	implicated	_	
16-29	3705-3707	in	_	
16-30	3708-3712	both	_	
16-31	3713-3722	cognitive	_	
16-32	3723-3726	and	_	
16-33	3727-3736	emotional	_	
16-34	3737-3747	processing	_	
16-35	3747-3748	.	_	

#Text=While myriad measures of decision making exist, the Balloon Analogue Risk Task (BART) is one of the few laboratory tasks that predicts real-world risk-taking and substance using adolescents.
17-1	3749-3754	While	_	
17-2	3755-3761	myriad	_	
17-3	3762-3770	measures	_	
17-4	3771-3773	of	_	
17-5	3774-3782	decision	_	
17-6	3783-3789	making	_	
17-7	3790-3795	exist	_	
17-8	3795-3796	,	_	
17-9	3797-3800	the	_	
17-10	3801-3808	Balloon	_	
17-11	3809-3817	Analogue	_	
17-12	3818-3822	Risk	_	
17-13	3823-3827	Task	_	
17-14	3828-3829	(	_	
17-15	3829-3833	BART	_	
17-16	3833-3834	)	_	
17-17	3835-3837	is	_	
17-18	3838-3841	one	_	
17-19	3842-3844	of	_	
17-20	3845-3848	the	_	
17-21	3849-3852	few	_	
17-22	3853-3863	laboratory	_	
17-23	3864-3869	tasks	_	
17-24	3870-3874	that	_	
17-25	3875-3883	predicts	_	
17-26	3884-3894	real-world	_	
17-27	3895-3906	risk-taking	_	
17-28	3907-3910	and	_	
17-29	3911-3920	substance	_	
17-30	3921-3926	using	_	
17-31	3927-3938	adolescents	_	
17-32	3938-3939	.	_	

#Text=In the BART, participants pump simulated air into a balloon, which increases the probability/risk of bursting.
18-1	3940-3942	In	_	
18-2	3943-3946	the	_	
18-3	3947-3951	BART	_	
18-4	3951-3952	,	_	
18-5	3953-3965	participants	_	
18-6	3966-3970	pump	_	
18-7	3971-3980	simulated	_	
18-8	3981-3984	air	_	
18-9	3985-3989	into	_	
18-10	3990-3991	a	_	
18-11	3992-3999	balloon	_	
18-12	3999-4000	,	_	
18-13	4001-4006	which	_	
18-14	4007-4016	increases	_	
18-15	4017-4020	the	_	
18-16	4021-4032	probability	_	
18-17	4032-4033	/	_	
18-18	4033-4037	risk	_	
18-19	4038-4040	of	_	
18-20	4041-4049	bursting	_	
18-21	4049-4050	.	_	

#Text=Participants can decide to “cash-out” at any time to collect accrued points, or continue pumping, which eventually causes the balloon to explode.
19-1	4051-4063	Participants	_	
19-2	4064-4067	can	_	
19-3	4068-4074	decide	_	
19-4	4075-4077	to	_	
19-5	4078-4079	“	_	
19-6	4079-4087	cash-out	_	
19-7	4087-4088	”	_	
19-8	4089-4091	at	_	
19-9	4092-4095	any	_	
19-10	4096-4100	time	_	
19-11	4101-4103	to	_	
19-12	4104-4111	collect	_	
19-13	4112-4119	accrued	_	
19-14	4120-4126	points	_	
19-15	4126-4127	,	_	
19-16	4128-4130	or	_	
19-17	4131-4139	continue	_	
19-18	4140-4147	pumping	_	
19-19	4147-4148	,	_	
19-20	4149-4154	which	_	
19-21	4155-4165	eventually	_	
19-22	4166-4172	causes	_	
19-23	4173-4176	the	_	
19-24	4177-4184	balloon	_	
19-25	4185-4187	to	_	
19-26	4188-4195	explode	_	
19-27	4195-4196	.	_	

#Text=The decision on each trial represents a conflict between reward accrual and potential negative consequences, making this task ideal for probing decision conflict.
20-1	4197-4200	The	_	
20-2	4201-4209	decision	_	
20-3	4210-4212	on	_	
20-4	4213-4217	each	_	
20-5	4218-4223	trial	_	
20-6	4224-4234	represents	_	
20-7	4235-4236	a	_	
20-8	4237-4245	conflict	_	
20-9	4246-4253	between	_	
20-10	4254-4260	reward	_	
20-11	4261-4268	accrual	_	
20-12	4269-4272	and	_	
20-13	4273-4282	potential	_	
20-14	4283-4291	negative	_	
20-15	4292-4304	consequences	_	
20-16	4304-4305	,	_	
20-17	4306-4312	making	_	
20-18	4313-4317	this	_	
20-19	4318-4322	task	_	
20-20	4323-4328	ideal	_	
20-21	4329-4332	for	_	
20-22	4333-4340	probing	_	
20-23	4341-4349	decision	_	
20-24	4350-4358	conflict	_	
20-25	4358-4359	.	_	

#Text=Neuroimaging studies of the BART have revealed increased responses during the risky decision phase in dorsal anterior cingulate cortex (dACC), insula, dorsolateral prefrontal cortex (DLPFC) and striatum, regions implicated in choice conflict, prediction of rewarding outcomes, and cognitive control.
21-1	4360-4372	Neuroimaging	_	
21-2	4373-4380	studies	_	
21-3	4381-4383	of	_	
21-4	4384-4387	the	_	
21-5	4388-4392	BART	_	
21-6	4393-4397	have	_	
21-7	4398-4406	revealed	_	
21-8	4407-4416	increased	_	
21-9	4417-4426	responses	_	
21-10	4427-4433	during	_	
21-11	4434-4437	the	_	
21-12	4438-4443	risky	_	
21-13	4444-4452	decision	_	
21-14	4453-4458	phase	_	
21-15	4459-4461	in	_	
21-16	4462-4468	dorsal	_	
21-17	4469-4477	anterior	_	
21-18	4478-4487	cingulate	_	
21-19	4488-4494	cortex	_	
21-20	4495-4496	(	_	
21-21	4496-4500	dACC	_	
21-22	4500-4501	)	_	
21-23	4501-4502	,	_	
21-24	4503-4509	insula	_	
21-25	4509-4510	,	_	
21-26	4511-4523	dorsolateral	_	
21-27	4524-4534	prefrontal	_	
21-28	4535-4541	cortex	_	
21-29	4542-4543	(	_	
21-30	4543-4548	DLPFC	_	
21-31	4548-4549	)	_	
21-32	4550-4553	and	_	
21-33	4554-4562	striatum	_	
21-34	4562-4563	,	_	
21-35	4564-4571	regions	_	
21-36	4572-4582	implicated	_	
21-37	4583-4585	in	_	
21-38	4586-4592	choice	_	
21-39	4593-4601	conflict	_	
21-40	4601-4602	,	_	
21-41	4603-4613	prediction	_	
21-42	4614-4616	of	_	
21-43	4617-4626	rewarding	_	
21-44	4627-4635	outcomes	_	
21-45	4635-4636	,	_	
21-46	4637-4640	and	_	
21-47	4641-4650	cognitive	_	
21-48	4651-4658	control	_	
21-49	4658-4659	.	_	

#Text=In the one study to date that examined the neural correlates of risky decision making on the BART in substance abusing adolescents, adolescents with substance use showed reduced engagement of middle and medial frontal gyrus, ACC, and insula during risk-taking, suggesting a potential aberrant mechanism in avoiding risk.
22-1	4660-4662	In	_	
22-2	4663-4666	the	_	
22-3	4667-4670	one	_	
22-4	4671-4676	study	_	
22-5	4677-4679	to	_	
22-6	4680-4684	date	_	
22-7	4685-4689	that	_	
22-8	4690-4698	examined	_	
22-9	4699-4702	the	_	
22-10	4703-4709	neural	_	
22-11	4710-4720	correlates	_	
22-12	4721-4723	of	_	
22-13	4724-4729	risky	_	
22-14	4730-4738	decision	_	
22-15	4739-4745	making	_	
22-16	4746-4748	on	_	
22-17	4749-4752	the	_	
22-18	4753-4757	BART	_	
22-19	4758-4760	in	_	
22-20	4761-4770	substance	_	
22-21	4771-4778	abusing	_	
22-22	4779-4790	adolescents	_	
22-23	4790-4791	,	_	
22-24	4792-4803	adolescents	_	
22-25	4804-4808	with	_	
22-26	4809-4818	substance	_	
22-27	4819-4822	use	_	
22-28	4823-4829	showed	_	
22-29	4830-4837	reduced	_	
22-30	4838-4848	engagement	_	
22-31	4849-4851	of	_	
22-32	4852-4858	middle	_	
22-33	4859-4862	and	_	
22-34	4863-4869	medial	_	
22-35	4870-4877	frontal	_	
22-36	4878-4883	gyrus	_	
22-37	4883-4884	,	_	
22-38	4885-4888	ACC	_	
22-39	4888-4889	,	_	
22-40	4890-4893	and	_	
22-41	4894-4900	insula	_	
22-42	4901-4907	during	_	
22-43	4908-4919	risk-taking	_	
22-44	4919-4920	,	_	
22-45	4921-4931	suggesting	_	
22-46	4932-4933	a	_	
22-47	4934-4943	potential	_	
22-48	4944-4952	aberrant	_	
22-49	4953-4962	mechanism	_	
22-50	4963-4965	in	_	
22-51	4966-4974	avoiding	_	
22-52	4975-4979	risk	_	
22-53	4979-4980	.	_	

#Text=Although prior studies have investigated risk taking and other cognitive functions in adolescent substance users, the relative differences compared to controls attributable to alcohol or marijuana use or the combination of alcohol and marijuana has been largely neglected.
23-1	4981-4989	Although	_	
23-2	4990-4995	prior	_	
23-3	4996-5003	studies	_	
23-4	5004-5008	have	_	
23-5	5009-5021	investigated	_	
23-6	5022-5026	risk	_	
23-7	5027-5033	taking	_	
23-8	5034-5037	and	_	
23-9	5038-5043	other	_	
23-10	5044-5053	cognitive	_	
23-11	5054-5063	functions	_	
23-12	5064-5066	in	_	
23-13	5067-5077	adolescent	_	
23-14	5078-5087	substance	_	
23-15	5088-5093	users	_	
23-16	5093-5094	,	_	
23-17	5095-5098	the	_	
23-18	5099-5107	relative	_	
23-19	5108-5119	differences	_	
23-20	5120-5128	compared	_	
23-21	5129-5131	to	_	
23-22	5132-5140	controls	_	
23-23	5141-5153	attributable	_	
23-24	5154-5156	to	_	
23-25	5157-5164	alcohol	_	
23-26	5165-5167	or	_	
23-27	5168-5177	marijuana	_	
23-28	5178-5181	use	_	
23-29	5182-5184	or	_	
23-30	5185-5188	the	_	
23-31	5189-5200	combination	_	
23-32	5201-5203	of	_	
23-33	5204-5211	alcohol	_	
23-34	5212-5215	and	_	
23-35	5216-5225	marijuana	_	
23-36	5226-5229	has	_	
23-37	5230-5234	been	_	
23-38	5235-5242	largely	_	
23-39	5243-5252	neglected	_	
23-40	5252-5253	.	_	

#Text=Thus, the current study aimed to examine differences between adolescents who reported minimal/no use of alcohol or marijuana, adolescents reporting frequent use of either alcohol or marijuana, and adolescents reporting frequent use of both substances.
24-1	5254-5258	Thus	_	
24-2	5258-5259	,	_	
24-3	5260-5263	the	_	
24-4	5264-5271	current	_	
24-5	5272-5277	study	_	
24-6	5278-5283	aimed	_	
24-7	5284-5286	to	_	
24-8	5287-5294	examine	_	
24-9	5295-5306	differences	_	
24-10	5307-5314	between	_	
24-11	5315-5326	adolescents	_	
24-12	5327-5330	who	_	
24-13	5331-5339	reported	_	
24-14	5340-5347	minimal	_	
24-15	5347-5348	/	_	
24-16	5348-5350	no	_	
24-17	5351-5354	use	_	
24-18	5355-5357	of	_	
24-19	5358-5365	alcohol	_	
24-20	5366-5368	or	_	
24-21	5369-5378	marijuana	_	
24-22	5378-5379	,	_	
24-23	5380-5391	adolescents	_	
24-24	5392-5401	reporting	_	
24-25	5402-5410	frequent	_	
24-26	5411-5414	use	_	
24-27	5415-5417	of	_	
24-28	5418-5424	either	_	
24-29	5425-5432	alcohol	_	
24-30	5433-5435	or	_	
24-31	5436-5445	marijuana	_	
24-32	5445-5446	,	_	
24-33	5447-5450	and	_	
24-34	5451-5462	adolescents	_	
24-35	5463-5472	reporting	_	
24-36	5473-5481	frequent	_	
24-37	5482-5485	use	_	
24-38	5486-5488	of	_	
24-39	5489-5493	both	_	
24-40	5494-5504	substances	_	
24-41	5504-5505	.	_	

#Text=Behaviorally, we expected that adolescents reporting alcohol and/or marijuana use would engage in more risk on the BART compared to non-users.
25-1	5506-5518	Behaviorally	_	
25-2	5518-5519	,	_	
25-3	5520-5522	we	_	
25-4	5523-5531	expected	_	
25-5	5532-5536	that	_	
25-6	5537-5548	adolescents	_	
25-7	5549-5558	reporting	_	
25-8	5559-5566	alcohol	_	
25-9	5567-5570	and	_	
25-10	5570-5571	/	_	
25-11	5571-5573	or	_	
25-12	5574-5583	marijuana	_	
25-13	5584-5587	use	_	
25-14	5588-5593	would	_	
25-15	5594-5600	engage	_	
25-16	5601-5603	in	_	
25-17	5604-5608	more	_	
25-18	5609-5613	risk	_	
25-19	5614-5616	on	_	
25-20	5617-5620	the	_	
25-21	5621-5625	BART	_	
25-22	5626-5634	compared	_	
25-23	5635-5637	to	_	
25-24	5638-5647	non-users	_	
25-25	5647-5648	.	_	

#Text=Next, we hypothesized that frequent alcohol use and/or marijuana use would be associated with reduced response in dACC and anterior insula during risky decision making.
26-1	5649-5653	Next	_	
26-2	5653-5654	,	_	
26-3	5655-5657	we	_	
26-4	5658-5670	hypothesized	_	
26-5	5671-5675	that	_	
26-6	5676-5684	frequent	_	
26-7	5685-5692	alcohol	_	
26-8	5693-5696	use	_	
26-9	5697-5700	and	_	
26-10	5700-5701	/	_	
26-11	5701-5703	or	_	
26-12	5704-5713	marijuana	_	
26-13	5714-5717	use	_	
26-14	5718-5723	would	_	
26-15	5724-5726	be	_	
26-16	5727-5737	associated	_	
26-17	5738-5742	with	_	
26-18	5743-5750	reduced	_	
26-19	5751-5759	response	_	
26-20	5760-5762	in	_	
26-21	5763-5767	dACC	_	
26-22	5768-5771	and	_	
26-23	5772-5780	anterior	_	
26-24	5781-5787	insula	_	
26-25	5788-5794	during	_	
26-26	5795-5800	risky	_	
26-27	5801-5809	decision	_	
26-28	5810-5816	making	_	
26-29	5816-5817	.	_	

#Text=Finally, frequent use of alcohol and marijuana was hypothesized to be associated with even greater reductions in BOLD response within regions implicated in decision making than individuals reporting use of a single substance.
27-1	5818-5825	Finally	_	
27-2	5825-5826	,	_	
27-3	5827-5835	frequent	_	
27-4	5836-5839	use	_	
27-5	5840-5842	of	_	
27-6	5843-5850	alcohol	_	
27-7	5851-5854	and	_	
27-8	5855-5864	marijuana	_	
27-9	5865-5868	was	_	
27-10	5869-5881	hypothesized	_	
27-11	5882-5884	to	_	
27-12	5885-5887	be	_	
27-13	5888-5898	associated	_	
27-14	5899-5903	with	_	
27-15	5904-5908	even	_	
27-16	5909-5916	greater	_	
27-17	5917-5927	reductions	_	
27-18	5928-5930	in	_	
27-19	5931-5935	BOLD	_	
27-20	5936-5944	response	_	
27-21	5945-5951	within	_	
27-22	5952-5959	regions	_	
27-23	5960-5970	implicated	_	
27-24	5971-5973	in	_	
27-25	5974-5982	decision	_	
27-26	5983-5989	making	_	
27-27	5990-5994	than	_	
27-28	5995-6006	individuals	_	
27-29	6007-6016	reporting	_	
27-30	6017-6020	use	_	
27-31	6021-6023	of	_	
27-32	6024-6025	a	_	
27-33	6026-6032	single	_	
27-34	6033-6042	substance	_	
27-35	6042-6043	.	_	

#Text=Methods
#Text=Participants
#Text=One hundred ninety-eight adolescents were recruited through an alternative to incarceration program intended to reintegrate youth into school settings.
28-1	6044-6051	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod	
28-2	6052-6064	Participants	_	
28-3	6065-6068	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-4	6069-6076	hundred	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-5	6077-6089	ninety-eight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-6	6090-6101	adolescents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-7	6102-6106	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-8	6107-6116	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-9	6117-6124	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-10	6125-6127	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-11	6128-6139	alternative	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-12	6140-6142	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-13	6143-6156	incarceration	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-14	6157-6164	program	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-15	6165-6173	intended	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-16	6174-6176	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-17	6177-6188	reintegrate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-18	6189-6194	youth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-19	6195-6199	into	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-20	6200-6206	school	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-21	6207-6215	settings	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]	
28-22	6215-6216	.	_	

#Text=Participants were recruited to take part in a study that was investigating an alcohol-related sexual risk reduction intervention; all data reported here were collected at the baseline session, prior to any intervention.
29-1	6217-6229	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-2	6230-6234	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-3	6235-6244	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-4	6245-6247	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-5	6248-6252	take	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-6	6253-6257	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-7	6258-6260	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-8	6261-6262	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-9	6263-6268	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-10	6269-6273	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-11	6274-6277	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-12	6278-6291	investigating	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-13	6292-6294	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-14	6295-6310	alcohol-related	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-15	6311-6317	sexual	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-16	6318-6322	risk	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-17	6323-6332	reduction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-18	6333-6345	intervention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-19	6345-6346	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-20	6347-6350	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-21	6351-6355	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-22	6356-6364	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-23	6365-6369	here	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-24	6370-6374	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-25	6375-6384	collected	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-26	6385-6387	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-27	6388-6391	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-28	6392-6400	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-29	6401-6408	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-30	6408-6409	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-31	6410-6415	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-32	6416-6418	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-33	6419-6422	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-34	6423-6435	intervention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]	
29-35	6435-6436	.	_	

#Text=Both informed assent (written) and informed parental/guardian consent (audiorecorded) were obtained prior to participation (see for details).
30-1	6437-6441	Both	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-2	6442-6450	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-3	6451-6457	assent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-4	6458-6459	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-5	6459-6466	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-6	6466-6467	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-7	6468-6471	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-8	6472-6480	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-9	6481-6489	parental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-10	6489-6490	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-11	6490-6498	guardian	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-12	6499-6506	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-13	6507-6508	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-14	6508-6521	audiorecorded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-15	6521-6522	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-16	6523-6527	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-17	6528-6536	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-18	6537-6542	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-19	6543-6545	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-20	6546-6559	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-21	6560-6561	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-22	6561-6564	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-23	6565-6568	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-24	6569-6576	details	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-25	6576-6577	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
30-26	6577-6578	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Participants were 14–18 years old, able to read and speak English, and were not currently taking psychotropic medications.
31-1	6579-6591	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-2	6592-6596	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-3	6597-6599	14	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-4	6599-6600	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-5	6600-6602	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-6	6603-6608	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-7	6609-6612	old	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-8	6612-6613	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-9	6614-6618	able	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-10	6619-6621	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-11	6622-6626	read	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-12	6627-6630	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-13	6631-6636	speak	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-14	6637-6644	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-15	6644-6645	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-16	6646-6649	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-17	6650-6654	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-18	6655-6658	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-19	6659-6668	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-20	6669-6675	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-21	6676-6688	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-22	6689-6700	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
31-23	6700-6701	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Individuals were excluded from MRI procedures if they reported any history of brain injury or a neurological condition, or any contraindications for MRI.
32-1	6702-6713	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-2	6714-6718	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-3	6719-6727	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-4	6728-6732	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-5	6733-6736	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[14]	
32-6	6737-6747	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-7	6748-6750	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-8	6751-6755	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-9	6756-6764	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-10	6765-6768	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-11	6769-6776	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-12	6777-6779	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-13	6780-6785	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-14	6786-6792	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-15	6793-6795	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-16	6796-6797	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-17	6798-6810	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-18	6811-6820	condition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-19	6820-6821	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-20	6822-6824	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-21	6825-6828	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-22	6829-6846	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-23	6847-6850	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
32-24	6851-6854	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[15]	
32-25	6854-6855	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=Participants were instructed to abstain from all substance use for a minimum of 24 hours prior to the MRI scan, which was verified by self-report prior to the scan session.
33-1	6856-6868	Participants	_	
33-2	6869-6873	were	_	
33-3	6874-6884	instructed	_	
33-4	6885-6887	to	_	
33-5	6888-6895	abstain	_	
33-6	6896-6900	from	_	
33-7	6901-6904	all	_	
33-8	6905-6914	substance	_	
33-9	6915-6918	use	_	
33-10	6919-6922	for	_	
33-11	6923-6924	a	_	
33-12	6925-6932	minimum	_	
33-13	6933-6935	of	_	
33-14	6936-6938	24	_	
33-15	6939-6944	hours	_	
33-16	6945-6950	prior	_	
33-17	6951-6953	to	_	
33-18	6954-6957	the	_	
33-19	6958-6961	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
33-20	6962-6966	scan	_	
33-21	6966-6967	,	_	
33-22	6968-6973	which	_	
33-23	6974-6977	was	_	
33-24	6978-6986	verified	_	
33-25	6987-6989	by	_	
33-26	6990-7001	self-report	_	
33-27	7002-7007	prior	_	
33-28	7008-7010	to	_	
33-29	7011-7014	the	_	
33-30	7015-7019	scan	_	
33-31	7020-7027	session	_	
33-32	7027-7028	.	_	

#Text=Youth were screened for indicators of acute intoxication; no individuals were non-compliant, and no youth needed to be rescheduled.
34-1	7029-7034	Youth	_	
34-2	7035-7039	were	_	
34-3	7040-7048	screened	_	
34-4	7049-7052	for	_	
34-5	7053-7063	indicators	_	
34-6	7064-7066	of	_	
34-7	7067-7072	acute	_	
34-8	7073-7085	intoxication	_	
34-9	7085-7086	;	_	
34-10	7087-7089	no	_	
34-11	7090-7101	individuals	_	
34-12	7102-7106	were	_	
34-13	7107-7120	non-compliant	_	
34-14	7120-7121	,	_	
34-15	7122-7125	and	_	
34-16	7126-7128	no	_	
34-17	7129-7134	youth	_	
34-18	7135-7141	needed	_	
34-19	7142-7144	to	_	
34-20	7145-7147	be	_	
34-21	7148-7159	rescheduled	_	
34-22	7159-7160	.	_	

#Text=Participants received $20 for completing baseline assessments and the MRI session.
35-1	7161-7173	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-2	7174-7182	received	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-3	7183-7186	$20	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-4	7187-7190	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-5	7191-7201	completing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-6	7202-7210	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-7	7211-7222	assessments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-8	7223-7226	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-9	7227-7230	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-10	7231-7234	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[17]	
35-11	7235-7242	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
35-12	7242-7243	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=All components of the study were completed with University Institutional Review Board Approval and a Federal Certificate of Confidentiality.
36-1	7244-7247	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-2	7248-7258	components	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-3	7259-7261	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-4	7262-7265	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-5	7266-7271	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-6	7272-7276	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-7	7277-7286	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-8	7287-7291	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-9	7292-7302	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-10	7303-7316	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-11	7317-7323	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-12	7324-7329	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-13	7330-7338	Approval	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-14	7339-7342	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-15	7343-7344	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-16	7345-7352	Federal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-17	7353-7364	Certificate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-18	7365-7367	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-19	7368-7383	Confidentiality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
36-20	7383-7384	.	_	

#Text=For the current study, participants were assigned to groups according to responses on the Risky Behavior questionnaire and Time Line Follow-Back (TLFB), both described below.
37-1	7385-7388	For	_	
37-2	7389-7392	the	_	
37-3	7393-7400	current	_	
37-4	7401-7406	study	_	
37-5	7406-7407	,	_	
37-6	7408-7420	participants	_	
37-7	7421-7425	were	_	
37-8	7426-7434	assigned	_	
37-9	7435-7437	to	_	
37-10	7438-7444	groups	_	
37-11	7445-7454	according	_	
37-12	7455-7457	to	_	
37-13	7458-7467	responses	_	
37-14	7468-7470	on	_	
37-15	7471-7474	the	_	
37-16	7475-7480	Risky	http://www.case.edu/ProvCaRe/provcare#Questionnaire[19]	
37-17	7481-7489	Behavior	http://www.case.edu/ProvCaRe/provcare#Questionnaire[19]	
37-18	7490-7503	questionnaire	http://www.case.edu/ProvCaRe/provcare#Questionnaire[19]	
37-19	7504-7507	and	_	
37-20	7508-7512	Time	_	
37-21	7513-7517	Line	_	
37-22	7518-7529	Follow-Back	_	
37-23	7530-7531	(	_	
37-24	7531-7535	TLFB	_	
37-25	7535-7536	)	_	
37-26	7536-7537	,	_	
37-27	7538-7542	both	_	
37-28	7543-7552	described	_	
37-29	7553-7558	below	_	
37-30	7558-7559	.	_	

#Text=To be classified as a non/infrequent user of alcohol or marijuana, participants had to endorse “Never” or “Occassionally” on the Risky Behavior questionnaire for the drug of interest and also report using alcohol or marijuana less than or equal to one time in the past month on the TLFB.
38-1	7560-7562	To	_	
38-2	7563-7565	be	_	
38-3	7566-7576	classified	_	
38-4	7577-7579	as	_	
38-5	7580-7581	a	_	
38-6	7582-7585	non	_	
38-7	7585-7586	/	_	
38-8	7586-7596	infrequent	_	
38-9	7597-7601	user	_	
38-10	7602-7604	of	_	
38-11	7605-7612	alcohol	_	
38-12	7613-7615	or	_	
38-13	7616-7625	marijuana	_	
38-14	7625-7626	,	_	
38-15	7627-7639	participants	_	
38-16	7640-7643	had	_	
38-17	7644-7646	to	_	
38-18	7647-7654	endorse	_	
38-19	7655-7656	“	_	
38-20	7656-7661	Never	_	
38-21	7661-7662	”	_	
38-22	7663-7665	or	_	
38-23	7666-7667	“	_	
38-24	7667-7680	Occassionally	_	
38-25	7680-7681	”	_	
38-26	7682-7684	on	_	
38-27	7685-7688	the	_	
38-28	7689-7694	Risky	http://www.case.edu/ProvCaRe/provcare#Questionnaire[20]	
38-29	7695-7703	Behavior	http://www.case.edu/ProvCaRe/provcare#Questionnaire[20]	
38-30	7704-7717	questionnaire	http://www.case.edu/ProvCaRe/provcare#Questionnaire[20]	
38-31	7718-7721	for	_	
38-32	7722-7725	the	_	
38-33	7726-7730	drug	_	
38-34	7731-7733	of	_	
38-35	7734-7742	interest	_	
38-36	7743-7746	and	_	
38-37	7747-7751	also	_	
38-38	7752-7758	report	_	
38-39	7759-7764	using	_	
38-40	7765-7772	alcohol	_	
38-41	7773-7775	or	_	
38-42	7776-7785	marijuana	_	
38-43	7786-7790	less	_	
38-44	7791-7795	than	_	
38-45	7796-7798	or	_	
38-46	7799-7804	equal	_	
38-47	7805-7807	to	_	
38-48	7808-7811	one	_	
38-49	7812-7816	time	_	
38-50	7817-7819	in	_	
38-51	7820-7823	the	_	
38-52	7824-7828	past	_	
38-53	7829-7834	month	_	
38-54	7835-7837	on	_	
38-55	7838-7841	the	_	
38-56	7842-7846	TLFB	_	
38-57	7846-7847	.	_	

#Text=Participants who were classified as primary alcohol or marijuana users reported using the respective drug more than one time in the past month on the TLFB.
39-1	7848-7860	Participants	_	
39-2	7861-7864	who	_	
39-3	7865-7869	were	_	
39-4	7870-7880	classified	_	
39-5	7881-7883	as	_	
39-6	7884-7891	primary	_	
39-7	7892-7899	alcohol	_	
39-8	7900-7902	or	_	
39-9	7903-7912	marijuana	_	
39-10	7913-7918	users	_	
39-11	7919-7927	reported	_	
39-12	7928-7933	using	_	
39-13	7934-7937	the	_	
39-14	7938-7948	respective	_	
39-15	7949-7953	drug	_	
39-16	7954-7958	more	_	
39-17	7959-7963	than	_	
39-18	7964-7967	one	_	
39-19	7968-7972	time	_	
39-20	7973-7975	in	_	
39-21	7976-7979	the	_	
39-22	7980-7984	past	_	
39-23	7985-7990	month	_	
39-24	7991-7993	on	_	
39-25	7994-7997	the	_	
39-26	7998-8002	TLFB	_	
39-27	8002-8003	.	_	

#Text=Two participants did not have data for classification into the relevant groups, so were dropped from the analysis.
40-1	8004-8007	Two	_	
40-2	8008-8020	participants	_	
40-3	8021-8024	did	_	
40-4	8025-8028	not	_	
40-5	8029-8033	have	_	
40-6	8034-8038	data	_	
40-7	8039-8042	for	_	
40-8	8043-8057	classification	_	
40-9	8058-8062	into	_	
40-10	8063-8066	the	_	
40-11	8067-8075	relevant	_	
40-12	8076-8082	groups	_	
40-13	8082-8083	,	_	
40-14	8084-8086	so	_	
40-15	8087-8091	were	_	
40-16	8092-8099	dropped	_	
40-17	8100-8104	from	_	
40-18	8105-8108	the	_	
40-19	8109-8117	analysis	_	
40-20	8117-8118	.	_	

#Text=For the final sample included in the fMRI analyses, 37 were non/infrequent users of both substances, 39 primarily used marijuana, 23 primarily used alcohol, and 90 used both alcohol and marijuana.
41-1	8119-8122	For	_	
41-2	8123-8126	the	_	
41-3	8127-8132	final	_	
41-4	8133-8139	sample	_	
41-5	8140-8148	included	_	
41-6	8149-8151	in	_	
41-7	8152-8155	the	_	
41-8	8156-8160	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
41-9	8161-8169	analyses	_	
41-10	8169-8170	,	_	
41-11	8171-8173	37	_	
41-12	8174-8178	were	_	
41-13	8179-8182	non	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
41-14	8182-8183	/	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
41-15	8183-8193	infrequent	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
41-16	8194-8199	users	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
41-17	8200-8202	of	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
41-18	8203-8207	both	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
41-19	8208-8218	substances	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[21]	
41-20	8218-8219	,	_	
41-21	8220-8222	39	_	
41-22	8223-8232	primarily	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[22]	
41-23	8233-8237	used	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[22]	
41-24	8238-8247	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#DrugAbuse[22]	
41-25	8247-8248	,	_	
41-26	8249-8251	23	_	
41-27	8252-8261	primarily	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[23]	
41-28	8262-8266	used	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[23]	
41-29	8267-8274	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[23]	
41-30	8274-8275	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[23]	
41-31	8276-8279	and	_	
41-32	8280-8282	90	_	
41-33	8283-8287	used	_	
41-34	8288-8292	both	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[24]	
41-35	8293-8300	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[24]	
41-36	8301-8304	and	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[24]	
41-37	8305-8314	marijuana	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence[24]	
41-38	8314-8315	.	_	

#Text=Assessments
#Text=Conner’s-Wells Self Report Scale-Short Version (CASS-S)
#Text=Given the high prevalence of Attention Deficit/Hyperactivity Disorder (AD/HD) among high risk youth, AD/HD symptoms were assessed with the Conner’s-Wells Self-Report Scale – Short version (CASS-S).
42-1	8316-8327	Assessments	_	
42-2	8328-8334	Conner	_	
42-3	8334-8335	’	_	
42-4	8335-8342	s-Wells	_	
42-5	8343-8347	Self	_	
42-6	8348-8354	Report	_	
42-7	8355-8366	Scale-Short	_	
42-8	8367-8374	Version	_	
42-9	8375-8376	(	_	
42-10	8376-8382	CASS-S	_	
42-11	8382-8383	)	_	
42-12	8384-8389	Given	_	
42-13	8390-8393	the	_	
42-14	8394-8398	high	_	
42-15	8399-8409	prevalence	_	
42-16	8410-8412	of	_	
42-17	8413-8422	Attention	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-18	8423-8430	Deficit	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-19	8430-8431	/	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-20	8431-8444	Hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-21	8445-8453	Disorder	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-22	8454-8455	(	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-23	8455-8457	AD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-24	8457-8458	/	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-25	8458-8460	HD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-26	8460-8461	)	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[25]	
42-27	8462-8467	among	_	
42-28	8468-8472	high	_	
42-29	8473-8477	risk	_	
42-30	8478-8483	youth	_	
42-31	8483-8484	,	_	
42-32	8485-8487	AD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[26]	
42-33	8487-8488	/	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[26]	
42-34	8488-8490	HD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[26]	
42-35	8491-8499	symptoms	_	
42-36	8500-8504	were	_	
42-37	8505-8513	assessed	_	
42-38	8514-8518	with	_	
42-39	8519-8522	the	_	
42-40	8523-8529	Conner	_	
42-41	8529-8530	’	_	
42-42	8530-8537	s-Wells	_	
42-43	8538-8549	Self-Report	_	
42-44	8550-8555	Scale	_	
42-45	8556-8557	–	_	
42-46	8558-8563	Short	_	
42-47	8564-8571	version	_	
42-48	8572-8573	(	_	
42-49	8573-8579	CASS-S	_	
42-50	8579-8580	)	_	
42-51	8580-8581	.	_	

#Text=Participants indicated how much they thought each of 27 statements applied using a 4-point scale (0=not at all true to 3=very much true).
43-1	8582-8594	Participants	_	
43-2	8595-8604	indicated	_	
43-3	8605-8608	how	_	
43-4	8609-8613	much	_	
43-5	8614-8618	they	_	
43-6	8619-8626	thought	_	
43-7	8627-8631	each	_	
43-8	8632-8634	of	_	
43-9	8635-8637	27	_	
43-10	8638-8648	statements	_	
43-11	8649-8656	applied	_	
43-12	8657-8662	using	_	
43-13	8663-8664	a	_	
43-14	8665-8666	4	_	
43-15	8666-8667	-	_	
43-16	8667-8672	point	_	
43-17	8673-8678	scale	_	
43-18	8679-8680	(	_	
43-19	8680-8681	0	_	
43-20	8681-8682	=	_	
43-21	8682-8685	not	_	
43-22	8686-8688	at	_	
43-23	8689-8692	all	_	
43-24	8693-8697	true	_	
43-25	8698-8700	to	_	
43-26	8701-8702	3	_	
43-27	8702-8703	=	_	
43-28	8703-8707	very	_	
43-29	8708-8712	much	_	
43-30	8713-8717	true	_	
43-31	8717-8718	)	_	
43-32	8718-8719	.	_	

#Text=Example statements include “I have too much energy to sit still for long” and “I bend the rules whenever I can.”
44-1	8720-8727	Example	_	
44-2	8728-8738	statements	_	
44-3	8739-8746	include	_	
44-4	8747-8748	“	_	
44-5	8748-8749	I	_	
44-6	8750-8754	have	_	
44-7	8755-8758	too	_	
44-8	8759-8763	much	_	
44-9	8764-8770	energy	_	
44-10	8771-8773	to	_	
44-11	8774-8777	sit	_	
44-12	8778-8783	still	_	
44-13	8784-8787	for	_	
44-14	8788-8792	long	_	
44-15	8792-8793	”	_	
44-16	8794-8797	and	_	
44-17	8798-8799	“	_	
44-18	8799-8800	I	_	
44-19	8801-8805	bend	_	
44-20	8806-8809	the	_	
44-21	8810-8815	rules	_	
44-22	8816-8824	whenever	_	
44-23	8825-8826	I	_	
44-24	8827-8830	can	_	
44-25	8830-8831	.	_	
44-26	8831-8832	”	_	

#Text=Scores were calculated as the sum of these items where higher scores indicated greater AD/HD symptomology, α = .91.
45-1	8833-8839	Scores	_	
45-2	8840-8844	were	_	
45-3	8845-8855	calculated	_	
45-4	8856-8858	as	_	
45-5	8859-8862	the	_	
45-6	8863-8866	sum	_	
45-7	8867-8869	of	_	
45-8	8870-8875	these	_	
45-9	8876-8881	items	_	
45-10	8882-8887	where	_	
45-11	8888-8894	higher	_	
45-12	8895-8901	scores	_	
45-13	8902-8911	indicated	_	
45-14	8912-8919	greater	_	
45-15	8920-8922	AD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[27]	
45-16	8922-8923	/	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[27]	
45-17	8923-8925	HD	http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[27]	
45-18	8926-8938	symptomology	_	
45-19	8938-8939	,	_	
45-20	8940-8941	α	_	
45-21	8942-8943	=	_	
45-22	8944-8947	.91	_	
45-23	8947-8948	.	_	

#Text=Child Behavior Checklist-Youth Self Report (CBCL)
#Text=Due to the relationship between externalizing and adolescent risk behavior, the CBCL was used to access youth externalizing behaviors.
46-1	8949-8954	Child	_	
46-2	8955-8963	Behavior	_	
46-3	8964-8979	Checklist-Youth	_	
46-4	8980-8984	Self	_	
46-5	8985-8991	Report	_	
46-6	8992-8993	(	_	
46-7	8993-8997	CBCL	_	
46-8	8997-8998	)	_	
46-9	8999-9002	Due	_	
46-10	9003-9005	to	_	
46-11	9006-9009	the	_	
46-12	9010-9022	relationship	_	
46-13	9023-9030	between	_	
46-14	9031-9044	externalizing	_	
46-15	9045-9048	and	_	
46-16	9049-9059	adolescent	_	
46-17	9060-9064	risk	_	
46-18	9065-9073	behavior	_	
46-19	9073-9074	,	_	
46-20	9075-9078	the	_	
46-21	9079-9083	CBCL	_	
46-22	9084-9087	was	_	
46-23	9088-9092	used	_	
46-24	9093-9095	to	_	
46-25	9096-9102	access	_	
46-26	9103-9108	youth	_	
46-27	9109-9122	externalizing	_	
46-28	9123-9132	behaviors	_	
46-29	9132-9133	.	_	

#Text=The CBCL-YSR externalizing scale includes 32 items, with higher sum scores indicating greater externalizing behavior, α = .94.
47-1	9134-9137	The	_	
47-2	9138-9146	CBCL-YSR	_	
47-3	9147-9160	externalizing	_	
47-4	9161-9166	scale	_	
47-5	9167-9175	includes	_	
47-6	9176-9178	32	_	
47-7	9179-9184	items	_	
47-8	9184-9185	,	_	
47-9	9186-9190	with	_	
47-10	9191-9197	higher	_	
47-11	9198-9201	sum	_	
47-12	9202-9208	scores	_	
47-13	9209-9219	indicating	_	
47-14	9220-9227	greater	_	
47-15	9228-9241	externalizing	_	
47-16	9242-9250	behavior	_	
47-17	9250-9251	,	_	
47-18	9252-9253	α	_	
47-19	9254-9255	=	_	
47-20	9256-9259	.94	_	
47-21	9259-9260	.	_	

#Text=This measure has been shown to be equally reliable across racial/ethnic groups of young people in our prior work.
48-1	9261-9265	This	_	
48-2	9266-9273	measure	_	
48-3	9274-9277	has	_	
48-4	9278-9282	been	_	
48-5	9283-9288	shown	_	
48-6	9289-9291	to	_	
48-7	9292-9294	be	_	
48-8	9295-9302	equally	_	
48-9	9303-9311	reliable	_	
48-10	9312-9318	across	_	
48-11	9319-9325	racial	_	
48-12	9325-9326	/	_	
48-13	9326-9332	ethnic	_	
48-14	9333-9339	groups	_	
48-15	9340-9342	of	_	
48-16	9343-9348	young	_	
48-17	9349-9355	people	_	
48-18	9356-9358	in	_	
48-19	9359-9362	our	_	
48-20	9363-9368	prior	_	
48-21	9369-9373	work	_	
48-22	9373-9374	.	_	

#Text=Children's Depression Inventory (CDI)
#Text=The CDI was used to assess potential group differences in depression, given the high rates of comorbidity between substance use and depression.
49-1	9375-9385	Children's	http://maven.renci.org/NeuroBridge/neurobridge#Children'sDepressionInventory[28]	
49-2	9386-9396	Depression	http://maven.renci.org/NeuroBridge/neurobridge#Children'sDepressionInventory[28]	
49-3	9397-9406	Inventory	http://maven.renci.org/NeuroBridge/neurobridge#Children'sDepressionInventory[28]	
49-4	9407-9408	(	http://maven.renci.org/NeuroBridge/neurobridge#Children'sDepressionInventory[28]	
49-5	9408-9411	CDI	http://maven.renci.org/NeuroBridge/neurobridge#Children'sDepressionInventory[28]	
49-6	9411-9412	)	http://maven.renci.org/NeuroBridge/neurobridge#Children'sDepressionInventory[28]	
49-7	9413-9416	The	_	
49-8	9417-9420	CDI	http://maven.renci.org/NeuroBridge/neurobridge#Children'sDepressionInventory	
49-9	9421-9424	was	_	
49-10	9425-9429	used	_	
49-11	9430-9432	to	_	
49-12	9433-9439	assess	_	
49-13	9440-9449	potential	_	
49-14	9450-9455	group	_	
49-15	9456-9467	differences	_	
49-16	9468-9470	in	_	
49-17	9471-9481	depression	_	
49-18	9481-9482	,	_	
49-19	9483-9488	given	_	
49-20	9489-9492	the	_	
49-21	9493-9497	high	_	
49-22	9498-9503	rates	_	
49-23	9504-9506	of	_	
49-24	9507-9518	comorbidity	_	
49-25	9519-9526	between	_	
49-26	9527-9536	substance	_	
49-27	9537-9540	use	_	
49-28	9541-9544	and	_	
49-29	9545-9555	depression	_	
49-30	9555-9556	.	_	

#Text=For each of 27 items, participants rate the degree to which statements about negative mood, interpersonal problems, ineffectiveness, anhedonia, and self-esteem are true (0=Not at all true to 2=Very true).
50-1	9557-9560	For	_	
50-2	9561-9565	each	_	
50-3	9566-9568	of	_	
50-4	9569-9571	27	_	
50-5	9572-9577	items	_	
50-6	9577-9578	,	_	
50-7	9579-9591	participants	_	
50-8	9592-9596	rate	_	
50-9	9597-9600	the	_	
50-10	9601-9607	degree	_	
50-11	9608-9610	to	_	
50-12	9611-9616	which	_	
50-13	9617-9627	statements	_	
50-14	9628-9633	about	_	
50-15	9634-9642	negative	_	
50-16	9643-9647	mood	_	
50-17	9647-9648	,	_	
50-18	9649-9662	interpersonal	_	
50-19	9663-9671	problems	_	
50-20	9671-9672	,	_	
50-21	9673-9688	ineffectiveness	_	
50-22	9688-9689	,	_	
50-23	9690-9699	anhedonia	_	
50-24	9699-9700	,	_	
50-25	9701-9704	and	_	
50-26	9705-9716	self-esteem	_	
50-27	9717-9720	are	_	
50-28	9721-9725	true	_	
50-29	9726-9727	(	_	
50-30	9727-9728	0	_	
50-31	9728-9729	=	_	
50-32	9729-9732	Not	_	
50-33	9733-9735	at	_	
50-34	9736-9739	all	_	
50-35	9740-9744	true	_	
50-36	9745-9747	to	_	
50-37	9748-9749	2	_	
50-38	9749-9750	=	_	
50-39	9750-9754	Very	_	
50-40	9755-9759	true	_	
50-41	9759-9760	)	_	
50-42	9760-9761	.	_	

#Text=A total score was calculated by summing across all items, with higher scores representing higher levels of depression, α = .84.
51-1	9762-9763	A	_	
51-2	9764-9769	total	_	
51-3	9770-9775	score	_	
51-4	9776-9779	was	_	
51-5	9780-9790	calculated	_	
51-6	9791-9793	by	_	
51-7	9794-9801	summing	_	
51-8	9802-9808	across	_	
51-9	9809-9812	all	_	
51-10	9813-9818	items	_	
51-11	9818-9819	,	_	
51-12	9820-9824	with	_	
51-13	9825-9831	higher	_	
51-14	9832-9838	scores	_	
51-15	9839-9851	representing	_	
51-16	9852-9858	higher	_	
51-17	9859-9865	levels	_	
51-18	9866-9868	of	_	
51-19	9869-9879	depression	_	
51-20	9879-9880	,	_	
51-21	9881-9882	α	_	
51-22	9883-9884	=	_	
51-23	9885-9888	.84	_	
51-24	9888-9889	.	_	

#Text=Revised Children's Manifest Anxiety Scale (RCMAS)
#Text=The RCMAS is a measure of anxiety, an important potential confound in adolescents with a history of substance use (Roberts et al. 2007).
52-1	9890-9897	Revised	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale[29]	
52-2	9898-9908	Children's	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale[29]	
52-3	9909-9917	Manifest	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale[29]	
52-4	9918-9925	Anxiety	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale[29]	
52-5	9926-9931	Scale	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale[29]	
52-6	9932-9933	(	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale[29]	
52-7	9933-9938	RCMAS	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale[29]	
52-8	9938-9939	)	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale[29]	
52-9	9940-9943	The	_	
52-10	9944-9949	RCMAS	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale	
52-11	9950-9952	is	_	
52-12	9953-9954	a	_	
52-13	9955-9962	measure	_	
52-14	9963-9965	of	_	
52-15	9966-9973	anxiety	_	
52-16	9973-9974	,	_	
52-17	9975-9977	an	_	
52-18	9978-9987	important	_	
52-19	9988-9997	potential	_	
52-20	9998-10006	confound	_	
52-21	10007-10009	in	_	
52-22	10010-10021	adolescents	_	
52-23	10022-10026	with	_	
52-24	10027-10028	a	_	
52-25	10029-10036	history	_	
52-26	10037-10039	of	_	
52-27	10040-10049	substance	_	
52-28	10050-10053	use	_	
52-29	10054-10055	(	_	
52-30	10055-10062	Roberts	_	
52-31	10063-10065	et	_	
52-32	10066-10068	al	_	
52-33	10068-10069	.	_	
52-34	10070-10074	2007	_	
52-35	10074-10075	)	_	
52-36	10075-10076	.	_	

#Text=The RCMAS is a 37-item questionnaire that requires participants to respond “Yes” or “No” to statements about physiological anxiety, worry, and social concerns.
53-1	10077-10080	The	_	
53-2	10081-10086	RCMAS	http://maven.renci.org/NeuroBridge/neurobridge#RevisedChildren'sManifestAnxietyScale	
53-3	10087-10089	is	_	
53-4	10090-10091	a	_	
53-5	10092-10094	37	_	
53-6	10094-10095	-	_	
53-7	10095-10099	item	_	
53-8	10100-10113	questionnaire	_	
53-9	10114-10118	that	_	
53-10	10119-10127	requires	_	
53-11	10128-10140	participants	_	
53-12	10141-10143	to	_	
53-13	10144-10151	respond	_	
53-14	10152-10153	“	_	
53-15	10153-10156	Yes	_	
53-16	10156-10157	”	_	
53-17	10158-10160	or	_	
53-18	10161-10162	“	_	
53-19	10162-10164	No	_	
53-20	10164-10165	”	_	
53-21	10166-10168	to	_	
53-22	10169-10179	statements	_	
53-23	10180-10185	about	_	
53-24	10186-10199	physiological	_	
53-25	10200-10207	anxiety	_	
53-26	10207-10208	,	_	
53-27	10209-10214	worry	_	
53-28	10214-10215	,	_	
53-29	10216-10219	and	_	
53-30	10220-10226	social	_	
53-31	10227-10235	concerns	_	
53-32	10235-10236	.	_	

#Text=A total score was computed by summing the total number of “Yes” responses on the 28 items that were not part of the “Lie” subscale; higher scores were indicative of higher anxiety, α = .87.
54-1	10237-10238	A	_	
54-2	10239-10244	total	_	
54-3	10245-10250	score	_	
54-4	10251-10254	was	_	
54-5	10255-10263	computed	_	
54-6	10264-10266	by	_	
54-7	10267-10274	summing	_	
54-8	10275-10278	the	_	
54-9	10279-10284	total	_	
54-10	10285-10291	number	_	
54-11	10292-10294	of	_	
54-12	10295-10296	“	_	
54-13	10296-10299	Yes	_	
54-14	10299-10300	”	_	
54-15	10301-10310	responses	_	
54-16	10311-10313	on	_	
54-17	10314-10317	the	_	
54-18	10318-10320	28	_	
54-19	10321-10326	items	_	
54-20	10327-10331	that	_	
54-21	10332-10336	were	_	
54-22	10337-10340	not	_	
54-23	10341-10345	part	_	
54-24	10346-10348	of	_	
54-25	10349-10352	the	_	
54-26	10353-10354	“	_	
54-27	10354-10357	Lie	_	
54-28	10357-10358	”	_	
54-29	10359-10367	subscale	_	
54-30	10367-10368	;	_	
54-31	10369-10375	higher	_	
54-32	10376-10382	scores	_	
54-33	10383-10387	were	_	
54-34	10388-10398	indicative	_	
54-35	10399-10401	of	_	
54-36	10402-10408	higher	_	
54-37	10409-10416	anxiety	_	
54-38	10416-10417	,	_	
54-39	10418-10419	α	_	
54-40	10420-10421	=	_	
54-41	10422-10425	.87	_	
54-42	10425-10426	.	_	

#Text=Impulsive Sensation Seeking (ImpSS)
#Text=To control for levels of sensation seeking across individuals, we used the ImpSS, a well-validated measure of impulsive sensation seeking.
55-1	10427-10436	Impulsive	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale[30]	
55-2	10437-10446	Sensation	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale[30]	
55-3	10447-10454	Seeking	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale[30]	
55-4	10455-10456	(	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale[30]	
55-5	10456-10461	ImpSS	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale[30]	
55-6	10461-10462	)	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale[30]	
55-7	10463-10465	To	_	
55-8	10466-10473	control	_	
55-9	10474-10477	for	_	
55-10	10478-10484	levels	_	
55-11	10485-10487	of	_	
55-12	10488-10497	sensation	_	
55-13	10498-10505	seeking	_	
55-14	10506-10512	across	_	
55-15	10513-10524	individuals	_	
55-16	10524-10525	,	_	
55-17	10526-10528	we	_	
55-18	10529-10533	used	_	
55-19	10534-10537	the	_	
55-20	10538-10543	ImpSS	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale	
55-21	10543-10544	,	_	
55-22	10545-10546	a	_	
55-23	10547-10561	well-validated	_	
55-24	10562-10569	measure	_	
55-25	10570-10572	of	_	
55-26	10573-10582	impulsive	_	
55-27	10583-10592	sensation	_	
55-28	10593-10600	seeking	_	
55-29	10600-10601	.	_	

#Text=For each of 19 items, “True” or “False” was selected to indicate whether the statement accurately described the participant.
56-1	10602-10605	For	_	
56-2	10606-10610	each	_	
56-3	10611-10613	of	_	
56-4	10614-10616	19	_	
56-5	10617-10622	items	_	
56-6	10622-10623	,	_	
56-7	10624-10625	“	_	
56-8	10625-10629	True	_	
56-9	10629-10630	”	_	
56-10	10631-10633	or	_	
56-11	10634-10635	“	_	
56-12	10635-10640	False	_	
56-13	10640-10641	”	_	
56-14	10642-10645	was	_	
56-15	10646-10654	selected	_	
56-16	10655-10657	to	_	
56-17	10658-10666	indicate	_	
56-18	10667-10674	whether	_	
56-19	10675-10678	the	_	
56-20	10679-10688	statement	_	
56-21	10689-10699	accurately	_	
56-22	10700-10709	described	_	
56-23	10710-10713	the	_	
56-24	10714-10725	participant	_	
56-25	10725-10726	.	_	

#Text=After reverse scoring two of the items, the total score was computed by summing the total number of “True” responses.
57-1	10727-10732	After	_	
57-2	10733-10740	reverse	_	
57-3	10741-10748	scoring	_	
57-4	10749-10752	two	_	
57-5	10753-10755	of	_	
57-6	10756-10759	the	_	
57-7	10760-10765	items	_	
57-8	10765-10766	,	_	
57-9	10767-10770	the	_	
57-10	10771-10776	total	_	
57-11	10777-10782	score	_	
57-12	10783-10786	was	_	
57-13	10787-10795	computed	_	
57-14	10796-10798	by	_	
57-15	10799-10806	summing	_	
57-16	10807-10810	the	_	
57-17	10811-10816	total	_	
57-18	10817-10823	number	_	
57-19	10824-10826	of	_	
57-20	10827-10828	“	_	
57-21	10828-10832	True	_	
57-22	10832-10833	”	_	
57-23	10834-10843	responses	_	
57-24	10843-10844	.	_	

#Text=Higher scores on the ImpSS indicate greater levels of impulsive sensation seeking, α = .77.
58-1	10845-10851	Higher	_	
58-2	10852-10858	scores	_	
58-3	10859-10861	on	_	
58-4	10862-10865	the	_	
58-5	10866-10871	ImpSS	http://maven.renci.org/NeuroBridge/neurobridge#ImpulsiveSensationSeekingScale	
58-6	10872-10880	indicate	_	
58-7	10881-10888	greater	_	
58-8	10889-10895	levels	_	
58-9	10896-10898	of	_	
58-10	10899-10908	impulsive	_	
58-11	10909-10918	sensation	_	
58-12	10919-10926	seeking	_	
58-13	10926-10927	,	_	
58-14	10928-10929	α	_	
58-15	10930-10931	=	_	
58-16	10932-10935	.77	_	
58-17	10935-10936	.	_	

#Text=Risky Behavior
#Text=In order to improve the validity of reporting of high-risk behaviors, youth completed self-report measures via an audio-computer assisted self-interview assessment system.
59-1	10937-10942	Risky	_	
59-2	10943-10951	Behavior	_	
59-3	10952-10954	In	_	
59-4	10955-10960	order	_	
59-5	10961-10963	to	_	
59-6	10964-10971	improve	_	
59-7	10972-10975	the	_	
59-8	10976-10984	validity	_	
59-9	10985-10987	of	_	
59-10	10988-10997	reporting	_	
59-11	10998-11000	of	_	
59-12	11001-11010	high-risk	_	
59-13	11011-11020	behaviors	_	
59-14	11020-11021	,	_	
59-15	11022-11027	youth	_	
59-16	11028-11037	completed	_	
59-17	11038-11049	self-report	_	
59-18	11050-11058	measures	_	
59-19	11059-11062	via	_	
59-20	11063-11065	an	_	
59-21	11066-11080	audio-computer	_	
59-22	11081-11089	assisted	_	
59-23	11090-11104	self-interview	_	
59-24	11105-11115	assessment	_	
59-25	11116-11122	system	_	
59-26	11122-11123	.	_	

#Text=Among other assessments, participants were asked whether they had ever used alcohol and/or marijuana, and if they responded “yes” they were asked to indicate how often they consumed each drug over the past three months using a response scale with the following options: “Never”, “Occasionally”, “Once a month”, “2–3 times a month”, “4–5 times a month”, “Once a week”, “2–3 times a week”, “4–5 times a week”, “Every day”.
60-1	11124-11129	Among	_	
60-2	11130-11135	other	_	
60-3	11136-11147	assessments	_	
60-4	11147-11148	,	_	
60-5	11149-11161	participants	_	
60-6	11162-11166	were	_	
60-7	11167-11172	asked	_	
60-8	11173-11180	whether	_	
60-9	11181-11185	they	_	
60-10	11186-11189	had	_	
60-11	11190-11194	ever	_	
60-12	11195-11199	used	_	
60-13	11200-11207	alcohol	_	
60-14	11208-11211	and	_	
60-15	11211-11212	/	_	
60-16	11212-11214	or	_	
60-17	11215-11224	marijuana	_	
60-18	11224-11225	,	_	
60-19	11226-11229	and	_	
60-20	11230-11232	if	_	
60-21	11233-11237	they	_	
60-22	11238-11247	responded	_	
60-23	11248-11249	“	_	
60-24	11249-11252	yes	_	
60-25	11252-11253	”	_	
60-26	11254-11258	they	_	
60-27	11259-11263	were	_	
60-28	11264-11269	asked	_	
60-29	11270-11272	to	_	
60-30	11273-11281	indicate	_	
60-31	11282-11285	how	_	
60-32	11286-11291	often	_	
60-33	11292-11296	they	_	
60-34	11297-11305	consumed	_	
60-35	11306-11310	each	_	
60-36	11311-11315	drug	_	
60-37	11316-11320	over	_	
60-38	11321-11324	the	_	
60-39	11325-11329	past	_	
60-40	11330-11335	three	_	
60-41	11336-11342	months	_	
60-42	11343-11348	using	_	
60-43	11349-11350	a	_	
60-44	11351-11359	response	_	
60-45	11360-11365	scale	_	
60-46	11366-11370	with	_	
60-47	11371-11374	the	_	
60-48	11375-11384	following	_	
60-49	11385-11392	options	_	
60-50	11392-11393	:	_	
60-51	11394-11395	“	_	
60-52	11395-11400	Never	_	
60-53	11400-11401	”	_	
60-54	11401-11402	,	_	
60-55	11403-11404	“	_	
60-56	11404-11416	Occasionally	_	
60-57	11416-11417	”	_	
60-58	11417-11418	,	_	
60-59	11419-11420	“	_	
60-60	11420-11424	Once	_	
60-61	11425-11426	a	_	
60-62	11427-11432	month	_	
60-63	11432-11433	”	_	
60-64	11433-11434	,	_	
60-65	11435-11436	“	_	
60-66	11436-11437	2	_	
60-67	11437-11438	–	_	
60-68	11438-11439	3	_	
60-69	11440-11445	times	_	
60-70	11446-11447	a	_	
60-71	11448-11453	month	_	
60-72	11453-11454	”	_	
60-73	11454-11455	,	_	
60-74	11456-11457	“	_	
60-75	11457-11458	4	_	
60-76	11458-11459	–	_	
60-77	11459-11460	5	_	
60-78	11461-11466	times	_	
60-79	11467-11468	a	_	
60-80	11469-11474	month	_	
60-81	11474-11475	”	_	
60-82	11475-11476	,	_	
60-83	11477-11478	“	_	
60-84	11478-11482	Once	_	
60-85	11483-11484	a	_	
60-86	11485-11489	week	_	
60-87	11489-11490	”	_	
60-88	11490-11491	,	_	
60-89	11492-11493	“	_	
60-90	11493-11494	2	_	
60-91	11494-11495	–	_	
60-92	11495-11496	3	_	
60-93	11497-11502	times	_	
60-94	11503-11504	a	_	
60-95	11505-11509	week	_	
60-96	11509-11510	”	_	
60-97	11510-11511	,	_	
60-98	11512-11513	“	_	
60-99	11513-11514	4	_	
60-100	11514-11515	–	_	
60-101	11515-11516	5	_	
60-102	11517-11522	times	_	
60-103	11523-11524	a	_	
60-104	11525-11529	week	_	
60-105	11529-11530	”	_	
60-106	11530-11531	,	_	
60-107	11532-11533	“	_	
60-108	11533-11538	Every	_	
60-109	11539-11542	day	_	
60-110	11542-11543	”	_	
60-111	11543-11544	.	_	

#Text=Participants were also asked whether they had used a number of other substances (past 3 months and lifetime use), which included cocaine, methamphetamine, prescription drugs (e.g.
61-1	11545-11557	Participants	_	
61-2	11558-11562	were	_	
61-3	11563-11567	also	_	
61-4	11568-11573	asked	_	
61-5	11574-11581	whether	_	
61-6	11582-11586	they	_	
61-7	11587-11590	had	_	
61-8	11591-11595	used	_	
61-9	11596-11597	a	_	
61-10	11598-11604	number	_	
61-11	11605-11607	of	_	
61-12	11608-11613	other	_	
61-13	11614-11624	substances	_	
61-14	11625-11626	(	_	
61-15	11626-11630	past	_	
61-16	11631-11632	3	_	
61-17	11633-11639	months	_	
61-18	11640-11643	and	_	
61-19	11644-11652	lifetime	_	
61-20	11653-11656	use	_	
61-21	11656-11657	)	_	
61-22	11657-11658	,	_	
61-23	11659-11664	which	_	
61-24	11665-11673	included	_	
61-25	11674-11681	cocaine	_	
61-26	11681-11682	,	_	
61-27	11683-11698	methamphetamine	_	
61-28	11698-11699	,	_	
61-29	11700-11712	prescription	_	
61-30	11713-11718	drugs	_	
61-31	11719-11720	(	_	
61-32	11720-11723	e.g	_	
61-33	11723-11724	.	_	

#Text=Adderall, Oxycontin), ecstasy, mushrooms, LSD, GHB, heroin and ketamine.
62-1	11725-11733	Adderall	_	
62-2	11733-11734	,	_	
62-3	11735-11744	Oxycontin	_	
62-4	11744-11745	)	_	
62-5	11745-11746	,	_	
62-6	11747-11754	ecstasy	_	
62-7	11754-11755	,	_	
62-8	11756-11765	mushrooms	_	
62-9	11765-11766	,	_	
62-10	11767-11770	LSD	_	
62-11	11770-11771	,	_	
62-12	11772-11775	GHB	_	
62-13	11775-11776	,	_	
62-14	11777-11783	heroin	_	
62-15	11784-11787	and	_	
62-16	11788-11796	ketamine	_	
62-17	11796-11797	.	_	

#Text=The total number of drugs used was summed to form a composite measure of hard drug use (past 3 months and lifetime).
63-1	11798-11801	The	_	
63-2	11802-11807	total	_	
63-3	11808-11814	number	_	
63-4	11815-11817	of	_	
63-5	11818-11823	drugs	_	
63-6	11824-11828	used	_	
63-7	11829-11832	was	_	
63-8	11833-11839	summed	_	
63-9	11840-11842	to	_	
63-10	11843-11847	form	_	
63-11	11848-11849	a	_	
63-12	11850-11859	composite	_	
63-13	11860-11867	measure	_	
63-14	11868-11870	of	_	
63-15	11871-11875	hard	_	
63-16	11876-11880	drug	_	
63-17	11881-11884	use	_	
63-18	11885-11886	(	_	
63-19	11886-11890	past	_	
63-20	11891-11892	3	_	
63-21	11893-11899	months	_	
63-22	11900-11903	and	_	
63-23	11904-11912	lifetime	_	
63-24	11912-11913	)	_	
63-25	11913-11914	.	_	

#Text=Participants were also asked about frequency of sexual intercourse and condom use (see for details).
64-1	11915-11927	Participants	_	
64-2	11928-11932	were	_	
64-3	11933-11937	also	_	
64-4	11938-11943	asked	_	
64-5	11944-11949	about	_	
64-6	11950-11959	frequency	_	
64-7	11960-11962	of	_	
64-8	11963-11969	sexual	_	
64-9	11970-11981	intercourse	_	
64-10	11982-11985	and	_	
64-11	11986-11992	condom	_	
64-12	11993-11996	use	_	
64-13	11997-11998	(	_	
64-14	11998-12001	see	_	
64-15	12002-12005	for	_	
64-16	12006-12013	details	_	
64-17	12013-12014	)	_	
64-18	12014-12015	.	_	

#Text=Time Line Follow-Back
#Text=All participants completed a TLFB interview to assess quantity and frequency of alcohol and frequency of marijuana use over the prior 30 days (see Table 1).
65-1	12016-12020	Time	_	
65-2	12021-12025	Line	_	
65-3	12026-12037	Follow-Back	_	
65-4	12038-12041	All	_	
65-5	12042-12054	participants	_	
65-6	12055-12064	completed	_	
65-7	12065-12066	a	_	
65-8	12067-12071	TLFB	_	
65-9	12072-12081	interview	_	
65-10	12082-12084	to	_	
65-11	12085-12091	assess	_	
65-12	12092-12100	quantity	_	
65-13	12101-12104	and	_	
65-14	12105-12114	frequency	_	
65-15	12115-12117	of	_	
65-16	12118-12125	alcohol	_	
65-17	12126-12129	and	_	
65-18	12130-12139	frequency	_	
65-19	12140-12142	of	_	
65-20	12143-12152	marijuana	_	
65-21	12153-12156	use	_	
65-22	12157-12161	over	_	
65-23	12162-12165	the	_	
65-24	12166-12171	prior	_	
65-25	12172-12174	30	_	
65-26	12175-12179	days	_	
65-27	12180-12181	(	_	
65-28	12181-12184	see	_	
65-29	12185-12190	Table	_	
65-30	12191-12192	1	_	
65-31	12192-12193	)	_	
65-32	12193-12194	.	_	

#Text=Modified Balloon Analogue Risk Task (BART)
#Text=The variant of the BART used in the current study was identical to the task used in a previous study and utilized three balloons of different colors: blue, pink, and white.
66-1	12195-12203	Modified	_	
66-2	12204-12211	Balloon	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[31]	
66-3	12212-12220	Analogue	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[31]	
66-4	12221-12225	Risk	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[31]	
66-5	12226-12230	Task	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[31]	
66-6	12231-12232	(	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[31]	
66-7	12232-12236	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[31]	
66-8	12236-12237	)	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask[31]	
66-9	12238-12241	The	_	
66-10	12242-12249	variant	_	
66-11	12250-12252	of	_	
66-12	12253-12256	the	_	
66-13	12257-12261	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask	
66-14	12262-12266	used	_	
66-15	12267-12269	in	_	
66-16	12270-12273	the	_	
66-17	12274-12281	current	_	
66-18	12282-12287	study	_	
66-19	12288-12291	was	_	
66-20	12292-12301	identical	_	
66-21	12302-12304	to	_	
66-22	12305-12308	the	_	
66-23	12309-12313	task	_	
66-24	12314-12318	used	_	
66-25	12319-12321	in	_	
66-26	12322-12323	a	_	
66-27	12324-12332	previous	_	
66-28	12333-12338	study	_	
66-29	12339-12342	and	_	
66-30	12343-12351	utilized	_	
66-31	12352-12357	three	_	
66-32	12358-12366	balloons	_	
66-33	12367-12369	of	_	
66-34	12370-12379	different	_	
66-35	12380-12386	colors	_	
66-36	12386-12387	:	_	
66-37	12388-12392	blue	_	
66-38	12392-12393	,	_	
66-39	12394-12398	pink	_	
66-40	12398-12399	,	_	
66-41	12400-12403	and	_	
66-42	12404-12409	white	_	
66-43	12409-12410	.	_	

#Text=Blue balloons exploded after 5 pumps on average, pink balloons exploded after 8 pumps, and white balloons did not explode and were used as the control condition.
67-1	12411-12415	Blue	_	
67-2	12416-12424	balloons	_	
67-3	12425-12433	exploded	_	
67-4	12434-12439	after	_	
67-5	12440-12441	5	_	
67-6	12442-12447	pumps	_	
67-7	12448-12450	on	_	
67-8	12451-12458	average	_	
67-9	12458-12459	,	_	
67-10	12460-12464	pink	_	
67-11	12465-12473	balloons	_	
67-12	12474-12482	exploded	_	
67-13	12483-12488	after	_	
67-14	12489-12490	8	_	
67-15	12491-12496	pumps	_	
67-16	12496-12497	,	_	
67-17	12498-12501	and	_	
67-18	12502-12507	white	_	
67-19	12508-12516	balloons	_	
67-20	12517-12520	did	_	
67-21	12521-12524	not	_	
67-22	12525-12532	explode	_	
67-23	12533-12536	and	_	
67-24	12537-12541	were	_	
67-25	12542-12546	used	_	
67-26	12547-12549	as	_	
67-27	12550-12553	the	_	
67-28	12554-12561	control	_	
67-29	12562-12571	condition	_	
67-30	12571-12572	.	_	

#Text=Each balloon sequence began with a balloon on the screen.
68-1	12573-12577	Each	_	
68-2	12578-12585	balloon	_	
68-3	12586-12594	sequence	_	
68-4	12595-12600	began	_	
68-5	12601-12605	with	_	
68-6	12606-12607	a	_	
68-7	12608-12615	balloon	_	
68-8	12616-12618	on	_	
68-9	12619-12622	the	_	
68-10	12623-12629	screen	_	
68-11	12629-12630	.	_	

#Text=Participants were instructed to either pump or cashout by pressing a button with their index or middle finger, respectively.
69-1	12631-12643	Participants	_	
69-2	12644-12648	were	_	
69-3	12649-12659	instructed	_	
69-4	12660-12662	to	_	
69-5	12663-12669	either	_	
69-6	12670-12674	pump	_	
69-7	12675-12677	or	_	
69-8	12678-12685	cashout	_	
69-9	12686-12688	by	_	
69-10	12689-12697	pressing	_	
69-11	12698-12699	a	_	
69-12	12700-12706	button	_	
69-13	12707-12711	with	_	
69-14	12712-12717	their	_	
69-15	12718-12723	index	_	
69-16	12724-12726	or	_	
69-17	12727-12733	middle	_	
69-18	12734-12740	finger	_	
69-19	12740-12741	,	_	
69-20	12742-12754	respectively	_	
69-21	12754-12755	.	_	

#Text=For blue and pink balloons, participants were instructed to pump until an explosion occurred or they decided to cash-out.
70-1	12756-12759	For	_	
70-2	12760-12764	blue	_	
70-3	12765-12768	and	_	
70-4	12769-12773	pink	_	
70-5	12774-12782	balloons	_	
70-6	12782-12783	,	_	
70-7	12784-12796	participants	_	
70-8	12797-12801	were	_	
70-9	12802-12812	instructed	_	
70-10	12813-12815	to	_	
70-11	12816-12820	pump	_	
70-12	12821-12826	until	_	
70-13	12827-12829	an	_	
70-14	12830-12839	explosion	_	
70-15	12840-12848	occurred	_	
70-16	12849-12851	or	_	
70-17	12852-12856	they	_	
70-18	12857-12864	decided	_	
70-19	12865-12867	to	_	
70-20	12868-12876	cash-out	_	
70-21	12876-12877	.	_	

#Text=Each decision to pump the balloon resulted in inflation over 200 milliseconds (msec), time during which participants could not make another pump response.
71-1	12878-12882	Each	_	
71-2	12883-12891	decision	_	
71-3	12892-12894	to	_	
71-4	12895-12899	pump	_	
71-5	12900-12903	the	_	
71-6	12904-12911	balloon	_	
71-7	12912-12920	resulted	_	
71-8	12921-12923	in	_	
71-9	12924-12933	inflation	_	
71-10	12934-12938	over	_	
71-11	12939-12942	200	_	
71-12	12943-12955	milliseconds	_	
71-13	12956-12957	(	_	
71-14	12957-12961	msec	_	
71-15	12961-12962	)	_	
71-16	12962-12963	,	_	
71-17	12964-12968	time	_	
71-18	12969-12975	during	_	
71-19	12976-12981	which	_	
71-20	12982-12994	participants	_	
71-21	12995-13000	could	_	
71-22	13001-13004	not	_	
71-23	13005-13009	make	_	
71-24	13010-13017	another	_	
71-25	13018-13022	pump	_	
71-26	13023-13031	response	_	
71-27	13031-13032	.	_	

#Text=During the pump, an inflation sound was played, the same sound used in the original BART.
72-1	13033-13039	During	_	
72-2	13040-13043	the	_	
72-3	13044-13048	pump	_	
72-4	13048-13049	,	_	
72-5	13050-13052	an	_	
72-6	13053-13062	inflation	_	
72-7	13063-13068	sound	_	
72-8	13069-13072	was	_	
72-9	13073-13079	played	_	
72-10	13079-13080	,	_	
72-11	13081-13084	the	_	
72-12	13085-13089	same	_	
72-13	13090-13095	sound	_	
72-14	13096-13100	used	_	
72-15	13101-13103	in	_	
72-16	13104-13107	the	_	
72-17	13108-13116	original	_	
72-18	13117-13121	BART	http://maven.renci.org/NeuroBridge/neurobridge#BalloonAnalogueRiskTask	
72-19	13121-13122	.	_	

#Text=For each balloon, a predetermined number of pumps was selected from a Gaussian distribution with the average number of pumps as the mean and a standard deviation of one.
73-1	13123-13126	For	_	
73-2	13127-13131	each	_	
73-3	13132-13139	balloon	_	
73-4	13139-13140	,	_	
73-5	13141-13142	a	_	
73-6	13143-13156	predetermined	_	
73-7	13157-13163	number	_	
73-8	13164-13166	of	_	
73-9	13167-13172	pumps	_	
73-10	13173-13176	was	_	
73-11	13177-13185	selected	_	
73-12	13186-13190	from	_	
73-13	13191-13192	a	_	
73-14	13193-13201	Gaussian	_	
73-15	13202-13214	distribution	_	
73-16	13215-13219	with	_	
73-17	13220-13223	the	_	
73-18	13224-13231	average	_	
73-19	13232-13238	number	_	
73-20	13239-13241	of	_	
73-21	13242-13247	pumps	_	
73-22	13248-13250	as	_	
73-23	13251-13254	the	_	
73-24	13255-13259	mean	_	
73-25	13260-13263	and	_	
73-26	13264-13265	a	_	
73-27	13266-13274	standard	_	
73-28	13275-13284	deviation	_	
73-29	13285-13287	of	_	
73-30	13288-13291	one	_	
73-31	13291-13292	.	_	

#Text=The minimum number of pumps for each balloon was 2 for blue and 5 for pink, and the maximum number of pumps was 8 and 11.
74-1	13293-13296	The	_	
74-2	13297-13304	minimum	_	
74-3	13305-13311	number	_	
74-4	13312-13314	of	_	
74-5	13315-13320	pumps	_	
74-6	13321-13324	for	_	
74-7	13325-13329	each	_	
74-8	13330-13337	balloon	_	
74-9	13338-13341	was	_	
74-10	13342-13343	2	_	
74-11	13344-13347	for	_	
74-12	13348-13352	blue	_	
74-13	13353-13356	and	_	
74-14	13357-13358	5	_	
74-15	13359-13362	for	_	
74-16	13363-13367	pink	_	
74-17	13367-13368	,	_	
74-18	13369-13372	and	_	
74-19	13373-13376	the	_	
74-20	13377-13384	maximum	_	
74-21	13385-13391	number	_	
74-22	13392-13394	of	_	
74-23	13395-13400	pumps	_	
74-24	13401-13404	was	_	
74-25	13405-13406	8	_	
74-26	13407-13410	and	_	
74-27	13411-13413	11	_	
74-28	13413-13414	.	_	

#Text=On explosion trials (i.e. those trials in which the number of pumps met the threshold for explosion), the balloon expanded for 50 msec, exploded on the screen with an accompaying explosion sound, and participants lost all points accumulated for the current balloon.
75-1	13415-13417	On	_	
75-2	13418-13427	explosion	_	
75-3	13428-13434	trials	_	
75-4	13435-13436	(	_	
75-5	13436-13439	i.e	_	
75-6	13439-13440	.	_	
75-7	13441-13446	those	_	
75-8	13447-13453	trials	_	
75-9	13454-13456	in	_	
75-10	13457-13462	which	_	
75-11	13463-13466	the	_	
75-12	13467-13473	number	_	
75-13	13474-13476	of	_	
75-14	13477-13482	pumps	_	
75-15	13483-13486	met	_	
75-16	13487-13490	the	_	
75-17	13491-13500	threshold	_	
75-18	13501-13504	for	_	
75-19	13505-13514	explosion	_	
75-20	13514-13515	)	_	
75-21	13515-13516	,	_	
75-22	13517-13520	the	_	
75-23	13521-13528	balloon	_	
75-24	13529-13537	expanded	_	
75-25	13538-13541	for	_	
75-26	13542-13544	50	_	
75-27	13545-13549	msec	_	
75-28	13549-13550	,	_	
75-29	13551-13559	exploded	_	
75-30	13560-13562	on	_	
75-31	13563-13566	the	_	
75-32	13567-13573	screen	_	
75-33	13574-13578	with	_	
75-34	13579-13581	an	_	
75-35	13582-13593	accompaying	_	
75-36	13594-13603	explosion	_	
75-37	13604-13609	sound	_	
75-38	13609-13610	,	_	
75-39	13611-13614	and	_	
75-40	13615-13627	participants	_	
75-41	13628-13632	lost	_	
75-42	13633-13636	all	_	
75-43	13637-13643	points	_	
75-44	13644-13655	accumulated	_	
75-45	13656-13659	for	_	
75-46	13660-13663	the	_	
75-47	13664-13671	current	_	
75-48	13672-13679	balloon	_	
75-49	13679-13680	.	_	

#Text=At any time, participants were able to cashout instead of continuing to pump.
76-1	13681-13683	At	_	
76-2	13684-13687	any	_	
76-3	13688-13692	time	_	
76-4	13692-13693	,	_	
76-5	13694-13706	participants	_	
76-6	13707-13711	were	_	
76-7	13712-13716	able	_	
76-8	13717-13719	to	_	
76-9	13720-13727	cashout	_	
76-10	13728-13735	instead	_	
76-11	13736-13738	of	_	
76-12	13739-13749	continuing	_	
76-13	13750-13752	to	_	
76-14	13753-13757	pump	_	
76-15	13757-13758	.	_	

#Text=Cashout responses resulted in an accumulation of the points earned on that balloon while the intact balloon remained on the screen; participants heard the sound of coins falling into a bank while the total number of points earned increased on the screen.
77-1	13759-13766	Cashout	_	
77-2	13767-13776	responses	_	
77-3	13777-13785	resulted	_	
77-4	13786-13788	in	_	
77-5	13789-13791	an	_	
77-6	13792-13804	accumulation	_	
77-7	13805-13807	of	_	
77-8	13808-13811	the	_	
77-9	13812-13818	points	_	
77-10	13819-13825	earned	_	
77-11	13826-13828	on	_	
77-12	13829-13833	that	_	
77-13	13834-13841	balloon	_	
77-14	13842-13847	while	_	
77-15	13848-13851	the	_	
77-16	13852-13858	intact	_	
77-17	13859-13866	balloon	_	
77-18	13867-13875	remained	_	
77-19	13876-13878	on	_	
77-20	13879-13882	the	_	
77-21	13883-13889	screen	_	
77-22	13889-13890	;	_	
77-23	13891-13903	participants	_	
77-24	13904-13909	heard	_	
77-25	13910-13913	the	_	
77-26	13914-13919	sound	_	
77-27	13920-13922	of	_	
77-28	13923-13928	coins	_	
77-29	13929-13936	falling	_	
77-30	13937-13941	into	_	
77-31	13942-13943	a	_	
77-32	13944-13948	bank	_	
77-33	13949-13954	while	_	
77-34	13955-13958	the	_	
77-35	13959-13964	total	_	
77-36	13965-13971	number	_	
77-37	13972-13974	of	_	
77-38	13975-13981	points	_	
77-39	13982-13988	earned	_	
77-40	13989-13998	increased	_	
77-41	13999-14001	on	_	
77-42	14002-14005	the	_	
77-43	14006-14012	screen	_	
77-44	14012-14013	.	_	

#Text=Both explosion and cashout outcomes were displayed for 2 seconds.
78-1	14014-14018	Both	_	
78-2	14019-14028	explosion	_	
78-3	14029-14032	and	_	
78-4	14033-14040	cashout	_	
78-5	14041-14049	outcomes	_	
78-6	14050-14054	were	_	
78-7	14055-14064	displayed	_	
78-8	14065-14068	for	_	
78-9	14069-14070	2	_	
78-10	14071-14078	seconds	_	
78-11	14078-14079	.	_	

#Text=Between balloons, a blank screen appeared 2 to 16 seconds.
79-1	14080-14087	Between	_	
79-2	14088-14096	balloons	_	
79-3	14096-14097	,	_	
79-4	14098-14099	a	_	
79-5	14100-14105	blank	_	
79-6	14106-14112	screen	_	
79-7	14113-14121	appeared	_	
79-8	14122-14123	2	_	
79-9	14124-14126	to	_	
79-10	14127-14129	16	_	
79-11	14130-14137	seconds	_	
79-12	14137-14138	.	_	

#Text=The number of allowable pumps for the white balloons was chosen to approximately match the number of anticipated pumps for the blue and pink balloons, so had a similar range of potential pumps as that of the blue and pink balloons (i.e. 2 to 11 pumps).
80-1	14139-14142	The	_	
80-2	14143-14149	number	_	
80-3	14150-14152	of	_	
80-4	14153-14162	allowable	_	
80-5	14163-14168	pumps	_	
80-6	14169-14172	for	_	
80-7	14173-14176	the	_	
80-8	14177-14182	white	_	
80-9	14183-14191	balloons	_	
80-10	14192-14195	was	_	
80-11	14196-14202	chosen	_	
80-12	14203-14205	to	_	
80-13	14206-14219	approximately	_	
80-14	14220-14225	match	_	
80-15	14226-14229	the	_	
80-16	14230-14236	number	_	
80-17	14237-14239	of	_	
80-18	14240-14251	anticipated	_	
80-19	14252-14257	pumps	_	
80-20	14258-14261	for	_	
80-21	14262-14265	the	_	
80-22	14266-14270	blue	_	
80-23	14271-14274	and	_	
80-24	14275-14279	pink	_	
80-25	14280-14288	balloons	_	
80-26	14288-14289	,	_	
80-27	14290-14292	so	_	
80-28	14293-14296	had	_	
80-29	14297-14298	a	_	
80-30	14299-14306	similar	_	
80-31	14307-14312	range	_	
80-32	14313-14315	of	_	
80-33	14316-14325	potential	_	
80-34	14326-14331	pumps	_	
80-35	14332-14334	as	_	
80-36	14335-14339	that	_	
80-37	14340-14342	of	_	
80-38	14343-14346	the	_	
80-39	14347-14351	blue	_	
80-40	14352-14355	and	_	
80-41	14356-14360	pink	_	
80-42	14361-14369	balloons	_	
80-43	14370-14371	(	_	
80-44	14371-14374	i.e	_	
80-45	14374-14375	.	_	
80-46	14376-14377	2	_	
80-47	14378-14380	to	_	
80-48	14381-14383	11	_	
80-49	14384-14389	pumps	_	
80-50	14389-14390	)	_	
80-51	14390-14391	.	_	

#Text=Because there was no outcome, per se, for white balloons, participants were instructed to pump until the balloon disappeared from the screen.
81-1	14392-14399	Because	_	
81-2	14400-14405	there	_	
81-3	14406-14409	was	_	
81-4	14410-14412	no	_	
81-5	14413-14420	outcome	_	
81-6	14420-14421	,	_	
81-7	14422-14425	per	_	
81-8	14426-14428	se	_	
81-9	14428-14429	,	_	
81-10	14430-14433	for	_	
81-11	14434-14439	white	_	
81-12	14440-14448	balloons	_	
81-13	14448-14449	,	_	
81-14	14450-14462	participants	_	
81-15	14463-14467	were	_	
81-16	14468-14478	instructed	_	
81-17	14479-14481	to	_	
81-18	14482-14486	pump	_	
81-19	14487-14492	until	_	
81-20	14493-14496	the	_	
81-21	14497-14504	balloon	_	
81-22	14505-14516	disappeared	_	
81-23	14517-14521	from	_	
81-24	14522-14525	the	_	
81-25	14526-14532	screen	_	
81-26	14532-14533	.	_	

#Text=The sequence of balloon bursting values was pseudorandomized within the run, and was presented in the same order for all participants.
82-1	14534-14537	The	_	
82-2	14538-14546	sequence	_	
82-3	14547-14549	of	_	
82-4	14550-14557	balloon	_	
82-5	14558-14566	bursting	_	
82-6	14567-14573	values	_	
82-7	14574-14577	was	_	
82-8	14578-14594	pseudorandomized	_	
82-9	14595-14601	within	_	
82-10	14602-14605	the	_	
82-11	14606-14609	run	_	
82-12	14609-14610	,	_	
82-13	14611-14614	and	_	
82-14	14615-14618	was	_	
82-15	14619-14628	presented	_	
82-16	14629-14631	in	_	
82-17	14632-14635	the	_	
82-18	14636-14640	same	_	
82-19	14641-14646	order	_	
82-20	14647-14650	for	_	
82-21	14651-14654	all	_	
82-22	14655-14667	participants	_	
82-23	14667-14668	.	_	

#Text=Participants did not receive any extra incentives for better task performance (i.e. higher total number of points).
83-1	14669-14681	Participants	_	
83-2	14682-14685	did	_	
83-3	14686-14689	not	_	
83-4	14690-14697	receive	_	
83-5	14698-14701	any	_	
83-6	14702-14707	extra	_	
83-7	14708-14718	incentives	_	
83-8	14719-14722	for	_	
83-9	14723-14729	better	_	
83-10	14730-14734	task	_	
83-11	14735-14746	performance	_	
83-12	14747-14748	(	_	
83-13	14748-14751	i.e	_	
83-14	14751-14752	.	_	
83-15	14753-14759	higher	_	
83-16	14760-14765	total	_	
83-17	14766-14772	number	_	
83-18	14773-14775	of	_	
83-19	14776-14782	points	_	
83-20	14782-14783	)	_	
83-21	14783-14784	.	_	

#Text=MRI acquisition
#Text=MRI data was collected on a 3T Siemens Trio (Erlangen, Germany) whole body scanner.
84-1	14785-14788	MRI	_	
84-2	14789-14800	acquisition	_	
84-3	14801-14804	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
84-4	14805-14809	data	_	
84-5	14810-14813	was	_	
84-6	14814-14823	collected	_	
84-7	14824-14826	on	_	
84-8	14827-14828	a	_	
84-9	14829-14831	3T	_	
84-10	14832-14839	Siemens	_	
84-11	14840-14844	Trio	_	
84-12	14845-14846	(	_	
84-13	14846-14854	Erlangen	_	
84-14	14854-14855	,	_	
84-15	14856-14863	Germany	_	
84-16	14863-14864	)	_	
84-17	14865-14870	whole	_	
84-18	14871-14875	body	_	
84-19	14876-14883	scanner	_	
84-20	14883-14884	.	_	

#Text=An echo-planar gradient-echo pulse sequence (TR=2000ms, TE=29, flip angle=75°, 33 axial slices, 64×64 matrix, 3.75 × 3.75 mm2, 3.5 mm thickness, 1 mm gap) was acquired with a 12-channel head coil, and images were acquired parallel to the ventral surface of a participant’s orbitofrontal cortex to reduce signal dropout and distortion in this region.
85-1	14885-14887	An	_	
85-2	14888-14899	echo-planar	_	
85-3	14900-14913	gradient-echo	_	
85-4	14914-14919	pulse	_	
85-5	14920-14928	sequence	_	
85-6	14929-14930	(	_	
85-7	14930-14932	TR	_	
85-8	14932-14933	=	_	
85-9	14933-14939	2000ms	_	
85-10	14939-14940	,	_	
85-11	14941-14943	TE	_	
85-12	14943-14944	=	_	
85-13	14944-14946	29	_	
85-14	14946-14947	,	_	
85-15	14948-14952	flip	_	
85-16	14953-14958	angle	_	
85-17	14958-14959	=	_	
85-18	14959-14961	75	_	
85-19	14961-14962	°	_	
85-20	14962-14963	,	_	
85-21	14964-14966	33	_	
85-22	14967-14972	axial	_	
85-23	14973-14979	slices	_	
85-24	14979-14980	,	_	
85-25	14981-14983	64	_	
85-26	14983-14984	×	_	
85-27	14984-14986	64	_	
85-28	14987-14993	matrix	_	
85-29	14993-14994	,	_	
85-30	14995-14999	3.75	_	
85-31	15000-15001	×	_	
85-32	15002-15006	3.75	_	
85-33	15007-15010	mm2	_	
85-34	15010-15011	,	_	
85-35	15012-15015	3.5	_	
85-36	15016-15018	mm	_	
85-37	15019-15028	thickness	_	
85-38	15028-15029	,	_	
85-39	15030-15031	1	_	
85-40	15032-15034	mm	_	
85-41	15035-15038	gap	_	
85-42	15038-15039	)	_	
85-43	15040-15043	was	_	
85-44	15044-15052	acquired	_	
85-45	15053-15057	with	_	
85-46	15058-15059	a	_	
85-47	15060-15062	12	_	
85-48	15062-15063	-	_	
85-49	15063-15070	channel	_	
85-50	15071-15075	head	_	
85-51	15076-15080	coil	_	
85-52	15080-15081	,	_	
85-53	15082-15085	and	_	
85-54	15086-15092	images	_	
85-55	15093-15097	were	_	
85-56	15098-15106	acquired	_	
85-57	15107-15115	parallel	_	
85-58	15116-15118	to	_	
85-59	15119-15122	the	_	
85-60	15123-15130	ventral	_	
85-61	15131-15138	surface	_	
85-62	15139-15141	of	_	
85-63	15142-15143	a	_	
85-64	15144-15155	participant	_	
85-65	15155-15156	’	_	
85-66	15156-15157	s	_	
85-67	15158-15171	orbitofrontal	_	
85-68	15172-15178	cortex	_	
85-69	15179-15181	to	_	
85-70	15182-15188	reduce	_	
85-71	15189-15195	signal	_	
85-72	15196-15203	dropout	_	
85-73	15204-15207	and	_	
85-74	15208-15218	distortion	_	
85-75	15219-15221	in	_	
85-76	15222-15226	this	_	
85-77	15227-15233	region	_	
85-78	15233-15234	.	_	

#Text=Three hundred EPI volumes were acquired during the session.
86-1	15235-15240	Three	_	
86-2	15241-15248	hundred	_	
86-3	15249-15252	EPI	_	
86-4	15253-15260	volumes	_	
86-5	15261-15265	were	_	
86-6	15266-15274	acquired	_	
86-7	15275-15281	during	_	
86-8	15282-15285	the	_	
86-9	15286-15293	session	_	
86-10	15293-15294	.	_	

#Text=In addition, a high resolution T1-weighted MP-RAGE anatomical image was acquired (TR=2530ms, TE=1.64ms, flip angle=7°, 192 sagittal slices, 256×256 matrix, slice thickness = 1mm, no gap).
87-1	15295-15297	In	_	
87-2	15298-15306	addition	_	
87-3	15306-15307	,	_	
87-4	15308-15309	a	_	
87-5	15310-15314	high	_	
87-6	15315-15325	resolution	_	
87-7	15326-15328	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
87-8	15328-15329	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
87-9	15329-15337	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[32]	
87-10	15338-15345	MP-RAGE	_	
87-11	15346-15356	anatomical	_	
87-12	15357-15362	image	_	
87-13	15363-15366	was	_	
87-14	15367-15375	acquired	_	
87-15	15376-15377	(	_	
87-16	15377-15379	TR	_	
87-17	15379-15380	=	_	
87-18	15380-15386	2530ms	_	
87-19	15386-15387	,	_	
87-20	15388-15390	TE	_	
87-21	15390-15391	=	_	
87-22	15391-15397	1.64ms	_	
87-23	15397-15398	,	_	
87-24	15399-15403	flip	_	
87-25	15404-15409	angle	_	
87-26	15409-15410	=	_	
87-27	15410-15411	7	_	
87-28	15411-15412	°	_	
87-29	15412-15413	,	_	
87-30	15414-15417	192	_	
87-31	15418-15426	sagittal	_	
87-32	15427-15433	slices	_	
87-33	15433-15434	,	_	
87-34	15435-15438	256	_	
87-35	15438-15439	×	_	
87-36	15439-15442	256	_	
87-37	15443-15449	matrix	_	
87-38	15449-15450	,	_	
87-39	15451-15456	slice	_	
87-40	15457-15466	thickness	_	
87-41	15467-15468	=	_	
87-42	15469-15472	1mm	_	
87-43	15472-15473	,	_	
87-44	15474-15476	no	_	
87-45	15477-15480	gap	_	
87-46	15480-15481	)	_	
87-47	15481-15482	.	_	

#Text=Image Analysis
#Text=The first 3 volumes of each functional run were discarded to allow the magnet to reach steady state.
88-1	15483-15488	Image	_	
88-2	15489-15497	Analysis	_	
88-3	15498-15501	The	_	
88-4	15502-15507	first	_	
88-5	15508-15509	3	_	
88-6	15510-15517	volumes	_	
88-7	15518-15520	of	_	
88-8	15521-15525	each	_	
88-9	15526-15536	functional	_	
88-10	15537-15540	run	_	
88-11	15541-15545	were	_	
88-12	15546-15555	discarded	_	
88-13	15556-15558	to	_	
88-14	15559-15564	allow	_	
88-15	15565-15568	the	_	
88-16	15569-15575	magnet	_	
88-17	15576-15578	to	_	
88-18	15579-15584	reach	_	
88-19	15585-15591	steady	_	
88-20	15592-15597	state	_	
88-21	15597-15598	.	_	

#Text=MCFLIRT (Motion Correction using FMRIB’s Linear Image Registration Tool) was used to motion correct images within a run; each volume was aligned to the first volume within the run.
89-1	15599-15606	MCFLIRT	_	
89-2	15607-15608	(	_	
89-3	15608-15614	Motion	_	
89-4	15615-15625	Correction	_	
89-5	15626-15631	using	_	
89-6	15632-15637	FMRIB	_	
89-7	15637-15638	’	_	
89-8	15638-15639	s	_	
89-9	15640-15646	Linear	_	
89-10	15647-15652	Image	_	
89-11	15653-15665	Registration	_	
89-12	15666-15670	Tool	_	
89-13	15670-15671	)	_	
89-14	15672-15675	was	_	
89-15	15676-15680	used	_	
89-16	15681-15683	to	_	
89-17	15684-15690	motion	_	
89-18	15691-15698	correct	_	
89-19	15699-15705	images	_	
89-20	15706-15712	within	_	
89-21	15713-15714	a	_	
89-22	15715-15718	run	_	
89-23	15718-15719	;	_	
89-24	15720-15724	each	_	
89-25	15725-15731	volume	_	
89-26	15732-15735	was	_	
89-27	15736-15743	aligned	_	
89-28	15744-15746	to	_	
89-29	15747-15750	the	_	
89-30	15751-15756	first	_	
89-31	15757-15763	volume	_	
89-32	15764-15770	within	_	
89-33	15771-15774	the	_	
89-34	15775-15778	run	_	
89-35	15778-15779	.	_	

#Text=Mean relative framewise displacement was computed for each subject, and participants with a mean exceeding 0.5 mm were excluded from subsequent analyses.
90-1	15780-15784	Mean	_	
90-2	15785-15793	relative	_	
90-3	15794-15803	framewise	_	
90-4	15804-15816	displacement	_	
90-5	15817-15820	was	_	
90-6	15821-15829	computed	_	
90-7	15830-15833	for	_	
90-8	15834-15838	each	_	
90-9	15839-15846	subject	_	
90-10	15846-15847	,	_	
90-11	15848-15851	and	_	
90-12	15852-15864	participants	_	
90-13	15865-15869	with	_	
90-14	15870-15871	a	_	
90-15	15872-15876	mean	_	
90-16	15877-15886	exceeding	_	
90-17	15887-15890	0.5	_	
90-18	15891-15893	mm	_	
90-19	15894-15898	were	_	
90-20	15899-15907	excluded	_	
90-21	15908-15912	from	_	
90-22	15913-15923	subsequent	_	
90-23	15924-15932	analyses	_	
90-24	15932-15933	.	_	

#Text=Images were deskulled using BET (Brain Extraction Tool), spatially smoothed with a 5 mm full-width half-max Gaussian kernel, temporally filtered using a high-pass filter of 50 sec, and grand mean intensity normalized; all of these steps were performed using FMRIB’s Expert Analysis Tool (FEAT).
91-1	15934-15940	Images	_	
91-2	15941-15945	were	_	
91-3	15946-15955	deskulled	_	
91-4	15956-15961	using	_	
91-5	15962-15965	BET	_	
91-6	15966-15967	(	_	
91-7	15967-15972	Brain	_	
91-8	15973-15983	Extraction	_	
91-9	15984-15988	Tool	_	
91-10	15988-15989	)	_	
91-11	15989-15990	,	_	
91-12	15991-16000	spatially	_	
91-13	16001-16009	smoothed	_	
91-14	16010-16014	with	_	
91-15	16015-16016	a	_	
91-16	16017-16018	5	_	
91-17	16019-16021	mm	_	
91-18	16022-16032	full-width	_	
91-19	16033-16041	half-max	_	
91-20	16042-16050	Gaussian	_	
91-21	16051-16057	kernel	_	
91-22	16057-16058	,	_	
91-23	16059-16069	temporally	_	
91-24	16070-16078	filtered	_	
91-25	16079-16084	using	_	
91-26	16085-16086	a	_	
91-27	16087-16096	high-pass	_	
91-28	16097-16103	filter	_	
91-29	16104-16106	of	_	
91-30	16107-16109	50	_	
91-31	16110-16113	sec	_	
91-32	16113-16114	,	_	
91-33	16115-16118	and	_	
91-34	16119-16124	grand	_	
91-35	16125-16129	mean	_	
91-36	16130-16139	intensity	_	
91-37	16140-16150	normalized	_	
91-38	16150-16151	;	_	
91-39	16152-16155	all	_	
91-40	16156-16158	of	_	
91-41	16159-16164	these	_	
91-42	16165-16170	steps	_	
91-43	16171-16175	were	_	
91-44	16176-16185	performed	_	
91-45	16186-16191	using	_	
91-46	16192-16197	FMRIB	_	
91-47	16197-16198	’	_	
91-48	16198-16199	s	_	
91-49	16200-16206	Expert	_	
91-50	16207-16215	Analysis	_	
91-51	16216-16220	Tool	_	
91-52	16221-16222	(	_	
91-53	16222-16226	FEAT	_	
91-54	16226-16227	)	_	
91-55	16227-16228	.	_	

#Text=BART Analysis
#Text=Each sequence of pumps for a given balloon was modeled as a block (mean pump), with the block duration equal to the total amount of time from the onset of the balloon to the last decision to pump.
92-1	16229-16233	BART	_	
92-2	16234-16242	Analysis	_	
92-3	16243-16247	Each	_	
92-4	16248-16256	sequence	_	
92-5	16257-16259	of	_	
92-6	16260-16265	pumps	_	
92-7	16266-16269	for	_	
92-8	16270-16271	a	_	
92-9	16272-16277	given	_	
92-10	16278-16285	balloon	_	
92-11	16286-16289	was	_	
92-12	16290-16297	modeled	_	
92-13	16298-16300	as	_	
92-14	16301-16302	a	_	
92-15	16303-16308	block	_	
92-16	16309-16310	(	_	
92-17	16310-16314	mean	_	
92-18	16315-16319	pump	_	
92-19	16319-16320	)	_	
92-20	16320-16321	,	_	
92-21	16322-16326	with	_	
92-22	16327-16330	the	_	
92-23	16331-16336	block	_	
92-24	16337-16345	duration	_	
92-25	16346-16351	equal	_	
92-26	16352-16354	to	_	
92-27	16355-16358	the	_	
92-28	16359-16364	total	_	
92-29	16365-16371	amount	_	
92-30	16372-16374	of	_	
92-31	16375-16379	time	_	
92-32	16380-16384	from	_	
92-33	16385-16388	the	_	
92-34	16389-16394	onset	_	
92-35	16395-16397	of	_	
92-36	16398-16401	the	_	
92-37	16402-16409	balloon	_	
92-38	16410-16412	to	_	
92-39	16413-16416	the	_	
92-40	16417-16421	last	_	
92-41	16422-16430	decision	_	
92-42	16431-16433	to	_	
92-43	16434-16438	pump	_	
92-44	16438-16439	.	_	

#Text=In addition, a parametric modulation regressor was included for each balloon to model the total number of pumps for a given balloon, which represented the increased risk of explosion with increased number of pumps (linear pump); the duration of a given event in the linear pump regressor was equal to the duration used for the corresponding event in the mean pump regressor (see Figure 1 in for details).
93-1	16440-16442	In	_	
93-2	16443-16451	addition	_	
93-3	16451-16452	,	_	
93-4	16453-16454	a	_	
93-5	16455-16465	parametric	_	
93-6	16466-16476	modulation	_	
93-7	16477-16486	regressor	_	
93-8	16487-16490	was	_	
93-9	16491-16499	included	_	
93-10	16500-16503	for	_	
93-11	16504-16508	each	_	
93-12	16509-16516	balloon	_	
93-13	16517-16519	to	_	
93-14	16520-16525	model	_	
93-15	16526-16529	the	_	
93-16	16530-16535	total	_	
93-17	16536-16542	number	_	
93-18	16543-16545	of	_	
93-19	16546-16551	pumps	_	
93-20	16552-16555	for	_	
93-21	16556-16557	a	_	
93-22	16558-16563	given	_	
93-23	16564-16571	balloon	_	
93-24	16571-16572	,	_	
93-25	16573-16578	which	_	
93-26	16579-16590	represented	_	
93-27	16591-16594	the	_	
93-28	16595-16604	increased	_	
93-29	16605-16609	risk	_	
93-30	16610-16612	of	_	
93-31	16613-16622	explosion	_	
93-32	16623-16627	with	_	
93-33	16628-16637	increased	_	
93-34	16638-16644	number	_	
93-35	16645-16647	of	_	
93-36	16648-16653	pumps	_	
93-37	16654-16655	(	_	
93-38	16655-16661	linear	_	
93-39	16662-16666	pump	_	
93-40	16666-16667	)	_	
93-41	16667-16668	;	_	
93-42	16669-16672	the	_	
93-43	16673-16681	duration	_	
93-44	16682-16684	of	_	
93-45	16685-16686	a	_	
93-46	16687-16692	given	_	
93-47	16693-16698	event	_	
93-48	16699-16701	in	_	
93-49	16702-16705	the	_	
93-50	16706-16712	linear	_	
93-51	16713-16717	pump	_	
93-52	16718-16727	regressor	_	
93-53	16728-16731	was	_	
93-54	16732-16737	equal	_	
93-55	16738-16740	to	_	
93-56	16741-16744	the	_	
93-57	16745-16753	duration	_	
93-58	16754-16758	used	_	
93-59	16759-16762	for	_	
93-60	16763-16766	the	_	
93-61	16767-16780	corresponding	_	
93-62	16781-16786	event	_	
93-63	16787-16789	in	_	
93-64	16790-16793	the	_	
93-65	16794-16798	mean	_	
93-66	16799-16803	pump	_	
93-67	16804-16813	regressor	_	
93-68	16814-16815	(	_	
93-69	16815-16818	see	_	
93-70	16819-16825	Figure	_	
93-71	16826-16827	1	_	
93-72	16828-16830	in	_	
93-73	16831-16834	for	_	
93-74	16835-16842	details	_	
93-75	16842-16843	)	_	
93-76	16843-16844	.	_	

#Text=Thus, the assumed amplitude for the mean pump regressor was one, whereas the linear regressor had varying amplitudes according to the number of pumps on a given balloon sequence.
94-1	16845-16849	Thus	_	
94-2	16849-16850	,	_	
94-3	16851-16854	the	_	
94-4	16855-16862	assumed	_	
94-5	16863-16872	amplitude	_	
94-6	16873-16876	for	_	
94-7	16877-16880	the	_	
94-8	16881-16885	mean	_	
94-9	16886-16890	pump	_	
94-10	16891-16900	regressor	_	
94-11	16901-16904	was	_	
94-12	16905-16908	one	_	
94-13	16908-16909	,	_	
94-14	16910-16917	whereas	_	
94-15	16918-16921	the	_	
94-16	16922-16928	linear	_	
94-17	16929-16938	regressor	_	
94-18	16939-16942	had	_	
94-19	16943-16950	varying	_	
94-20	16951-16961	amplitudes	_	
94-21	16962-16971	according	_	
94-22	16972-16974	to	_	
94-23	16975-16978	the	_	
94-24	16979-16985	number	_	
94-25	16986-16988	of	_	
94-26	16989-16994	pumps	_	
94-27	16995-16997	on	_	
94-28	16998-16999	a	_	
94-29	17000-17005	given	_	
94-30	17006-17013	balloon	_	
94-31	17014-17022	sequence	_	
94-32	17022-17023	.	_	

#Text=Linear pump regressors were orthogonalized with respect to the mean pump regressor.
95-1	17024-17030	Linear	_	
95-2	17031-17035	pump	_	
95-3	17036-17046	regressors	_	
95-4	17047-17051	were	_	
95-5	17052-17066	orthogonalized	_	
95-6	17067-17071	with	_	
95-7	17072-17079	respect	_	
95-8	17080-17082	to	_	
95-9	17083-17086	the	_	
95-10	17087-17091	mean	_	
95-11	17092-17096	pump	_	
95-12	17097-17106	regressor	_	
95-13	17106-17107	.	_	

#Text=Note that while prior studies have used a constant duration for all pumps (e.g.), this strategy was implemented in an event-related design, where each pump is modeled separately.
96-1	17108-17112	Note	_	
96-2	17113-17117	that	_	
96-3	17118-17123	while	_	
96-4	17124-17129	prior	_	
96-5	17130-17137	studies	_	
96-6	17138-17142	have	_	
96-7	17143-17147	used	_	
96-8	17148-17149	a	_	
96-9	17150-17158	constant	_	
96-10	17159-17167	duration	_	
96-11	17168-17171	for	_	
96-12	17172-17175	all	_	
96-13	17176-17181	pumps	_	
96-14	17182-17183	(	_	
96-15	17183-17186	e.g	_	
96-16	17186-17187	.	_	
96-17	17187-17188	)	_	
96-18	17188-17189	,	_	
96-19	17190-17194	this	_	
96-20	17195-17203	strategy	_	
96-21	17204-17207	was	_	
96-22	17208-17219	implemented	_	
96-23	17220-17222	in	_	
96-24	17223-17225	an	_	
96-25	17226-17239	event-related	_	
96-26	17240-17246	design	_	
96-27	17246-17247	,	_	
96-28	17248-17253	where	_	
96-29	17254-17258	each	_	
96-30	17259-17263	pump	_	
96-31	17264-17266	is	_	
96-32	17267-17274	modeled	_	
96-33	17275-17285	separately	_	
96-34	17285-17286	.	_	

#Text=In the current analysis approach, the entire pumping sequence for a given balloon is modeled as a block, and depending on how many pumps were chosen, the block length may differ from balloon to balloon.
97-1	17287-17289	In	_	
97-2	17290-17293	the	_	
97-3	17294-17301	current	_	
97-4	17302-17310	analysis	_	
97-5	17311-17319	approach	_	
97-6	17319-17320	,	_	
97-7	17321-17324	the	_	
97-8	17325-17331	entire	_	
97-9	17332-17339	pumping	_	
97-10	17340-17348	sequence	_	
97-11	17349-17352	for	_	
97-12	17353-17354	a	_	
97-13	17355-17360	given	_	
97-14	17361-17368	balloon	_	
97-15	17369-17371	is	_	
97-16	17372-17379	modeled	_	
97-17	17380-17382	as	_	
97-18	17383-17384	a	_	
97-19	17385-17390	block	_	
97-20	17390-17391	,	_	
97-21	17392-17395	and	_	
97-22	17396-17405	depending	_	
97-23	17406-17408	on	_	
97-24	17409-17412	how	_	
97-25	17413-17417	many	_	
97-26	17418-17423	pumps	_	
97-27	17424-17428	were	_	
97-28	17429-17435	chosen	_	
97-29	17435-17436	,	_	
97-30	17437-17440	the	_	
97-31	17441-17446	block	_	
97-32	17447-17453	length	_	
97-33	17454-17457	may	_	
97-34	17458-17464	differ	_	
97-35	17465-17469	from	_	
97-36	17470-17477	balloon	_	
97-37	17478-17480	to	_	
97-38	17481-17488	balloon	_	
97-39	17488-17489	.	_	

#Text=While we considered choosing a mean block length as the duration as in, we decided against this strategy because this duration would encompass both the pump decisions as well as the outcome on some proportion of the balloons, thus leading to an incorrect model of the events that occurred throughout the task.
98-1	17490-17495	While	_	
98-2	17496-17498	we	_	
98-3	17499-17509	considered	_	
98-4	17510-17518	choosing	_	
98-5	17519-17520	a	_	
98-6	17521-17525	mean	_	
98-7	17526-17531	block	_	
98-8	17532-17538	length	_	
98-9	17539-17541	as	_	
98-10	17542-17545	the	_	
98-11	17546-17554	duration	_	
98-12	17555-17557	as	_	
98-13	17558-17560	in	_	
98-14	17560-17561	,	_	
98-15	17562-17564	we	_	
98-16	17565-17572	decided	_	
98-17	17573-17580	against	_	
98-18	17581-17585	this	_	
98-19	17586-17594	strategy	_	
98-20	17595-17602	because	_	
98-21	17603-17607	this	_	
98-22	17608-17616	duration	_	
98-23	17617-17622	would	_	
98-24	17623-17632	encompass	_	
98-25	17633-17637	both	_	
98-26	17638-17641	the	_	
98-27	17642-17646	pump	_	
98-28	17647-17656	decisions	_	
98-29	17657-17659	as	_	
98-30	17660-17664	well	_	
98-31	17665-17667	as	_	
98-32	17668-17671	the	_	
98-33	17672-17679	outcome	_	
98-34	17680-17682	on	_	
98-35	17683-17687	some	_	
98-36	17688-17698	proportion	_	
98-37	17699-17701	of	_	
98-38	17702-17705	the	_	
98-39	17706-17714	balloons	_	
98-40	17714-17715	,	_	
98-41	17716-17720	thus	_	
98-42	17721-17728	leading	_	
98-43	17729-17731	to	_	
98-44	17732-17734	an	_	
98-45	17735-17744	incorrect	_	
98-46	17745-17750	model	_	
98-47	17751-17753	of	_	
98-48	17754-17757	the	_	
98-49	17758-17764	events	_	
98-50	17765-17769	that	_	
98-51	17770-17778	occurred	_	
98-52	17779-17789	throughout	_	
98-53	17790-17793	the	_	
98-54	17794-17798	task	_	
98-55	17798-17799	.	_	

#Text=White balloons were modeled in the same manner as color balloons, with both a mean and linear regressor.
99-1	17800-17805	White	_	
99-2	17806-17814	balloons	_	
99-3	17815-17819	were	_	
99-4	17820-17827	modeled	_	
99-5	17828-17830	in	_	
99-6	17831-17834	the	_	
99-7	17835-17839	same	_	
99-8	17840-17846	manner	_	
99-9	17847-17849	as	_	
99-10	17850-17855	color	_	
99-11	17856-17864	balloons	_	
99-12	17864-17865	,	_	
99-13	17866-17870	with	_	
99-14	17871-17875	both	_	
99-15	17876-17877	a	_	
99-16	17878-17882	mean	_	
99-17	17883-17886	and	_	
99-18	17887-17893	linear	_	
99-19	17894-17903	regressor	_	
99-20	17903-17904	.	_	

#Text=For Explosions, the outcome was modeled separately from the decision phase despite the close temporal proximity of these events.
100-1	17905-17908	For	_	
100-2	17909-17919	Explosions	_	
100-3	17919-17920	,	_	
100-4	17921-17924	the	_	
100-5	17925-17932	outcome	_	
100-6	17933-17936	was	_	
100-7	17937-17944	modeled	_	
100-8	17945-17955	separately	_	
100-9	17956-17960	from	_	
100-10	17961-17964	the	_	
100-11	17965-17973	decision	_	
100-12	17974-17979	phase	_	
100-13	17980-17987	despite	_	
100-14	17988-17991	the	_	
100-15	17992-17997	close	_	
100-16	17998-18006	temporal	_	
100-17	18007-18016	proximity	_	
100-18	18017-18019	of	_	
100-19	18020-18025	these	_	
100-20	18026-18032	events	_	
100-21	18032-18033	.	_	

#Text=For Cashout responses (Cashout), we included the decision to cashout as well as the outcome phase of the trial.
101-1	18034-18037	For	_	
101-2	18038-18045	Cashout	_	
101-3	18046-18055	responses	_	
101-4	18056-18057	(	_	
101-5	18057-18064	Cashout	_	
101-6	18064-18065	)	_	
101-7	18065-18066	,	_	
101-8	18067-18069	we	_	
101-9	18070-18078	included	_	
101-10	18079-18082	the	_	
101-11	18083-18091	decision	_	
101-12	18092-18094	to	_	
101-13	18095-18102	cashout	_	
101-14	18103-18105	as	_	
101-15	18106-18110	well	_	
101-16	18111-18113	as	_	
101-17	18114-18117	the	_	
101-18	18118-18125	outcome	_	
101-19	18126-18131	phase	_	
101-20	18132-18134	of	_	
101-21	18135-18138	the	_	
101-22	18139-18144	trial	_	
101-23	18144-18145	.	_	

#Text=Because many participants only had one or two explosions for a particular balloon type, we did not examine group level statistics for cashouts or explosions, as this was an insufficient number of trials for a valid fMRI analysis.
102-1	18146-18153	Because	_	
102-2	18154-18158	many	_	
102-3	18159-18171	participants	_	
102-4	18172-18176	only	_	
102-5	18177-18180	had	_	
102-6	18181-18184	one	_	
102-7	18185-18187	or	_	
102-8	18188-18191	two	_	
102-9	18192-18202	explosions	_	
102-10	18203-18206	for	_	
102-11	18207-18208	a	_	
102-12	18209-18219	particular	_	
102-13	18220-18227	balloon	_	
102-14	18228-18232	type	_	
102-15	18232-18233	,	_	
102-16	18234-18236	we	_	
102-17	18237-18240	did	_	
102-18	18241-18244	not	_	
102-19	18245-18252	examine	_	
102-20	18253-18258	group	_	
102-21	18259-18264	level	_	
102-22	18265-18275	statistics	_	
102-23	18276-18279	for	_	
102-24	18280-18288	cashouts	_	
102-25	18289-18291	or	_	
102-26	18292-18302	explosions	_	
102-27	18302-18303	,	_	
102-28	18304-18306	as	_	
102-29	18307-18311	this	_	
102-30	18312-18315	was	_	
102-31	18316-18318	an	_	
102-32	18319-18331	insufficient	_	
102-33	18332-18338	number	_	
102-34	18339-18341	of	_	
102-35	18342-18348	trials	_	
102-36	18349-18352	for	_	
102-37	18353-18354	a	_	
102-38	18355-18360	valid	_	
102-39	18361-18365	fMRI	_	
102-40	18366-18374	analysis	_	
102-41	18374-18375	.	_	

#Text=Statistical analyses were performed using FMRIB’s Easy Analysis Tool (FEAT).
103-1	18376-18387	Statistical	_	
103-2	18388-18396	analyses	_	
103-3	18397-18401	were	_	
103-4	18402-18411	performed	_	
103-5	18412-18417	using	_	
103-6	18418-18423	FMRIB	_	
103-7	18423-18424	’	_	
103-8	18424-18425	s	_	
103-9	18426-18430	Easy	_	
103-10	18431-18439	Analysis	_	
103-11	18440-18444	Tool	_	
103-12	18445-18446	(	_	
103-13	18446-18450	FEAT	_	
103-14	18450-18451	)	_	
103-15	18451-18452	.	_	

#Text=Timing files were convolved with a double gamma hemodynamic response function and entered into a multiple regression along with first-order movement parameters.
104-1	18453-18459	Timing	_	
104-2	18460-18465	files	_	
104-3	18466-18470	were	_	
104-4	18471-18480	convolved	_	
104-5	18481-18485	with	_	
104-6	18486-18487	a	_	
104-7	18488-18494	double	_	
104-8	18495-18500	gamma	_	
104-9	18501-18512	hemodynamic	_	
104-10	18513-18521	response	_	
104-11	18522-18530	function	_	
104-12	18531-18534	and	_	
104-13	18535-18542	entered	_	
104-14	18543-18547	into	_	
104-15	18548-18549	a	_	
104-16	18550-18558	multiple	_	
104-17	18559-18569	regression	_	
104-18	18570-18575	along	_	
104-19	18576-18580	with	_	
104-20	18581-18592	first-order	_	
104-21	18593-18601	movement	_	
104-22	18602-18612	parameters	_	
104-23	18612-18613	.	_	

#Text=Analyses were conducted using FMRIB’s Improved Linear Model (FILM) with local autocorrelation estimation.
105-1	18614-18622	Analyses	_	
105-2	18623-18627	were	_	
105-3	18628-18637	conducted	_	
105-4	18638-18643	using	_	
105-5	18644-18649	FMRIB	_	
105-6	18649-18650	’	_	
105-7	18650-18651	s	_	
105-8	18652-18660	Improved	_	
105-9	18661-18667	Linear	_	
105-10	18668-18673	Model	_	
105-11	18674-18675	(	_	
105-12	18675-18679	FILM	_	
105-13	18679-18680	)	_	
105-14	18681-18685	with	_	
105-15	18686-18691	local	_	
105-16	18692-18707	autocorrelation	_	
105-17	18708-18718	estimation	_	
105-18	18718-18719	.	_	

#Text=Parameter estimates for each condition were combined to generate our primary contrasts: Mean Color vs.
106-1	18720-18729	Parameter	_	
106-2	18730-18739	estimates	_	
106-3	18740-18743	for	_	
106-4	18744-18748	each	_	
106-5	18749-18758	condition	_	
106-6	18759-18763	were	_	
106-7	18764-18772	combined	_	
106-8	18773-18775	to	_	
106-9	18776-18784	generate	_	
106-10	18785-18788	our	_	
106-11	18789-18796	primary	_	
106-12	18797-18806	contrasts	_	
106-13	18806-18807	:	_	
106-14	18808-18812	Mean	_	
106-15	18813-18818	Color	_	
106-16	18819-18821	vs	_	
106-17	18821-18822	.	_	

#Text=Mean White (mean risk) and Linear Color vs.
107-1	18823-18827	Mean	_	
107-2	18828-18833	White	_	
107-3	18834-18835	(	_	
107-4	18835-18839	mean	_	
107-5	18840-18844	risk	_	
107-6	18844-18845	)	_	
107-7	18846-18849	and	_	
107-8	18850-18856	Linear	_	
107-9	18857-18862	Color	_	
107-10	18863-18865	vs	_	
107-11	18865-18866	.	_	

#Text=Linear White (linear risk).
108-1	18867-18873	Linear	_	
108-2	18874-18879	White	_	
108-3	18880-18881	(	_	
108-4	18881-18887	linear	_	
108-5	18888-18892	risk	_	
108-6	18892-18893	)	_	
108-7	18893-18894	.	_	

#Text=The mean risk contrast modeled the mean level of response for risky versus riskless decisions across all balloons, whereas the linear risk contrast modeled the difference in partial correlations between BOLD response and number of pumps during risky and riskless choices.
109-1	18895-18898	The	_	
109-2	18899-18903	mean	_	
109-3	18904-18908	risk	_	
109-4	18909-18917	contrast	_	
109-5	18918-18925	modeled	_	
109-6	18926-18929	the	_	
109-7	18930-18934	mean	_	
109-8	18935-18940	level	_	
109-9	18941-18943	of	_	
109-10	18944-18952	response	_	
109-11	18953-18956	for	_	
109-12	18957-18962	risky	_	
109-13	18963-18969	versus	_	
109-14	18970-18978	riskless	_	
109-15	18979-18988	decisions	_	
109-16	18989-18995	across	_	
109-17	18996-18999	all	_	
109-18	19000-19008	balloons	_	
109-19	19008-19009	,	_	
109-20	19010-19017	whereas	_	
109-21	19018-19021	the	_	
109-22	19022-19028	linear	_	
109-23	19029-19033	risk	_	
109-24	19034-19042	contrast	_	
109-25	19043-19050	modeled	_	
109-26	19051-19054	the	_	
109-27	19055-19065	difference	_	
109-28	19066-19068	in	_	
109-29	19069-19076	partial	_	
109-30	19077-19089	correlations	_	
109-31	19090-19097	between	_	
109-32	19098-19102	BOLD	_	
109-33	19103-19111	response	_	
109-34	19112-19115	and	_	
109-35	19116-19122	number	_	
109-36	19123-19125	of	_	
109-37	19126-19131	pumps	_	
109-38	19132-19138	during	_	
109-39	19139-19144	risky	_	
109-40	19145-19148	and	_	
109-41	19149-19157	riskless	_	
109-42	19158-19165	choices	_	
109-43	19165-19166	.	_	

#Text=Contrast maps were registered to the participant’s high-resolution anatomical image and the MNI 152 brain template using FMRIB’s Linear Image Registration Tool (FLIRT).
110-1	19167-19175	Contrast	_	
110-2	19176-19180	maps	_	
110-3	19181-19185	were	_	
110-4	19186-19196	registered	_	
110-5	19197-19199	to	_	
110-6	19200-19203	the	_	
110-7	19204-19215	participant	_	
110-8	19215-19216	’	_	
110-9	19216-19217	s	_	
110-10	19218-19233	high-resolution	_	
110-11	19234-19244	anatomical	_	
110-12	19245-19250	image	_	
110-13	19251-19254	and	_	
110-14	19255-19258	the	_	
110-15	19259-19262	MNI	_	
110-16	19263-19266	152	_	
110-17	19267-19272	brain	_	
110-18	19273-19281	template	_	
110-19	19282-19287	using	_	
110-20	19288-19293	FMRIB	_	
110-21	19293-19294	’	_	
110-22	19294-19295	s	_	
110-23	19296-19302	Linear	_	
110-24	19303-19308	Image	_	
110-25	19309-19321	Registration	_	
110-26	19322-19326	Tool	_	
110-27	19327-19328	(	_	
110-28	19328-19333	FLIRT	_	
110-29	19333-19334	)	_	
110-30	19334-19335	.	_	

#Text=Group analysis
#Text=Group analyses were conducted using FMRIB’s Local Analysis of Mixed Effects (FLAME) Stage 1.
111-1	19336-19341	Group	_	
111-2	19342-19350	analysis	_	
111-3	19351-19356	Group	_	
111-4	19357-19365	analyses	_	
111-5	19366-19370	were	_	
111-6	19371-19380	conducted	_	
111-7	19381-19386	using	_	
111-8	19387-19392	FMRIB	_	
111-9	19392-19393	’	_	
111-10	19393-19394	s	_	
111-11	19395-19400	Local	_	
111-12	19401-19409	Analysis	_	
111-13	19410-19412	of	_	
111-14	19413-19418	Mixed	_	
111-15	19419-19426	Effects	_	
111-16	19427-19428	(	_	
111-17	19428-19433	FLAME	_	
111-18	19433-19434	)	_	
111-19	19435-19440	Stage	_	
111-20	19441-19442	1	_	
111-21	19442-19443	.	_	

#Text=Analyses were corrected for multiple comparisons using cluster-based correction in FSL (; voxel z > 2.3, cluster p < .025); a cluster level significance of p < .025 was used to account for the fact that we tested two separate contrasts.
112-1	19444-19452	Analyses	_	
112-2	19453-19457	were	_	
112-3	19458-19467	corrected	_	
112-4	19468-19471	for	_	
112-5	19472-19480	multiple	_	
112-6	19481-19492	comparisons	_	
112-7	19493-19498	using	_	
112-8	19499-19512	cluster-based	_	
112-9	19513-19523	correction	_	
112-10	19524-19526	in	_	
112-11	19527-19530	FSL	_	
112-12	19531-19532	(	_	
112-13	19532-19533	;	_	
112-14	19534-19539	voxel	_	
112-15	19540-19541	z	_	
112-16	19542-19543	>	_	
112-17	19544-19547	2.3	_	
112-18	19547-19548	,	_	
112-19	19549-19556	cluster	_	
112-20	19557-19558	p	_	
112-21	19559-19560	<	_	
112-22	19561-19565	.025	_	
112-23	19565-19566	)	_	
112-24	19566-19567	;	_	
112-25	19568-19569	a	_	
112-26	19570-19577	cluster	_	
112-27	19578-19583	level	_	
112-28	19584-19596	significance	_	
112-29	19597-19599	of	_	
112-30	19600-19601	p	_	
112-31	19602-19603	<	_	
112-32	19604-19608	.025	_	
112-33	19609-19612	was	_	
112-34	19613-19617	used	_	
112-35	19618-19620	to	_	
112-36	19621-19628	account	_	
112-37	19629-19632	for	_	
112-38	19633-19636	the	_	
112-39	19637-19641	fact	_	
112-40	19642-19646	that	_	
112-41	19647-19649	we	_	
112-42	19650-19656	tested	_	
112-43	19657-19660	two	_	
112-44	19661-19669	separate	_	
112-45	19670-19679	contrasts	_	
112-46	19679-19680	.	_	

#Text=A voxel level significance of z > 2.3 has been shown to sufficiently control false positives in event related designs when using FSL’s FLAME 1 for group level inference (Eklund et al., 2016).
113-1	19681-19682	A	_	
113-2	19683-19688	voxel	_	
113-3	19689-19694	level	_	
113-4	19695-19707	significance	_	
113-5	19708-19710	of	_	
113-6	19711-19712	z	_	
113-7	19713-19714	>	_	
113-8	19715-19718	2.3	_	
113-9	19719-19722	has	_	
113-10	19723-19727	been	_	
113-11	19728-19733	shown	_	
113-12	19734-19736	to	_	
113-13	19737-19749	sufficiently	_	
113-14	19750-19757	control	_	
113-15	19758-19763	false	_	
113-16	19764-19773	positives	_	
113-17	19774-19776	in	_	
113-18	19777-19782	event	_	
113-19	19783-19790	related	_	
113-20	19791-19798	designs	_	
113-21	19799-19803	when	_	
113-22	19804-19809	using	_	
113-23	19810-19813	FSL	_	
113-24	19813-19814	’	_	
113-25	19814-19815	s	_	
113-26	19816-19821	FLAME	_	
113-27	19822-19823	1	_	
113-28	19824-19827	for	_	
113-29	19828-19833	group	_	
113-30	19834-19839	level	_	
113-31	19840-19849	inference	_	
113-32	19850-19851	(	_	
113-33	19851-19857	Eklund	_	
113-34	19858-19860	et	_	
113-35	19861-19863	al	_	
113-36	19863-19864	.	_	
113-37	19864-19865	,	_	
113-38	19866-19870	2016	_	
113-39	19870-19871	)	_	
113-40	19871-19872	.	_	

#Text=Group differences were assessed using a one-way ANOVA with group (Controls, Primary Marijuana, Primary Alcohol, Primary Alcohol and Marijauna) as the between subjects factor.
114-1	19873-19878	Group	_	
114-2	19879-19890	differences	_	
114-3	19891-19895	were	_	
114-4	19896-19904	assessed	_	
114-5	19905-19910	using	_	
114-6	19911-19912	a	_	
114-7	19913-19920	one-way	_	
114-8	19921-19926	ANOVA	_	
114-9	19927-19931	with	_	
114-10	19932-19937	group	_	
114-11	19938-19939	(	_	
114-12	19939-19947	Controls	_	
114-13	19947-19948	,	_	
114-14	19949-19956	Primary	_	
114-15	19957-19966	Marijuana	_	
114-16	19966-19967	,	_	
114-17	19968-19975	Primary	_	
114-18	19976-19983	Alcohol	_	
114-19	19983-19984	,	_	
114-20	19985-19992	Primary	_	
114-21	19993-20000	Alcohol	_	
114-22	20001-20004	and	_	
114-23	20005-20014	Marijauna	_	
114-24	20014-20015	)	_	
114-25	20016-20018	as	_	
114-26	20019-20022	the	_	
114-27	20023-20030	between	_	
114-28	20031-20039	subjects	_	
114-29	20040-20046	factor	_	
114-30	20046-20047	.	_	

#Text=Regions showing significance in the omnibus test were further interrogated using pairwise Tukey tests.
115-1	20048-20055	Regions	_	
115-2	20056-20063	showing	_	
115-3	20064-20076	significance	_	
115-4	20077-20079	in	_	
115-5	20080-20083	the	_	
115-6	20084-20091	omnibus	_	
115-7	20092-20096	test	_	
115-8	20097-20101	were	_	
115-9	20102-20109	further	_	
115-10	20110-20122	interrogated	_	
115-11	20123-20128	using	_	
115-12	20129-20137	pairwise	_	
115-13	20138-20143	Tukey	_	
115-14	20144-20149	tests	_	
115-15	20149-20150	.	_	

#Text=In addition, we conducted one-way ANCOVAs that controlled for potential confounding factors such as hard drug use, gender, anxiety, depression, ADHD, impulsivity, and externalizing.
116-1	20151-20153	In	_	
116-2	20154-20162	addition	_	
116-3	20162-20163	,	_	
116-4	20164-20166	we	_	
116-5	20167-20176	conducted	_	
116-6	20177-20184	one-way	_	
116-7	20185-20192	ANCOVAs	_	
116-8	20193-20197	that	_	
116-9	20198-20208	controlled	_	
116-10	20209-20212	for	_	
116-11	20213-20222	potential	_	
116-12	20223-20234	confounding	_	
116-13	20235-20242	factors	_	
116-14	20243-20247	such	_	
116-15	20248-20250	as	_	
116-16	20251-20255	hard	_	
116-17	20256-20260	drug	_	
116-18	20261-20264	use	_	
116-19	20264-20265	,	_	
116-20	20266-20272	gender	_	
116-21	20272-20273	,	_	
116-22	20274-20281	anxiety	_	
116-23	20281-20282	,	_	
116-24	20283-20293	depression	_	
116-25	20293-20294	,	_	
116-26	20295-20299	ADHD	_	
116-27	20299-20300	,	_	
116-28	20301-20312	impulsivity	_	
116-29	20312-20313	,	_	
116-30	20314-20317	and	_	
116-31	20318-20331	externalizing	_	
116-32	20331-20332	.	_	

#Text=Because these follow-up analyses were intended to rule out potential confounding variables, we did not require a cluster level significance that was more stringent than the level used in the primary analyses (i.e., cluster p < .025).
117-1	20333-20340	Because	_	
117-2	20341-20346	these	_	
117-3	20347-20356	follow-up	_	
117-4	20357-20365	analyses	_	
117-5	20366-20370	were	_	
117-6	20371-20379	intended	_	
117-7	20380-20382	to	_	
117-8	20383-20387	rule	_	
117-9	20388-20391	out	_	
117-10	20392-20401	potential	_	
117-11	20402-20413	confounding	_	
117-12	20414-20423	variables	_	
117-13	20423-20424	,	_	
117-14	20425-20427	we	_	
117-15	20428-20431	did	_	
117-16	20432-20435	not	_	
117-17	20436-20443	require	_	
117-18	20444-20445	a	_	
117-19	20446-20453	cluster	_	
117-20	20454-20459	level	_	
117-21	20460-20472	significance	_	
117-22	20473-20477	that	_	
117-23	20478-20481	was	_	
117-24	20482-20486	more	_	
117-25	20487-20496	stringent	_	
117-26	20497-20501	than	_	
117-27	20502-20505	the	_	
117-28	20506-20511	level	_	
117-29	20512-20516	used	_	
117-30	20517-20519	in	_	
117-31	20520-20523	the	_	
117-32	20524-20531	primary	_	
117-33	20532-20540	analyses	_	
117-34	20541-20542	(	_	
117-35	20542-20545	i.e	_	
117-36	20545-20546	.	_	
117-37	20546-20547	,	_	
117-38	20548-20555	cluster	_	
117-39	20556-20557	p	_	
117-40	20558-20559	<	_	
117-41	20560-20564	.025	_	
117-42	20564-20565	)	_	
117-43	20565-20566	.	_	

#Text=In addition to between group analyses on the main contrasts of interest, we also examined the correlation between each contrast of interest and the total number of adjusted average pumps to examine how neural response related to behavioral risk taking.
118-1	20567-20569	In	_	
118-2	20570-20578	addition	_	
118-3	20579-20581	to	_	
118-4	20582-20589	between	_	
118-5	20590-20595	group	_	
118-6	20596-20604	analyses	_	
118-7	20605-20607	on	_	
118-8	20608-20611	the	_	
118-9	20612-20616	main	_	
118-10	20617-20626	contrasts	_	
118-11	20627-20629	of	_	
118-12	20630-20638	interest	_	
118-13	20638-20639	,	_	
118-14	20640-20642	we	_	
118-15	20643-20647	also	_	
118-16	20648-20656	examined	_	
118-17	20657-20660	the	_	
118-18	20661-20672	correlation	_	
118-19	20673-20680	between	_	
118-20	20681-20685	each	_	
118-21	20686-20694	contrast	_	
118-22	20695-20697	of	_	
118-23	20698-20706	interest	_	
118-24	20707-20710	and	_	
118-25	20711-20714	the	_	
118-26	20715-20720	total	_	
118-27	20721-20727	number	_	
118-28	20728-20730	of	_	
118-29	20731-20739	adjusted	_	
118-30	20740-20747	average	_	
118-31	20748-20753	pumps	_	
118-32	20754-20756	to	_	
118-33	20757-20764	examine	_	
118-34	20765-20768	how	_	
118-35	20769-20775	neural	_	
118-36	20776-20784	response	_	
118-37	20785-20792	related	_	
118-38	20793-20795	to	_	
118-39	20796-20806	behavioral	_	
118-40	20807-20811	risk	_	
118-41	20812-20818	taking	_	
118-42	20818-20819	.	_	

#Text=We examined these correlations across all participants as well as in analysis that examined how the relationship between BOLD response and adjusted average pumps differed by group.
119-1	20820-20822	We	_	
119-2	20823-20831	examined	_	
119-3	20832-20837	these	_	
119-4	20838-20850	correlations	_	
119-5	20851-20857	across	_	
119-6	20858-20861	all	_	
119-7	20862-20874	participants	_	
119-8	20875-20877	as	_	
119-9	20878-20882	well	_	
119-10	20883-20885	as	_	
119-11	20886-20888	in	_	
119-12	20889-20897	analysis	_	
119-13	20898-20902	that	_	
119-14	20903-20911	examined	_	
119-15	20912-20915	how	_	
119-16	20916-20919	the	_	
119-17	20920-20932	relationship	_	
119-18	20933-20940	between	_	
119-19	20941-20945	BOLD	_	
119-20	20946-20954	response	_	
119-21	20955-20958	and	_	
119-22	20959-20967	adjusted	_	
119-23	20968-20975	average	_	
119-24	20976-20981	pumps	_	
119-25	20982-20990	differed	_	
119-26	20991-20993	by	_	
119-27	20994-20999	group	_	
119-28	20999-21000	.	_	

#Text=Results
#Text=Demographics/Behavior
#Text=All effects reported below include 189 partipants; seven participants were dropped because of in-scanner movement (mean framewise displacement > 0.5 mm).
120-1	21001-21008	Results	_	
120-2	21009-21021	Demographics	_	
120-3	21021-21022	/	_	
120-4	21022-21030	Behavior	_	
120-5	21031-21034	All	_	
120-6	21035-21042	effects	_	
120-7	21043-21051	reported	_	
120-8	21052-21057	below	_	
120-9	21058-21065	include	_	
120-10	21066-21069	189	_	
120-11	21070-21080	partipants	_	
120-12	21080-21081	;	_	
120-13	21082-21087	seven	_	
120-14	21088-21100	participants	_	
120-15	21101-21105	were	_	
120-16	21106-21113	dropped	_	
120-17	21114-21121	because	_	
120-18	21122-21124	of	_	
120-19	21125-21135	in-scanner	_	
120-20	21136-21144	movement	_	
120-21	21145-21146	(	_	
120-22	21146-21150	mean	_	
120-23	21151-21160	framewise	_	
120-24	21161-21173	displacement	_	
120-25	21174-21175	>	_	
120-26	21176-21179	0.5	_	
120-27	21180-21182	mm	_	
120-28	21182-21183	)	_	
120-29	21183-21184	.	_	

#Text=Demographics and performance on the BART for each group from the final sample of 189 participants included in the analyses are presented in Table 1.
121-1	21185-21197	Demographics	_	
121-2	21198-21201	and	_	
121-3	21202-21213	performance	_	
121-4	21214-21216	on	_	
121-5	21217-21220	the	_	
121-6	21221-21225	BART	_	
121-7	21226-21229	for	_	
121-8	21230-21234	each	_	
121-9	21235-21240	group	_	
121-10	21241-21245	from	_	
121-11	21246-21249	the	_	
121-12	21250-21255	final	_	
121-13	21256-21262	sample	_	
121-14	21263-21265	of	_	
121-15	21266-21269	189	_	
121-16	21270-21282	participants	_	
121-17	21283-21291	included	_	
121-18	21292-21294	in	_	
121-19	21295-21298	the	_	
121-20	21299-21307	analyses	_	
121-21	21308-21311	are	_	
121-22	21312-21321	presented	_	
121-23	21322-21324	in	_	
121-24	21325-21330	Table	_	
121-25	21331-21332	1	_	
121-26	21332-21333	.	_	

#Text=Youth had been involved in the juvenile justice system for low-level status offenses primarily including assault or fighting (47.1%), burglary (23.5%), and possession of a controlled substance (22.1%).
122-1	21334-21339	Youth	_	
122-2	21340-21343	had	_	
122-3	21344-21348	been	_	
122-4	21349-21357	involved	_	
122-5	21358-21360	in	_	
122-6	21361-21364	the	_	
122-7	21365-21373	juvenile	_	
122-8	21374-21381	justice	_	
122-9	21382-21388	system	_	
122-10	21389-21392	for	_	
122-11	21393-21402	low-level	_	
122-12	21403-21409	status	_	
122-13	21410-21418	offenses	_	
122-14	21419-21428	primarily	_	
122-15	21429-21438	including	_	
122-16	21439-21446	assault	_	
122-17	21447-21449	or	_	
122-18	21450-21458	fighting	_	
122-19	21459-21460	(	_	
122-20	21460-21465	47.1%	_	
122-21	21465-21466	)	_	
122-22	21466-21467	,	_	
122-23	21468-21476	burglary	_	
122-24	21477-21478	(	_	
122-25	21478-21483	23.5%	_	
122-26	21483-21484	)	_	
122-27	21484-21485	,	_	
122-28	21486-21489	and	_	
122-29	21490-21500	possession	_	
122-30	21501-21503	of	_	
122-31	21504-21505	a	_	
122-32	21506-21516	controlled	_	
122-33	21517-21526	substance	_	
122-34	21527-21528	(	_	
122-35	21528-21533	22.1%	_	
122-36	21533-21534	)	_	
122-37	21534-21535	.	_	

#Text=The groups differed in the number of other drugs used (lifetime: F(3, 185) = 7.44, p < .001; last 3 months: F(3, 185) = 7.97, p < .001), with the alcohol and marijuana group reporting greater use than the other groups.
123-1	21536-21539	The	_	
123-2	21540-21546	groups	_	
123-3	21547-21555	differed	_	
123-4	21556-21558	in	_	
123-5	21559-21562	the	_	
123-6	21563-21569	number	_	
123-7	21570-21572	of	_	
123-8	21573-21578	other	_	
123-9	21579-21584	drugs	_	
123-10	21585-21589	used	_	
123-11	21590-21591	(	_	
123-12	21591-21599	lifetime	_	
123-13	21599-21600	:	_	
123-14	21601-21602	F	_	
123-15	21602-21603	(	_	
123-16	21603-21604	3	_	
123-17	21604-21605	,	_	
123-18	21606-21609	185	_	
123-19	21609-21610	)	_	
123-20	21611-21612	=	_	
123-21	21613-21617	7.44	_	
123-22	21617-21618	,	_	
123-23	21619-21620	p	_	
123-24	21621-21622	<	_	
123-25	21623-21627	.001	_	
123-26	21627-21628	;	_	
123-27	21629-21633	last	_	
123-28	21634-21635	3	_	
123-29	21636-21642	months	_	
123-30	21642-21643	:	_	
123-31	21644-21645	F	_	
123-32	21645-21646	(	_	
123-33	21646-21647	3	_	
123-34	21647-21648	,	_	
123-35	21649-21652	185	_	
123-36	21652-21653	)	_	
123-37	21654-21655	=	_	
123-38	21656-21660	7.97	_	
123-39	21660-21661	,	_	
123-40	21662-21663	p	_	
123-41	21664-21665	<	_	
123-42	21666-21670	.001	_	
123-43	21670-21671	)	_	
123-44	21671-21672	,	_	
123-45	21673-21677	with	_	
123-46	21678-21681	the	_	
123-47	21682-21689	alcohol	_	
123-48	21690-21693	and	_	
123-49	21694-21703	marijuana	_	
123-50	21704-21709	group	_	
123-51	21710-21719	reporting	_	
123-52	21720-21727	greater	_	
123-53	21728-21731	use	_	
123-54	21732-21736	than	_	
123-55	21737-21740	the	_	
123-56	21741-21746	other	_	
123-57	21747-21753	groups	_	
123-58	21753-21754	.	_	

#Text=There were also significant differences in the proportion of males (χ2=19.94, p < .001) and proportion of smokers (χ2=8.97, p < .05) across the four groups, with the alcohol and marijuana group containing more males and smokers than the control group.
124-1	21755-21760	There	_	
124-2	21761-21765	were	_	
124-3	21766-21770	also	_	
124-4	21771-21782	significant	_	
124-5	21783-21794	differences	_	
124-6	21795-21797	in	_	
124-7	21798-21801	the	_	
124-8	21802-21812	proportion	_	
124-9	21813-21815	of	_	
124-10	21816-21821	males	_	
124-11	21822-21823	(	_	
124-12	21823-21825	χ2	_	
124-13	21825-21826	=	_	
124-14	21826-21831	19.94	_	
124-15	21831-21832	,	_	
124-16	21833-21834	p	_	
124-17	21835-21836	<	_	
124-18	21837-21841	.001	_	
124-19	21841-21842	)	_	
124-20	21843-21846	and	_	
124-21	21847-21857	proportion	_	
124-22	21858-21860	of	_	
124-23	21861-21868	smokers	_	
124-24	21869-21870	(	_	
124-25	21870-21872	χ2	_	
124-26	21872-21873	=	_	
124-27	21873-21877	8.97	_	
124-28	21877-21878	,	_	
124-29	21879-21880	p	_	
124-30	21881-21882	<	_	
124-31	21883-21886	.05	_	
124-32	21886-21887	)	_	
124-33	21888-21894	across	_	
124-34	21895-21898	the	_	
124-35	21899-21903	four	_	
124-36	21904-21910	groups	_	
124-37	21910-21911	,	_	
124-38	21912-21916	with	_	
124-39	21917-21920	the	_	
124-40	21921-21928	alcohol	_	
124-41	21929-21932	and	_	
124-42	21933-21942	marijuana	_	
124-43	21943-21948	group	_	
124-44	21949-21959	containing	_	
124-45	21960-21964	more	_	
124-46	21965-21970	males	_	
124-47	21971-21974	and	_	
124-48	21975-21982	smokers	_	
124-49	21983-21987	than	_	
124-50	21988-21991	the	_	
124-51	21992-21999	control	_	
124-52	22000-22005	group	_	
124-53	22005-22006	.	_	

#Text=On the BART, there were no effects of group on adjusted pumps (F(3, 185) = 1.97, p = 0.12), proportion of explosions (F(3, 185) = 0.80, p = 0.50), or mean balloon duration for color balloons (F(3, 185) = 0.95, p = 0.42) or white balloons (F(3, 185) = 0.38, p = 0.77).
125-1	22007-22009	On	_	
125-2	22010-22013	the	_	
125-3	22014-22018	BART	_	
125-4	22018-22019	,	_	
125-5	22020-22025	there	_	
125-6	22026-22030	were	_	
125-7	22031-22033	no	_	
125-8	22034-22041	effects	_	
125-9	22042-22044	of	_	
125-10	22045-22050	group	_	
125-11	22051-22053	on	_	
125-12	22054-22062	adjusted	_	
125-13	22063-22068	pumps	_	
125-14	22069-22070	(	_	
125-15	22070-22071	F	_	
125-16	22071-22072	(	_	
125-17	22072-22073	3	_	
125-18	22073-22074	,	_	
125-19	22075-22078	185	_	
125-20	22078-22079	)	_	
125-21	22080-22081	=	_	
125-22	22082-22086	1.97	_	
125-23	22086-22087	,	_	
125-24	22088-22089	p	_	
125-25	22090-22091	=	_	
125-26	22092-22096	0.12	_	
125-27	22096-22097	)	_	
125-28	22097-22098	,	_	
125-29	22099-22109	proportion	_	
125-30	22110-22112	of	_	
125-31	22113-22123	explosions	_	
125-32	22124-22125	(	_	
125-33	22125-22126	F	_	
125-34	22126-22127	(	_	
125-35	22127-22128	3	_	
125-36	22128-22129	,	_	
125-37	22130-22133	185	_	
125-38	22133-22134	)	_	
125-39	22135-22136	=	_	
125-40	22137-22141	0.80	_	
125-41	22141-22142	,	_	
125-42	22143-22144	p	_	
125-43	22145-22146	=	_	
125-44	22147-22151	0.50	_	
125-45	22151-22152	)	_	
125-46	22152-22153	,	_	
125-47	22154-22156	or	_	
125-48	22157-22161	mean	_	
125-49	22162-22169	balloon	_	
125-50	22170-22178	duration	_	
125-51	22179-22182	for	_	
125-52	22183-22188	color	_	
125-53	22189-22197	balloons	_	
125-54	22198-22199	(	_	
125-55	22199-22200	F	_	
125-56	22200-22201	(	_	
125-57	22201-22202	3	_	
125-58	22202-22203	,	_	
125-59	22204-22207	185	_	
125-60	22207-22208	)	_	
125-61	22209-22210	=	_	
125-62	22211-22215	0.95	_	
125-63	22215-22216	,	_	
125-64	22217-22218	p	_	
125-65	22219-22220	=	_	
125-66	22221-22225	0.42	_	
125-67	22225-22226	)	_	
125-68	22227-22229	or	_	
125-69	22230-22235	white	_	
125-70	22236-22244	balloons	_	
125-71	22245-22246	(	_	
125-72	22246-22247	F	_	
125-73	22247-22248	(	_	
125-74	22248-22249	3	_	
125-75	22249-22250	,	_	
125-76	22251-22254	185	_	
125-77	22254-22255	)	_	
125-78	22256-22257	=	_	
125-79	22258-22262	0.38	_	
125-80	22262-22263	,	_	
125-81	22264-22265	p	_	
125-82	22266-22267	=	_	
125-83	22268-22272	0.77	_	
125-84	22272-22273	)	_	
125-85	22273-22274	.	_	

#Text=Significant group differences were also noted for the IMPSS, Connors, and CBCL (see Table 1).
#Text=fMRI Results: Main effects on the BART
#Text=In the mean risk contrast (i.e. mean color > mean white), risky choices were associated with greater activation than riskless choices in dACC/SMA, bilateral dorsal/ventral striatum (DS/VS) and anterior insula (for complete list see Fig 1, Table 2).
126-1	22275-22286	Significant	_	
126-2	22287-22292	group	_	
126-3	22293-22304	differences	_	
126-4	22305-22309	were	_	
126-5	22310-22314	also	_	
126-6	22315-22320	noted	_	
126-7	22321-22324	for	_	
126-8	22325-22328	the	_	
126-9	22329-22334	IMPSS	_	
126-10	22334-22335	,	_	
126-11	22336-22343	Connors	_	
126-12	22343-22344	,	_	
126-13	22345-22348	and	_	
126-14	22349-22353	CBCL	_	
126-15	22354-22355	(	_	
126-16	22355-22358	see	_	
126-17	22359-22364	Table	_	
126-18	22365-22366	1	_	
126-19	22366-22367	)	_	
126-20	22367-22368	.	_	
126-21	22369-22373	fMRI	_	
126-22	22374-22381	Results	_	
126-23	22381-22382	:	_	
126-24	22383-22387	Main	_	
126-25	22388-22395	effects	_	
126-26	22396-22398	on	_	
126-27	22399-22402	the	_	
126-28	22403-22407	BART	_	
126-29	22408-22410	In	_	
126-30	22411-22414	the	_	
126-31	22415-22419	mean	_	
126-32	22420-22424	risk	_	
126-33	22425-22433	contrast	_	
126-34	22434-22435	(	_	
126-35	22435-22438	i.e	_	
126-36	22438-22439	.	_	
126-37	22440-22444	mean	_	
126-38	22445-22450	color	_	
126-39	22451-22452	>	_	
126-40	22453-22457	mean	_	
126-41	22458-22463	white	_	
126-42	22463-22464	)	_	
126-43	22464-22465	,	_	
126-44	22466-22471	risky	_	
126-45	22472-22479	choices	_	
126-46	22480-22484	were	_	
126-47	22485-22495	associated	_	
126-48	22496-22500	with	_	
126-49	22501-22508	greater	_	
126-50	22509-22519	activation	_	
126-51	22520-22524	than	_	
126-52	22525-22533	riskless	_	
126-53	22534-22541	choices	_	
126-54	22542-22544	in	_	
126-55	22545-22549	dACC	_	
126-56	22549-22550	/	_	
126-57	22550-22553	SMA	_	
126-58	22553-22554	,	_	
126-59	22555-22564	bilateral	_	
126-60	22565-22571	dorsal	_	
126-61	22571-22572	/	_	
126-62	22572-22579	ventral	_	
126-63	22580-22588	striatum	_	
126-64	22589-22590	(	_	
126-65	22590-22592	DS	_	
126-66	22592-22593	/	_	
126-67	22593-22595	VS	_	
126-68	22595-22596	)	_	
126-69	22597-22600	and	_	
126-70	22601-22609	anterior	_	
126-71	22610-22616	insula	_	
126-72	22617-22618	(	_	
126-73	22618-22621	for	_	
126-74	22622-22630	complete	_	
126-75	22631-22635	list	_	
126-76	22636-22639	see	_	
126-77	22640-22643	Fig	_	
126-78	22644-22645	1	_	
126-79	22645-22646	,	_	
126-80	22647-22652	Table	_	
126-81	22653-22654	2	_	
126-82	22654-22655	)	_	
126-83	22655-22656	.	_	

#Text=In the contrast of linear risk (i.e. linear color > linear white), greater activation was found in pre/subgenual ACC/rostromedial MPFC, bilateral orbitofrontal cortex (OFC), as well as other regions throughout the temporal and parietal cortices (see Fig 1, Table 2 for complete list).
127-1	22657-22659	In	_	
127-2	22660-22663	the	_	
127-3	22664-22672	contrast	_	
127-4	22673-22675	of	_	
127-5	22676-22682	linear	_	
127-6	22683-22687	risk	_	
127-7	22688-22689	(	_	
127-8	22689-22692	i.e	_	
127-9	22692-22693	.	_	
127-10	22694-22700	linear	_	
127-11	22701-22706	color	_	
127-12	22707-22708	>	_	
127-13	22709-22715	linear	_	
127-14	22716-22721	white	_	
127-15	22721-22722	)	_	
127-16	22722-22723	,	_	
127-17	22724-22731	greater	_	
127-18	22732-22742	activation	_	
127-19	22743-22746	was	_	
127-20	22747-22752	found	_	
127-21	22753-22755	in	_	
127-22	22756-22759	pre	_	
127-23	22759-22760	/	_	
127-24	22760-22769	subgenual	_	
127-25	22770-22773	ACC	_	
127-26	22773-22774	/	_	
127-27	22774-22786	rostromedial	_	
127-28	22787-22791	MPFC	_	
127-29	22791-22792	,	_	
127-30	22793-22802	bilateral	_	
127-31	22803-22816	orbitofrontal	_	
127-32	22817-22823	cortex	_	
127-33	22824-22825	(	_	
127-34	22825-22828	OFC	_	
127-35	22828-22829	)	_	
127-36	22829-22830	,	_	
127-37	22831-22833	as	_	
127-38	22834-22838	well	_	
127-39	22839-22841	as	_	
127-40	22842-22847	other	_	
127-41	22848-22855	regions	_	
127-42	22856-22866	throughout	_	
127-43	22867-22870	the	_	
127-44	22871-22879	temporal	_	
127-45	22880-22883	and	_	
127-46	22884-22892	parietal	_	
127-47	22893-22901	cortices	_	
127-48	22902-22903	(	_	
127-49	22903-22906	see	_	
127-50	22907-22910	Fig	_	
127-51	22911-22912	1	_	
127-52	22912-22913	,	_	
127-53	22914-22919	Table	_	
127-54	22920-22921	2	_	
127-55	22922-22925	for	_	
127-56	22926-22934	complete	_	
127-57	22935-22939	list	_	
127-58	22939-22940	)	_	
127-59	22940-22941	.	_	

#Text=Moderating Effect of Substance Use on BOLD Response and Task-Based Risk-taking
#Text=The omnibus F-test that examined whether there were any differences across the four groups demonstrated a significant effect for the mean risk contrast in a single cluster that included bilateral VS, thalamus/brainstem and left anterior insula/inferior frontal gyrus (IFG).
128-1	22942-22952	Moderating	_	
128-2	22953-22959	Effect	_	
128-3	22960-22962	of	_	
128-4	22963-22972	Substance	_	
128-5	22973-22976	Use	_	
128-6	22977-22979	on	_	
128-7	22980-22984	BOLD	_	
128-8	22985-22993	Response	_	
128-9	22994-22997	and	_	
128-10	22998-23008	Task-Based	_	
128-11	23009-23020	Risk-taking	_	
128-12	23021-23024	The	_	
128-13	23025-23032	omnibus	_	
128-14	23033-23039	F-test	_	
128-15	23040-23044	that	_	
128-16	23045-23053	examined	_	
128-17	23054-23061	whether	_	
128-18	23062-23067	there	_	
128-19	23068-23072	were	_	
128-20	23073-23076	any	_	
128-21	23077-23088	differences	_	
128-22	23089-23095	across	_	
128-23	23096-23099	the	_	
128-24	23100-23104	four	_	
128-25	23105-23111	groups	_	
128-26	23112-23124	demonstrated	_	
128-27	23125-23126	a	_	
128-28	23127-23138	significant	_	
128-29	23139-23145	effect	_	
128-30	23146-23149	for	_	
128-31	23150-23153	the	_	
128-32	23154-23158	mean	_	
128-33	23159-23163	risk	_	
128-34	23164-23172	contrast	_	
128-35	23173-23175	in	_	
128-36	23176-23177	a	_	
128-37	23178-23184	single	_	
128-38	23185-23192	cluster	_	
128-39	23193-23197	that	_	
128-40	23198-23206	included	_	
128-41	23207-23216	bilateral	_	
128-42	23217-23219	VS	_	
128-43	23219-23220	,	_	
128-44	23221-23229	thalamus	_	
128-45	23229-23230	/	_	
128-46	23230-23239	brainstem	_	
128-47	23240-23243	and	_	
128-48	23244-23248	left	_	
128-49	23249-23257	anterior	_	
128-50	23258-23264	insula	_	
128-51	23264-23265	/	_	
128-52	23265-23273	inferior	_	
128-53	23274-23281	frontal	_	
128-54	23282-23287	gyrus	_	
128-55	23288-23289	(	_	
128-56	23289-23292	IFG	_	
128-57	23292-23293	)	_	
128-58	23293-23294	.	_	

#Text=Examination of percent signal change within this cluster by group revealed that the control group had greater response than the group using both alcohol and marijuana (p < .0001; Figure 2a).
129-1	23295-23306	Examination	_	
129-2	23307-23309	of	_	
129-3	23310-23317	percent	_	
129-4	23318-23324	signal	_	
129-5	23325-23331	change	_	
129-6	23332-23338	within	_	
129-7	23339-23343	this	_	
129-8	23344-23351	cluster	_	
129-9	23352-23354	by	_	
129-10	23355-23360	group	_	
129-11	23361-23369	revealed	_	
129-12	23370-23374	that	_	
129-13	23375-23378	the	_	
129-14	23379-23386	control	_	
129-15	23387-23392	group	_	
129-16	23393-23396	had	_	
129-17	23397-23404	greater	_	
129-18	23405-23413	response	_	
129-19	23414-23418	than	_	
129-20	23419-23422	the	_	
129-21	23423-23428	group	_	
129-22	23429-23434	using	_	
129-23	23435-23439	both	_	
129-24	23440-23447	alcohol	_	
129-25	23448-23451	and	_	
129-26	23452-23461	marijuana	_	
129-27	23462-23463	(	_	
129-28	23463-23464	p	_	
129-29	23465-23466	<	_	
129-30	23467-23472	.0001	_	
129-31	23472-23473	;	_	
129-32	23474-23480	Figure	_	
129-33	23481-23483	2a	_	
129-34	23483-23484	)	_	
129-35	23484-23485	.	_	

#Text=In the linear risk contrast, the omnibus F-test revealed group differences in supplementary motor area (SMA)/dorsal ACC, right putamen/insula, left insula/putamen/thalamus, and left postcentral gyrus (PoCG)/superior parietal lobe (SPL).
130-1	23486-23488	In	_	
130-2	23489-23492	the	_	
130-3	23493-23499	linear	_	
130-4	23500-23504	risk	_	
130-5	23505-23513	contrast	_	
130-6	23513-23514	,	_	
130-7	23515-23518	the	_	
130-8	23519-23526	omnibus	_	
130-9	23527-23533	F-test	_	
130-10	23534-23542	revealed	_	
130-11	23543-23548	group	_	
130-12	23549-23560	differences	_	
130-13	23561-23563	in	_	
130-14	23564-23577	supplementary	_	
130-15	23578-23583	motor	_	
130-16	23584-23588	area	_	
130-17	23589-23590	(	_	
130-18	23590-23593	SMA	_	
130-19	23593-23594	)	_	
130-20	23594-23595	/	_	
130-21	23595-23601	dorsal	_	
130-22	23602-23605	ACC	_	
130-23	23605-23606	,	_	
130-24	23607-23612	right	_	
130-25	23613-23620	putamen	_	
130-26	23620-23621	/	_	
130-27	23621-23627	insula	_	
130-28	23627-23628	,	_	
130-29	23629-23633	left	_	
130-30	23634-23640	insula	_	
130-31	23640-23641	/	_	
130-32	23641-23648	putamen	_	
130-33	23648-23649	/	_	
130-34	23649-23657	thalamus	_	
130-35	23657-23658	,	_	
130-36	23659-23662	and	_	
130-37	23663-23667	left	_	
130-38	23668-23679	postcentral	_	
130-39	23680-23685	gyrus	_	
130-40	23686-23687	(	_	
130-41	23687-23691	PoCG	_	
130-42	23691-23692	)	_	
130-43	23692-23693	/	_	
130-44	23693-23701	superior	_	
130-45	23702-23710	parietal	_	
130-46	23711-23715	lobe	_	
130-47	23716-23717	(	_	
130-48	23717-23720	SPL	_	
130-49	23720-23721	)	_	
130-50	23721-23722	.	_	

#Text=Examination of percent signal change in these regions revealed that the group using alcohol and marijuana had greater response than the control group in supplementary motor area (SMA)/dorsal ACC, right putamen/insula, and left insula/putamen/thalamus (all p’s < .01), and greater response than the marijuana-only group and the control group in the left PoCG/SPL (p = .02 and p = .01, respectively) (see Figure 2b), but did not differ from the alcohol-only group.
131-1	23723-23734	Examination	_	
131-2	23735-23737	of	_	
131-3	23738-23745	percent	_	
131-4	23746-23752	signal	_	
131-5	23753-23759	change	_	
131-6	23760-23762	in	_	
131-7	23763-23768	these	_	
131-8	23769-23776	regions	_	
131-9	23777-23785	revealed	_	
131-10	23786-23790	that	_	
131-11	23791-23794	the	_	
131-12	23795-23800	group	_	
131-13	23801-23806	using	_	
131-14	23807-23814	alcohol	_	
131-15	23815-23818	and	_	
131-16	23819-23828	marijuana	_	
131-17	23829-23832	had	_	
131-18	23833-23840	greater	_	
131-19	23841-23849	response	_	
131-20	23850-23854	than	_	
131-21	23855-23858	the	_	
131-22	23859-23866	control	_	
131-23	23867-23872	group	_	
131-24	23873-23875	in	_	
131-25	23876-23889	supplementary	_	
131-26	23890-23895	motor	_	
131-27	23896-23900	area	_	
131-28	23901-23902	(	_	
131-29	23902-23905	SMA	_	
131-30	23905-23906	)	_	
131-31	23906-23907	/	_	
131-32	23907-23913	dorsal	_	
131-33	23914-23917	ACC	_	
131-34	23917-23918	,	_	
131-35	23919-23924	right	_	
131-36	23925-23932	putamen	_	
131-37	23932-23933	/	_	
131-38	23933-23939	insula	_	
131-39	23939-23940	,	_	
131-40	23941-23944	and	_	
131-41	23945-23949	left	_	
131-42	23950-23956	insula	_	
131-43	23956-23957	/	_	
131-44	23957-23964	putamen	_	
131-45	23964-23965	/	_	
131-46	23965-23973	thalamus	_	
131-47	23974-23975	(	_	
131-48	23975-23978	all	_	
131-49	23979-23980	p	_	
131-50	23980-23981	’	_	
131-51	23981-23982	s	_	
131-52	23983-23984	<	_	
131-53	23985-23988	.01	_	
131-54	23988-23989	)	_	
131-55	23989-23990	,	_	
131-56	23991-23994	and	_	
131-57	23995-24002	greater	_	
131-58	24003-24011	response	_	
131-59	24012-24016	than	_	
131-60	24017-24020	the	_	
131-61	24021-24035	marijuana-only	_	
131-62	24036-24041	group	_	
131-63	24042-24045	and	_	
131-64	24046-24049	the	_	
131-65	24050-24057	control	_	
131-66	24058-24063	group	_	
131-67	24064-24066	in	_	
131-68	24067-24070	the	_	
131-69	24071-24075	left	_	
131-70	24076-24080	PoCG	_	
131-71	24080-24081	/	_	
131-72	24081-24084	SPL	_	
131-73	24085-24086	(	_	
131-74	24086-24087	p	_	
131-75	24088-24089	=	_	
131-76	24090-24093	.02	_	
131-77	24094-24097	and	_	
131-78	24098-24099	p	_	
131-79	24100-24101	=	_	
131-80	24102-24105	.01	_	
131-81	24105-24106	,	_	
131-82	24107-24119	respectively	_	
131-83	24119-24120	)	_	
131-84	24121-24122	(	_	
131-85	24122-24125	see	_	
131-86	24126-24132	Figure	_	
131-87	24133-24135	2b	_	
131-88	24135-24136	)	_	
131-89	24136-24137	,	_	
131-90	24138-24141	but	_	
131-91	24142-24145	did	_	
131-92	24146-24149	not	_	
131-93	24150-24156	differ	_	
131-94	24157-24161	from	_	
131-95	24162-24165	the	_	
131-96	24166-24178	alcohol-only	_	
131-97	24179-24184	group	_	
131-98	24184-24185	.	_	

#Text=Because the groups differed on hard drug use and gender, the above analyses were also conducted controlling for gender and hard drug use (past 3 months and ever), in three separate models (see Table 3).
132-1	24186-24193	Because	_	
132-2	24194-24197	the	_	
132-3	24198-24204	groups	_	
132-4	24205-24213	differed	_	
132-5	24214-24216	on	_	
132-6	24217-24221	hard	_	
132-7	24222-24226	drug	_	
132-8	24227-24230	use	_	
132-9	24231-24234	and	_	
132-10	24235-24241	gender	_	
132-11	24241-24242	,	_	
132-12	24243-24246	the	_	
132-13	24247-24252	above	_	
132-14	24253-24261	analyses	_	
132-15	24262-24266	were	_	
132-16	24267-24271	also	_	
132-17	24272-24281	conducted	_	
132-18	24282-24293	controlling	_	
132-19	24294-24297	for	_	
132-20	24298-24304	gender	_	
132-21	24305-24308	and	_	
132-22	24309-24313	hard	_	
132-23	24314-24318	drug	_	
132-24	24319-24322	use	_	
132-25	24323-24324	(	_	
132-26	24324-24328	past	_	
132-27	24329-24330	3	_	
132-28	24331-24337	months	_	
132-29	24338-24341	and	_	
132-30	24342-24346	ever	_	
132-31	24346-24347	)	_	
132-32	24347-24348	,	_	
132-33	24349-24351	in	_	
132-34	24352-24357	three	_	
132-35	24358-24366	separate	_	
132-36	24367-24373	models	_	
132-37	24374-24375	(	_	
132-38	24375-24378	see	_	
132-39	24379-24384	Table	_	
132-40	24385-24386	3	_	
132-41	24386-24387	)	_	
132-42	24387-24388	.	_	

#Text=Controlling for these variables changed the results to some degree, with the most notable changes occurring when controlling for gender.
133-1	24389-24400	Controlling	_	
133-2	24401-24404	for	_	
133-3	24405-24410	these	_	
133-4	24411-24420	variables	_	
133-5	24421-24428	changed	_	
133-6	24429-24432	the	_	
133-7	24433-24440	results	_	
133-8	24441-24443	to	_	
133-9	24444-24448	some	_	
133-10	24449-24455	degree	_	
133-11	24455-24456	,	_	
133-12	24457-24461	with	_	
133-13	24462-24465	the	_	
133-14	24466-24470	most	_	
133-15	24471-24478	notable	_	
133-16	24479-24486	changes	_	
133-17	24487-24496	occurring	_	
133-18	24497-24501	when	_	
133-19	24502-24513	controlling	_	
133-20	24514-24517	for	_	
133-21	24518-24524	gender	_	
133-22	24524-24525	.	_	

#Text=When gender was controlled, the cluster showing signficance in the mean risk contrast was reduced in overall extent of activation, with group differences being restricted primarily to left lateralized NAc, putamen, and thalamus.
134-1	24526-24530	When	_	
134-2	24531-24537	gender	_	
134-3	24538-24541	was	_	
134-4	24542-24552	controlled	_	
134-5	24552-24553	,	_	
134-6	24554-24557	the	_	
134-7	24558-24565	cluster	_	
134-8	24566-24573	showing	_	
134-9	24574-24585	signficance	_	
134-10	24586-24588	in	_	
134-11	24589-24592	the	_	
134-12	24593-24597	mean	_	
134-13	24598-24602	risk	_	
134-14	24603-24611	contrast	_	
134-15	24612-24615	was	_	
134-16	24616-24623	reduced	_	
134-17	24624-24626	in	_	
134-18	24627-24634	overall	_	
134-19	24635-24641	extent	_	
134-20	24642-24644	of	_	
134-21	24645-24655	activation	_	
134-22	24655-24656	,	_	
134-23	24657-24661	with	_	
134-24	24662-24667	group	_	
134-25	24668-24679	differences	_	
134-26	24680-24685	being	_	
134-27	24686-24696	restricted	_	
134-28	24697-24706	primarily	_	
134-29	24707-24709	to	_	
134-30	24710-24714	left	_	
134-31	24715-24726	lateralized	_	
134-32	24727-24730	NAc	_	
134-33	24730-24731	,	_	
134-34	24732-24739	putamen	_	
134-35	24739-24740	,	_	
134-36	24741-24744	and	_	
134-37	24745-24753	thalamus	_	
134-38	24753-24754	.	_	

#Text=In contrast, controlling for hard drug use resulted in very little change to overall cluster extent.
135-1	24755-24757	In	_	
135-2	24758-24766	contrast	_	
135-3	24766-24767	,	_	
135-4	24768-24779	controlling	_	
135-5	24780-24783	for	_	
135-6	24784-24788	hard	_	
135-7	24789-24793	drug	_	
135-8	24794-24797	use	_	
135-9	24798-24806	resulted	_	
135-10	24807-24809	in	_	
135-11	24810-24814	very	_	
135-12	24815-24821	little	_	
135-13	24822-24828	change	_	
135-14	24829-24831	to	_	
135-15	24832-24839	overall	_	
135-16	24840-24847	cluster	_	
135-17	24848-24854	extent	_	
135-18	24854-24855	.	_	

#Text=We also examined the group effects while controlling for the clinical variables of anxiety, depression, ADHD, impulsivity, and externalizing, and found that while cluster sizes were reduced to some degree, the group differences remained significant in all clusters except the left putamen/insula, which was no longer significant once controlling for age or externalizing.
136-1	24856-24858	We	_	
136-2	24859-24863	also	_	
136-3	24864-24872	examined	_	
136-4	24873-24876	the	_	
136-5	24877-24882	group	_	
136-6	24883-24890	effects	_	
136-7	24891-24896	while	_	
136-8	24897-24908	controlling	_	
136-9	24909-24912	for	_	
136-10	24913-24916	the	_	
136-11	24917-24925	clinical	_	
136-12	24926-24935	variables	_	
136-13	24936-24938	of	_	
136-14	24939-24946	anxiety	_	
136-15	24946-24947	,	_	
136-16	24948-24958	depression	_	
136-17	24958-24959	,	_	
136-18	24960-24964	ADHD	_	
136-19	24964-24965	,	_	
136-20	24966-24977	impulsivity	_	
136-21	24977-24978	,	_	
136-22	24979-24982	and	_	
136-23	24983-24996	externalizing	_	
136-24	24996-24997	,	_	
136-25	24998-25001	and	_	
136-26	25002-25007	found	_	
136-27	25008-25012	that	_	
136-28	25013-25018	while	_	
136-29	25019-25026	cluster	_	
136-30	25027-25032	sizes	_	
136-31	25033-25037	were	_	
136-32	25038-25045	reduced	_	
136-33	25046-25048	to	_	
136-34	25049-25053	some	_	
136-35	25054-25060	degree	_	
136-36	25060-25061	,	_	
136-37	25062-25065	the	_	
136-38	25066-25071	group	_	
136-39	25072-25083	differences	_	
136-40	25084-25092	remained	_	
136-41	25093-25104	significant	_	
136-42	25105-25107	in	_	
136-43	25108-25111	all	_	
136-44	25112-25120	clusters	_	
136-45	25121-25127	except	_	
136-46	25128-25131	the	_	
136-47	25132-25136	left	_	
136-48	25137-25144	putamen	_	
136-49	25144-25145	/	_	
136-50	25145-25151	insula	_	
136-51	25151-25152	,	_	
136-52	25153-25158	which	_	
136-53	25159-25162	was	_	
136-54	25163-25165	no	_	
136-55	25166-25172	longer	_	
136-56	25173-25184	significant	_	
136-57	25185-25189	once	_	
136-58	25190-25201	controlling	_	
136-59	25202-25205	for	_	
136-60	25206-25209	age	_	
136-61	25210-25212	or	_	
136-62	25213-25226	externalizing	_	
136-63	25226-25227	.	_	

#Text=Notably, this effect was similar to that reported when controlling for gender.
137-1	25228-25235	Notably	_	
137-2	25235-25236	,	_	
137-3	25237-25241	this	_	
137-4	25242-25248	effect	_	
137-5	25249-25252	was	_	
137-6	25253-25260	similar	_	
137-7	25261-25263	to	_	
137-8	25264-25268	that	_	
137-9	25269-25277	reported	_	
137-10	25278-25282	when	_	
137-11	25283-25294	controlling	_	
137-12	25295-25298	for	_	
137-13	25299-25305	gender	_	
137-14	25305-25306	.	_	

#Text=In all other cases, inclusion of the additional potential confounding variable resulted in changes in the cluster extent, but main group differences remained significant (see Table 3 for cluster sizes and Supplementary Figure 1 and 2 for group maps that included covariates of interest in the mean and linear risk contrasts, respectively).
138-1	25307-25309	In	_	
138-2	25310-25313	all	_	
138-3	25314-25319	other	_	
138-4	25320-25325	cases	_	
138-5	25325-25326	,	_	
138-6	25327-25336	inclusion	_	
138-7	25337-25339	of	_	
138-8	25340-25343	the	_	
138-9	25344-25354	additional	_	
138-10	25355-25364	potential	_	
138-11	25365-25376	confounding	_	
138-12	25377-25385	variable	_	
138-13	25386-25394	resulted	_	
138-14	25395-25397	in	_	
138-15	25398-25405	changes	_	
138-16	25406-25408	in	_	
138-17	25409-25412	the	_	
138-18	25413-25420	cluster	_	
138-19	25421-25427	extent	_	
138-20	25427-25428	,	_	
138-21	25429-25432	but	_	
138-22	25433-25437	main	_	
138-23	25438-25443	group	_	
138-24	25444-25455	differences	_	
138-25	25456-25464	remained	_	
138-26	25465-25476	significant	_	
138-27	25477-25478	(	_	
138-28	25478-25481	see	_	
138-29	25482-25487	Table	_	
138-30	25488-25489	3	_	
138-31	25490-25493	for	_	
138-32	25494-25501	cluster	_	
138-33	25502-25507	sizes	_	
138-34	25508-25511	and	_	
138-35	25512-25525	Supplementary	_	
138-36	25526-25532	Figure	_	
138-37	25533-25534	1	_	
138-38	25535-25538	and	_	
138-39	25539-25540	2	_	
138-40	25541-25544	for	_	
138-41	25545-25550	group	_	
138-42	25551-25555	maps	_	
138-43	25556-25560	that	_	
138-44	25561-25569	included	_	
138-45	25570-25580	covariates	_	
138-46	25581-25583	of	_	
138-47	25584-25592	interest	_	
138-48	25593-25595	in	_	
138-49	25596-25599	the	_	
138-50	25600-25604	mean	_	
138-51	25605-25608	and	_	
138-52	25609-25615	linear	_	
138-53	25616-25620	risk	_	
138-54	25621-25630	contrasts	_	
138-55	25630-25631	,	_	
138-56	25632-25644	respectively	_	
138-57	25644-25645	)	_	
138-58	25645-25646	.	_	

#Text=Finally, we examined our group differences after controlling for all variables in the context of a multiple regression.
139-1	25647-25654	Finally	_	
139-2	25654-25655	,	_	
139-3	25656-25658	we	_	
139-4	25659-25667	examined	_	
139-5	25668-25671	our	_	
139-6	25672-25677	group	_	
139-7	25678-25689	differences	_	
139-8	25690-25695	after	_	
139-9	25696-25707	controlling	_	
139-10	25708-25711	for	_	
139-11	25712-25715	all	_	
139-12	25716-25725	variables	_	
139-13	25726-25728	in	_	
139-14	25729-25732	the	_	
139-15	25733-25740	context	_	
139-16	25741-25743	of	_	
139-17	25744-25745	a	_	
139-18	25746-25754	multiple	_	
139-19	25755-25765	regression	_	
139-20	25765-25766	.	_	

#Text=As seen in Supplementary Figure 3, the only cluster that was no longer significant was the dorsal ACC/SMA cluster, which was reduced to a cluster size of 346 voxels.
140-1	25767-25769	As	_	
140-2	25770-25774	seen	_	
140-3	25775-25777	in	_	
140-4	25778-25791	Supplementary	_	
140-5	25792-25798	Figure	_	
140-6	25799-25800	3	_	
140-7	25800-25801	,	_	
140-8	25802-25805	the	_	
140-9	25806-25810	only	_	
140-10	25811-25818	cluster	_	
140-11	25819-25823	that	_	
140-12	25824-25827	was	_	
140-13	25828-25830	no	_	
140-14	25831-25837	longer	_	
140-15	25838-25849	significant	_	
140-16	25850-25853	was	_	
140-17	25854-25857	the	_	
140-18	25858-25864	dorsal	_	
140-19	25865-25868	ACC	_	
140-20	25868-25869	/	_	
140-21	25869-25872	SMA	_	
140-22	25873-25880	cluster	_	
140-23	25880-25881	,	_	
140-24	25882-25887	which	_	
140-25	25888-25891	was	_	
140-26	25892-25899	reduced	_	
140-27	25900-25902	to	_	
140-28	25903-25904	a	_	
140-29	25905-25912	cluster	_	
140-30	25913-25917	size	_	
140-31	25918-25920	of	_	
140-32	25921-25924	346	_	
140-33	25925-25931	voxels	_	
140-34	25931-25932	.	_	

#Text=Relationships Between BOLD Response and Behavioral Risk Taking
#Text=Examination of the correlations between the mean and linear contrast and behavioral performance on the BART revealed several significant relationships.
141-1	25933-25946	Relationships	_	
141-2	25947-25954	Between	_	
141-3	25955-25959	BOLD	_	
141-4	25960-25968	Response	_	
141-5	25969-25972	and	_	
141-6	25973-25983	Behavioral	_	
141-7	25984-25988	Risk	_	
141-8	25989-25995	Taking	_	
141-9	25996-26007	Examination	_	
141-10	26008-26010	of	_	
141-11	26011-26014	the	_	
141-12	26015-26027	correlations	_	
141-13	26028-26035	between	_	
141-14	26036-26039	the	_	
141-15	26040-26044	mean	_	
141-16	26045-26048	and	_	
141-17	26049-26055	linear	_	
141-18	26056-26064	contrast	_	
141-19	26065-26068	and	_	
141-20	26069-26079	behavioral	_	
141-21	26080-26091	performance	_	
141-22	26092-26094	on	_	
141-23	26095-26098	the	_	
141-24	26099-26103	BART	_	
141-25	26104-26112	revealed	_	
141-26	26113-26120	several	_	
141-27	26121-26132	significant	_	
141-28	26133-26146	relationships	_	
141-29	26146-26147	.	_	

#Text=In the mean contrast, there was a negative correlation between adjusted average pumps and response throughout the brain including ventral ACC, bilateral orbitofrontal cortex/insula, bilateral IFG, and precentral gyrus (see supplemental Table for complete list).
142-1	26148-26150	In	_	
142-2	26151-26154	the	_	
142-3	26155-26159	mean	_	
142-4	26160-26168	contrast	_	
142-5	26168-26169	,	_	
142-6	26170-26175	there	_	
142-7	26176-26179	was	_	
142-8	26180-26181	a	_	
142-9	26182-26190	negative	_	
142-10	26191-26202	correlation	_	
142-11	26203-26210	between	_	
142-12	26211-26219	adjusted	_	
142-13	26220-26227	average	_	
142-14	26228-26233	pumps	_	
142-15	26234-26237	and	_	
142-16	26238-26246	response	_	
142-17	26247-26257	throughout	_	
142-18	26258-26261	the	_	
142-19	26262-26267	brain	_	
142-20	26268-26277	including	_	
142-21	26278-26285	ventral	_	
142-22	26286-26289	ACC	_	
142-23	26289-26290	,	_	
142-24	26291-26300	bilateral	_	
142-25	26301-26314	orbitofrontal	_	
142-26	26315-26321	cortex	_	
142-27	26321-26322	/	_	
142-28	26322-26328	insula	_	
142-29	26328-26329	,	_	
142-30	26330-26339	bilateral	_	
142-31	26340-26343	IFG	_	
142-32	26343-26344	,	_	
142-33	26345-26348	and	_	
142-34	26349-26359	precentral	_	
142-35	26360-26365	gyrus	_	
142-36	26366-26367	(	_	
142-37	26367-26370	see	_	
142-38	26371-26383	supplemental	_	
142-39	26384-26389	Table	_	
142-40	26390-26393	for	_	
142-41	26394-26402	complete	_	
142-42	26403-26407	list	_	
142-43	26407-26408	)	_	
142-44	26408-26409	.	_	

#Text=For the linear contrast, there was a positive relationship between adjusted average pumps and response in the right visual processing stream (occipital pole, lateral occipital cortex, and middle temporal gyrus).
143-1	26410-26413	For	_	
143-2	26414-26417	the	_	
143-3	26418-26424	linear	_	
143-4	26425-26433	contrast	_	
143-5	26433-26434	,	_	
143-6	26435-26440	there	_	
143-7	26441-26444	was	_	
143-8	26445-26446	a	_	
143-9	26447-26455	positive	_	
143-10	26456-26468	relationship	_	
143-11	26469-26476	between	_	
143-12	26477-26485	adjusted	_	
143-13	26486-26493	average	_	
143-14	26494-26499	pumps	_	
143-15	26500-26503	and	_	
143-16	26504-26512	response	_	
143-17	26513-26515	in	_	
143-18	26516-26519	the	_	
143-19	26520-26525	right	_	
143-20	26526-26532	visual	_	
143-21	26533-26543	processing	_	
143-22	26544-26550	stream	_	
143-23	26551-26552	(	_	
143-24	26552-26561	occipital	_	
143-25	26562-26566	pole	_	
143-26	26566-26567	,	_	
143-27	26568-26575	lateral	_	
143-28	26576-26585	occipital	_	
143-29	26586-26592	cortex	_	
143-30	26592-26593	,	_	
143-31	26594-26597	and	_	
143-32	26598-26604	middle	_	
143-33	26605-26613	temporal	_	
143-34	26614-26619	gyrus	_	
143-35	26619-26620	)	_	
143-36	26620-26621	.	_	

#Text=There were no significant group differences in the relationship between adjusted avearge pumps and BOLD response in either contrast.
144-1	26622-26627	There	_	
144-2	26628-26632	were	_	
144-3	26633-26635	no	_	
144-4	26636-26647	significant	_	
144-5	26648-26653	group	_	
144-6	26654-26665	differences	_	
144-7	26666-26668	in	_	
144-8	26669-26672	the	_	
144-9	26673-26685	relationship	_	
144-10	26686-26693	between	_	
144-11	26694-26702	adjusted	_	
144-12	26703-26710	avearge	_	
144-13	26711-26716	pumps	_	
144-14	26717-26720	and	_	
144-15	26721-26725	BOLD	_	
144-16	26726-26734	response	_	
144-17	26735-26737	in	_	
144-18	26738-26744	either	_	
144-19	26745-26753	contrast	_	
144-20	26753-26754	.	_	

#Text=Discussion
#Text=The goal of this study was to examine the neural mechanisms of risk taking that differ among adolescent alcohol and marijuana users compared to non-users/infrequent users.
145-1	26755-26765	Discussion	_	
145-2	26766-26769	The	_	
145-3	26770-26774	goal	_	
145-4	26775-26777	of	_	
145-5	26778-26782	this	_	
145-6	26783-26788	study	_	
145-7	26789-26792	was	_	
145-8	26793-26795	to	_	
145-9	26796-26803	examine	_	
145-10	26804-26807	the	_	
145-11	26808-26814	neural	_	
145-12	26815-26825	mechanisms	_	
145-13	26826-26828	of	_	
145-14	26829-26833	risk	_	
145-15	26834-26840	taking	_	
145-16	26841-26845	that	_	
145-17	26846-26852	differ	_	
145-18	26853-26858	among	_	
145-19	26859-26869	adolescent	_	
145-20	26870-26877	alcohol	_	
145-21	26878-26881	and	_	
145-22	26882-26891	marijuana	_	
145-23	26892-26897	users	_	
145-24	26898-26906	compared	_	
145-25	26907-26909	to	_	
145-26	26910-26919	non-users	_	
145-27	26919-26920	/	_	
145-28	26920-26930	infrequent	_	
145-29	26931-26936	users	_	
145-30	26936-26937	.	_	

#Text=Although we observed no behavioral differences on the BART across the four groups, activation differences during risky decision making emerged in the striatum, thalamus, and anterior insula/IFG in the mean risk contrast, and in SMA/dACC, putamen/insula, and PoCG/SPL in the linear risk contrast.
146-1	26938-26946	Although	_	
146-2	26947-26949	we	_	
146-3	26950-26958	observed	_	
146-4	26959-26961	no	_	
146-5	26962-26972	behavioral	_	
146-6	26973-26984	differences	_	
146-7	26985-26987	on	_	
146-8	26988-26991	the	_	
146-9	26992-26996	BART	_	
146-10	26997-27003	across	_	
146-11	27004-27007	the	_	
146-12	27008-27012	four	_	
146-13	27013-27019	groups	_	
146-14	27019-27020	,	_	
146-15	27021-27031	activation	_	
146-16	27032-27043	differences	_	
146-17	27044-27050	during	_	
146-18	27051-27056	risky	_	
146-19	27057-27065	decision	_	
146-20	27066-27072	making	_	
146-21	27073-27080	emerged	_	
146-22	27081-27083	in	_	
146-23	27084-27087	the	_	
146-24	27088-27096	striatum	_	
146-25	27096-27097	,	_	
146-26	27098-27106	thalamus	_	
146-27	27106-27107	,	_	
146-28	27108-27111	and	_	
146-29	27112-27120	anterior	_	
146-30	27121-27127	insula	_	
146-31	27127-27128	/	_	
146-32	27128-27131	IFG	_	
146-33	27132-27134	in	_	
146-34	27135-27138	the	_	
146-35	27139-27143	mean	_	
146-36	27144-27148	risk	_	
146-37	27149-27157	contrast	_	
146-38	27157-27158	,	_	
146-39	27159-27162	and	_	
146-40	27163-27165	in	_	
146-41	27166-27169	SMA	_	
146-42	27169-27170	/	_	
146-43	27170-27174	dACC	_	
146-44	27174-27175	,	_	
146-45	27176-27183	putamen	_	
146-46	27183-27184	/	_	
146-47	27184-27190	insula	_	
146-48	27190-27191	,	_	
146-49	27192-27195	and	_	
146-50	27196-27200	PoCG	_	
146-51	27200-27201	/	_	
146-52	27201-27204	SPL	_	
146-53	27205-27207	in	_	
146-54	27208-27211	the	_	
146-55	27212-27218	linear	_	
146-56	27219-27223	risk	_	
146-57	27224-27232	contrast	_	
146-58	27232-27233	.	_	

#Text=Interestingly, differences between groups were isolated to comparisons of controls to the alcohol+marijuana group and alcohol-only group, and the comparison of the marijuana-only group to the alcohol+marijuana group.
147-1	27234-27247	Interestingly	_	
147-2	27247-27248	,	_	
147-3	27249-27260	differences	_	
147-4	27261-27268	between	_	
147-5	27269-27275	groups	_	
147-6	27276-27280	were	_	
147-7	27281-27289	isolated	_	
147-8	27290-27292	to	_	
147-9	27293-27304	comparisons	_	
147-10	27305-27307	of	_	
147-11	27308-27316	controls	_	
147-12	27317-27319	to	_	
147-13	27320-27323	the	_	
147-14	27324-27331	alcohol	_	
147-15	27331-27332	+	_	
147-16	27332-27341	marijuana	_	
147-17	27342-27347	group	_	
147-18	27348-27351	and	_	
147-19	27352-27364	alcohol-only	_	
147-20	27365-27370	group	_	
147-21	27370-27371	,	_	
147-22	27372-27375	and	_	
147-23	27376-27379	the	_	
147-24	27380-27390	comparison	_	
147-25	27391-27393	of	_	
147-26	27394-27397	the	_	
147-27	27398-27412	marijuana-only	_	
147-28	27413-27418	group	_	
147-29	27419-27421	to	_	
147-30	27422-27425	the	_	
147-31	27426-27433	alcohol	_	
147-32	27433-27434	+	_	
147-33	27434-27443	marijuana	_	
147-34	27444-27449	group	_	
147-35	27449-27450	.	_	

#Text=While the group differences in the mean risk contrast may suggest differential valuation of rewarding outcomes, group differences in the linear risk contrast point to reduced differentiation of potential risk across balloons despite increased risk of explosion as pumps increased.
148-1	27451-27456	While	_	
148-2	27457-27460	the	_	
148-3	27461-27466	group	_	
148-4	27467-27478	differences	_	
148-5	27479-27481	in	_	
148-6	27482-27485	the	_	
148-7	27486-27490	mean	_	
148-8	27491-27495	risk	_	
148-9	27496-27504	contrast	_	
148-10	27505-27508	may	_	
148-11	27509-27516	suggest	_	
148-12	27517-27529	differential	_	
148-13	27530-27539	valuation	_	
148-14	27540-27542	of	_	
148-15	27543-27552	rewarding	_	
148-16	27553-27561	outcomes	_	
148-17	27561-27562	,	_	
148-18	27563-27568	group	_	
148-19	27569-27580	differences	_	
148-20	27581-27583	in	_	
148-21	27584-27587	the	_	
148-22	27588-27594	linear	_	
148-23	27595-27599	risk	_	
148-24	27600-27608	contrast	_	
148-25	27609-27614	point	_	
148-26	27615-27617	to	_	
148-27	27618-27625	reduced	_	
148-28	27626-27641	differentiation	_	
148-29	27642-27644	of	_	
148-30	27645-27654	potential	_	
148-31	27655-27659	risk	_	
148-32	27660-27666	across	_	
148-33	27667-27675	balloons	_	
148-34	27676-27683	despite	_	
148-35	27684-27693	increased	_	
148-36	27694-27698	risk	_	
148-37	27699-27701	of	_	
148-38	27702-27711	explosion	_	
148-39	27712-27714	as	_	
148-40	27715-27720	pumps	_	
148-41	27721-27730	increased	_	
148-42	27730-27731	.	_	

#Text=Both of these possibilities are discussed below in the context of group differences.
149-1	27732-27736	Both	_	
149-2	27737-27739	of	_	
149-3	27740-27745	these	_	
149-4	27746-27759	possibilities	_	
149-5	27760-27763	are	_	
149-6	27764-27773	discussed	_	
149-7	27774-27779	below	_	
149-8	27780-27782	in	_	
149-9	27783-27786	the	_	
149-10	27787-27794	context	_	
149-11	27795-27797	of	_	
149-12	27798-27803	group	_	
149-13	27804-27815	differences	_	
149-14	27815-27816	.	_	

#Text=Compared to controls, frequent use of alcohol+marijuana was associated with reduced response in VS and bilateral thalamus in the mean risk contrast.
150-1	27817-27825	Compared	_	
150-2	27826-27828	to	_	
150-3	27829-27837	controls	_	
150-4	27837-27838	,	_	
150-5	27839-27847	frequent	_	
150-6	27848-27851	use	_	
150-7	27852-27854	of	_	
150-8	27855-27862	alcohol	_	
150-9	27862-27863	+	_	
150-10	27863-27872	marijuana	_	
150-11	27873-27876	was	_	
150-12	27877-27887	associated	_	
150-13	27888-27892	with	_	
150-14	27893-27900	reduced	_	
150-15	27901-27909	response	_	
150-16	27910-27912	in	_	
150-17	27913-27915	VS	_	
150-18	27916-27919	and	_	
150-19	27920-27929	bilateral	_	
150-20	27930-27938	thalamus	_	
150-21	27939-27941	in	_	
150-22	27942-27945	the	_	
150-23	27946-27950	mean	_	
150-24	27951-27955	risk	_	
150-25	27956-27964	contrast	_	
150-26	27964-27965	.	_	

#Text=Of note, the observed reduction in VS response among frequent substance users replicates other work in substance using adolescents and adolescents with a family history of alcoholism.
151-1	27966-27968	Of	_	
151-2	27969-27973	note	_	
151-3	27973-27974	,	_	
151-4	27975-27978	the	_	
151-5	27979-27987	observed	_	
151-6	27988-27997	reduction	_	
151-7	27998-28000	in	_	
151-8	28001-28003	VS	_	
151-9	28004-28012	response	_	
151-10	28013-28018	among	_	
151-11	28019-28027	frequent	_	
151-12	28028-28037	substance	_	
151-13	28038-28043	users	_	
151-14	28044-28054	replicates	_	
151-15	28055-28060	other	_	
151-16	28061-28065	work	_	
151-17	28066-28068	in	_	
151-18	28069-28078	substance	_	
151-19	28079-28084	using	_	
151-20	28085-28096	adolescents	_	
151-21	28097-28100	and	_	
151-22	28101-28112	adolescents	_	
151-23	28113-28117	with	_	
151-24	28118-28119	a	_	
151-25	28120-28126	family	_	
151-26	28127-28134	history	_	
151-27	28135-28137	of	_	
151-28	28138-28148	alcoholism	_	
151-29	28148-28149	.	_	

#Text=The VS has been implicated in reward processes, including reward anticipation, reward receipt, and encoding of temporal difference errors.
152-1	28150-28153	The	_	
152-2	28154-28156	VS	_	
152-3	28157-28160	has	_	
152-4	28161-28165	been	_	
152-5	28166-28176	implicated	_	
152-6	28177-28179	in	_	
152-7	28180-28186	reward	_	
152-8	28187-28196	processes	_	
152-9	28196-28197	,	_	
152-10	28198-28207	including	_	
152-11	28208-28214	reward	_	
152-12	28215-28227	anticipation	_	
152-13	28227-28228	,	_	
152-14	28229-28235	reward	_	
152-15	28236-28243	receipt	_	
152-16	28243-28244	,	_	
152-17	28245-28248	and	_	
152-18	28249-28257	encoding	_	
152-19	28258-28260	of	_	
152-20	28261-28269	temporal	_	
152-21	28270-28280	difference	_	
152-22	28281-28287	errors	_	
152-23	28287-28288	.	_	

#Text=In the BART, VS may play a significant role in anticipation of a positive outcome, leading to an approach-based motivational state and risk engagement.
153-1	28289-28291	In	_	
153-2	28292-28295	the	_	
153-3	28296-28300	BART	_	
153-4	28300-28301	,	_	
153-5	28302-28304	VS	_	
153-6	28305-28308	may	_	
153-7	28309-28313	play	_	
153-8	28314-28315	a	_	
153-9	28316-28327	significant	_	
153-10	28328-28332	role	_	
153-11	28333-28335	in	_	
153-12	28336-28348	anticipation	_	
153-13	28349-28351	of	_	
153-14	28352-28353	a	_	
153-15	28354-28362	positive	_	
153-16	28363-28370	outcome	_	
153-17	28370-28371	,	_	
153-18	28372-28379	leading	_	
153-19	28380-28382	to	_	
153-20	28383-28385	an	_	
153-21	28386-28400	approach-based	_	
153-22	28401-28413	motivational	_	
153-23	28414-28419	state	_	
153-24	28420-28423	and	_	
153-25	28424-28428	risk	_	
153-26	28429-28439	engagement	_	
153-27	28439-28440	.	_	

#Text=The valuation of each action may be greater for non-users, who may place greater value on each pump (i.e., reward), thereby resulting in greater VS response.
154-1	28441-28444	The	_	
154-2	28445-28454	valuation	_	
154-3	28455-28457	of	_	
154-4	28458-28462	each	_	
154-5	28463-28469	action	_	
154-6	28470-28473	may	_	
154-7	28474-28476	be	_	
154-8	28477-28484	greater	_	
154-9	28485-28488	for	_	
154-10	28489-28498	non-users	_	
154-11	28498-28499	,	_	
154-12	28500-28503	who	_	
154-13	28504-28507	may	_	
154-14	28508-28513	place	_	
154-15	28514-28521	greater	_	
154-16	28522-28527	value	_	
154-17	28528-28530	on	_	
154-18	28531-28535	each	_	
154-19	28536-28540	pump	_	
154-20	28541-28542	(	_	
154-21	28542-28545	i.e	_	
154-22	28545-28546	.	_	
154-23	28546-28547	,	_	
154-24	28548-28554	reward	_	
154-25	28554-28555	)	_	
154-26	28555-28556	,	_	
154-27	28557-28564	thereby	_	
154-28	28565-28574	resulting	_	
154-29	28575-28577	in	_	
154-30	28578-28585	greater	_	
154-31	28586-28588	VS	_	
154-32	28589-28597	response	_	
154-33	28597-28598	.	_	

#Text=Future studies that parametrically manipulate per-pump value and separate anticipatory and outcome related processes may allow clearer differentiation of the precise mechanism contributing to differential striatal engagement in adolescent polysubstance alcohol+marijuana user.
155-1	28599-28605	Future	_	
155-2	28606-28613	studies	_	
155-3	28614-28618	that	_	
155-4	28619-28633	parametrically	_	
155-5	28634-28644	manipulate	_	
155-6	28645-28653	per-pump	_	
155-7	28654-28659	value	_	
155-8	28660-28663	and	_	
155-9	28664-28672	separate	_	
155-10	28673-28685	anticipatory	_	
155-11	28686-28689	and	_	
155-12	28690-28697	outcome	_	
155-13	28698-28705	related	_	
155-14	28706-28715	processes	_	
155-15	28716-28719	may	_	
155-16	28720-28725	allow	_	
155-17	28726-28733	clearer	_	
155-18	28734-28749	differentiation	_	
155-19	28750-28752	of	_	
155-20	28753-28756	the	_	
155-21	28757-28764	precise	_	
155-22	28765-28774	mechanism	_	
155-23	28775-28787	contributing	_	
155-24	28788-28790	to	_	
155-25	28791-28803	differential	_	
155-26	28804-28812	striatal	_	
155-27	28813-28823	engagement	_	
155-28	28824-28826	in	_	
155-29	28827-28837	adolescent	_	
155-30	28838-28851	polysubstance	_	
155-31	28852-28859	alcohol	_	
155-32	28859-28860	+	_	
155-33	28860-28869	marijuana	_	
155-34	28870-28874	user	_	
155-35	28874-28875	.	_	

#Text=While multiple regions showed group differences in the linear contrast, the difference in SMA is most relevant to prior work using the BART to examine risky decision making (e.g.).
156-1	28876-28881	While	_	
156-2	28882-28890	multiple	_	
156-3	28891-28898	regions	_	
156-4	28899-28905	showed	_	
156-5	28906-28911	group	_	
156-6	28912-28923	differences	_	
156-7	28924-28926	in	_	
156-8	28927-28930	the	_	
156-9	28931-28937	linear	_	
156-10	28938-28946	contrast	_	
156-11	28946-28947	,	_	
156-12	28948-28951	the	_	
156-13	28952-28962	difference	_	
156-14	28963-28965	in	_	
156-15	28966-28969	SMA	_	
156-16	28970-28972	is	_	
156-17	28973-28977	most	_	
156-18	28978-28986	relevant	_	
156-19	28987-28989	to	_	
156-20	28990-28995	prior	_	
156-21	28996-29000	work	_	
156-22	29001-29006	using	_	
156-23	29007-29010	the	_	
156-24	29011-29015	BART	_	
156-25	29016-29018	to	_	
156-26	29019-29026	examine	_	
156-27	29027-29032	risky	_	
156-28	29033-29041	decision	_	
156-29	29042-29048	making	_	
156-30	29049-29050	(	_	
156-31	29050-29053	e.g	_	
156-32	29053-29054	.	_	
156-33	29054-29055	)	_	
156-34	29055-29056	.	_	

#Text=The SMA/dACC plays a role in detecting conflict at the response level, and has been implicated in risk-taking, particularly in light of the opposing influences of potential positive and negative outcomes; in the BART, reduced response in SMA/dACC as function of pump number is proposed to coincide with a “de-escalation of risk appraisal”.
157-1	29057-29060	The	_	
157-2	29061-29064	SMA	_	
157-3	29064-29065	/	_	
157-4	29065-29069	dACC	_	
157-5	29070-29075	plays	_	
157-6	29076-29077	a	_	
157-7	29078-29082	role	_	
157-8	29083-29085	in	_	
157-9	29086-29095	detecting	_	
157-10	29096-29104	conflict	_	
157-11	29105-29107	at	_	
157-12	29108-29111	the	_	
157-13	29112-29120	response	_	
157-14	29121-29126	level	_	
157-15	29126-29127	,	_	
157-16	29128-29131	and	_	
157-17	29132-29135	has	_	
157-18	29136-29140	been	_	
157-19	29141-29151	implicated	_	
157-20	29152-29154	in	_	
157-21	29155-29166	risk-taking	_	
157-22	29166-29167	,	_	
157-23	29168-29180	particularly	_	
157-24	29181-29183	in	_	
157-25	29184-29189	light	_	
157-26	29190-29192	of	_	
157-27	29193-29196	the	_	
157-28	29197-29205	opposing	_	
157-29	29206-29216	influences	_	
157-30	29217-29219	of	_	
157-31	29220-29229	potential	_	
157-32	29230-29238	positive	_	
157-33	29239-29242	and	_	
157-34	29243-29251	negative	_	
157-35	29252-29260	outcomes	_	
157-36	29260-29261	;	_	
157-37	29262-29264	in	_	
157-38	29265-29268	the	_	
157-39	29269-29273	BART	_	
157-40	29273-29274	,	_	
157-41	29275-29282	reduced	_	
157-42	29283-29291	response	_	
157-43	29292-29294	in	_	
157-44	29295-29298	SMA	_	
157-45	29298-29299	/	_	
157-46	29299-29303	dACC	_	
157-47	29304-29306	as	_	
157-48	29307-29315	function	_	
157-49	29316-29318	of	_	
157-50	29319-29323	pump	_	
157-51	29324-29330	number	_	
157-52	29331-29333	is	_	
157-53	29334-29342	proposed	_	
157-54	29343-29345	to	_	
157-55	29346-29354	coincide	_	
157-56	29355-29359	with	_	
157-57	29360-29361	a	_	
157-58	29362-29363	“	_	
157-59	29363-29376	de-escalation	_	
157-60	29377-29379	of	_	
157-61	29380-29384	risk	_	
157-62	29385-29394	appraisal	_	
157-63	29394-29395	”	_	
157-64	29395-29396	.	_	

#Text=In other words, more risk taking is expected when levels of SMA/dACC (and other regions) are reduced; we found evidence of this pattern of cognitive neural processing for the high-risk adolescents within this study.
158-1	29397-29399	In	_	
158-2	29400-29405	other	_	
158-3	29406-29411	words	_	
158-4	29411-29412	,	_	
158-5	29413-29417	more	_	
158-6	29418-29422	risk	_	
158-7	29423-29429	taking	_	
158-8	29430-29432	is	_	
158-9	29433-29441	expected	_	
158-10	29442-29446	when	_	
158-11	29447-29453	levels	_	
158-12	29454-29456	of	_	
158-13	29457-29460	SMA	_	
158-14	29460-29461	/	_	
158-15	29461-29465	dACC	_	
158-16	29466-29467	(	_	
158-17	29467-29470	and	_	
158-18	29471-29476	other	_	
158-19	29477-29484	regions	_	
158-20	29484-29485	)	_	
158-21	29486-29489	are	_	
158-22	29490-29497	reduced	_	
158-23	29497-29498	;	_	
158-24	29499-29501	we	_	
158-25	29502-29507	found	_	
158-26	29508-29516	evidence	_	
158-27	29517-29519	of	_	
158-28	29520-29524	this	_	
158-29	29525-29532	pattern	_	
158-30	29533-29535	of	_	
158-31	29536-29545	cognitive	_	
158-32	29546-29552	neural	_	
158-33	29553-29563	processing	_	
158-34	29564-29567	for	_	
158-35	29568-29571	the	_	
158-36	29572-29581	high-risk	_	
158-37	29582-29593	adolescents	_	
158-38	29594-29600	within	_	
158-39	29601-29605	this	_	
158-40	29606-29611	study	_	
158-41	29611-29612	.	_	

#Text=We found that the relationship between pumps and dACC/SMA response was more negative in the control group as compared to youth using alcohol+marijuana, suggesting greater sensitivity of dACC/SMA to levels of risk as assessed by non-using youth.
159-1	29613-29615	We	_	
159-2	29616-29621	found	_	
159-3	29622-29626	that	_	
159-4	29627-29630	the	_	
159-5	29631-29643	relationship	_	
159-6	29644-29651	between	_	
159-7	29652-29657	pumps	_	
159-8	29658-29661	and	_	
159-9	29662-29666	dACC	_	
159-10	29666-29667	/	_	
159-11	29667-29670	SMA	_	
159-12	29671-29679	response	_	
159-13	29680-29683	was	_	
159-14	29684-29688	more	_	
159-15	29689-29697	negative	_	
159-16	29698-29700	in	_	
159-17	29701-29704	the	_	
159-18	29705-29712	control	_	
159-19	29713-29718	group	_	
159-20	29719-29721	as	_	
159-21	29722-29730	compared	_	
159-22	29731-29733	to	_	
159-23	29734-29739	youth	_	
159-24	29740-29745	using	_	
159-25	29746-29753	alcohol	_	
159-26	29753-29754	+	_	
159-27	29754-29763	marijuana	_	
159-28	29763-29764	,	_	
159-29	29765-29775	suggesting	_	
159-30	29776-29783	greater	_	
159-31	29784-29795	sensitivity	_	
159-32	29796-29798	of	_	
159-33	29799-29803	dACC	_	
159-34	29803-29804	/	_	
159-35	29804-29807	SMA	_	
159-36	29808-29810	to	_	
159-37	29811-29817	levels	_	
159-38	29818-29820	of	_	
159-39	29821-29825	risk	_	
159-40	29826-29828	as	_	
159-41	29829-29837	assessed	_	
159-42	29838-29840	by	_	
159-43	29841-29850	non-using	_	
159-44	29851-29856	youth	_	
159-45	29856-29857	.	_	

#Text=This finding is opposite to that of, who reported that heavier weekly alcohol use was associated with greater decreases the relationship between pump number and dACC/SMA response.
160-1	29858-29862	This	_	
160-2	29863-29870	finding	_	
160-3	29871-29873	is	_	
160-4	29874-29882	opposite	_	
160-5	29883-29885	to	_	
160-6	29886-29890	that	_	
160-7	29891-29893	of	_	
160-8	29893-29894	,	_	
160-9	29895-29898	who	_	
160-10	29899-29907	reported	_	
160-11	29908-29912	that	_	
160-12	29913-29920	heavier	_	
160-13	29921-29927	weekly	_	
160-14	29928-29935	alcohol	_	
160-15	29936-29939	use	_	
160-16	29940-29943	was	_	
160-17	29944-29954	associated	_	
160-18	29955-29959	with	_	
160-19	29960-29967	greater	_	
160-20	29968-29977	decreases	_	
160-21	29978-29981	the	_	
160-22	29982-29994	relationship	_	
160-23	29995-30002	between	_	
160-24	30003-30007	pump	_	
160-25	30008-30014	number	_	
160-26	30015-30018	and	_	
160-27	30019-30023	dACC	_	
160-28	30023-30024	/	_	
160-29	30024-30027	SMA	_	
160-30	30028-30036	response	_	
160-31	30036-30037	.	_	

#Text=While the disparate results between these two studies may be attributable to numerous factors including sample or design differences, the sample used here was significantly younger than the Bogg et al. study.
161-1	30038-30043	While	_	
161-2	30044-30047	the	_	
161-3	30048-30057	disparate	_	
161-4	30058-30065	results	_	
161-5	30066-30073	between	_	
161-6	30074-30079	these	_	
161-7	30080-30083	two	_	
161-8	30084-30091	studies	_	
161-9	30092-30095	may	_	
161-10	30096-30098	be	_	
161-11	30099-30111	attributable	_	
161-12	30112-30114	to	_	
161-13	30115-30123	numerous	_	
161-14	30124-30131	factors	_	
161-15	30132-30141	including	_	
161-16	30142-30148	sample	_	
161-17	30149-30151	or	_	
161-18	30152-30158	design	_	
161-19	30159-30170	differences	_	
161-20	30170-30171	,	_	
161-21	30172-30175	the	_	
161-22	30176-30182	sample	_	
161-23	30183-30187	used	_	
161-24	30188-30192	here	_	
161-25	30193-30196	was	_	
161-26	30197-30210	significantly	_	
161-27	30211-30218	younger	_	
161-28	30219-30223	than	_	
161-29	30224-30227	the	_	
161-30	30228-30232	Bogg	_	
161-31	30233-30235	et	_	
161-32	30236-30238	al	_	
161-33	30238-30239	.	_	
161-34	30240-30245	study	_	
161-35	30245-30246	.	_	

#Text=Studies continue to reflect that adolescents engage portions of the dACC/SMA to a lesser degree than adults, which could have driven observed outcomes with our adolescent sample.
162-1	30247-30254	Studies	_	
162-2	30255-30263	continue	_	
162-3	30264-30266	to	_	
162-4	30267-30274	reflect	_	
162-5	30275-30279	that	_	
162-6	30280-30291	adolescents	_	
162-7	30292-30298	engage	_	
162-8	30299-30307	portions	_	
162-9	30308-30310	of	_	
162-10	30311-30314	the	_	
162-11	30315-30319	dACC	_	
162-12	30319-30320	/	_	
162-13	30320-30323	SMA	_	
162-14	30324-30326	to	_	
162-15	30327-30328	a	_	
162-16	30329-30335	lesser	_	
162-17	30336-30342	degree	_	
162-18	30343-30347	than	_	
162-19	30348-30354	adults	_	
162-20	30354-30355	,	_	
162-21	30356-30361	which	_	
162-22	30362-30367	could	_	
162-23	30368-30372	have	_	
162-24	30373-30379	driven	_	
162-25	30380-30388	observed	_	
162-26	30389-30397	outcomes	_	
162-27	30398-30402	with	_	
162-28	30403-30406	our	_	
162-29	30407-30417	adolescent	_	
162-30	30418-30424	sample	_	
162-31	30424-30425	.	_	

#Text=However, design differences may be a more salient difference; used an event related modeling approach that enabled the separation of each pump decision, whereas this study modeled each sequence of pumps as a single block.
163-1	30426-30433	However	_	
163-2	30433-30434	,	_	
163-3	30435-30441	design	_	
163-4	30442-30453	differences	_	
163-5	30454-30457	may	_	
163-6	30458-30460	be	_	
163-7	30461-30462	a	_	
163-8	30463-30467	more	_	
163-9	30468-30475	salient	_	
163-10	30476-30486	difference	_	
163-11	30486-30487	;	_	
163-12	30488-30492	used	_	
163-13	30493-30495	an	_	
163-14	30496-30501	event	_	
163-15	30502-30509	related	_	
163-16	30510-30518	modeling	_	
163-17	30519-30527	approach	_	
163-18	30528-30532	that	_	
163-19	30533-30540	enabled	_	
163-20	30541-30544	the	_	
163-21	30545-30555	separation	_	
163-22	30556-30558	of	_	
163-23	30559-30563	each	_	
163-24	30564-30568	pump	_	
163-25	30569-30577	decision	_	
163-26	30577-30578	,	_	
163-27	30579-30586	whereas	_	
163-28	30587-30591	this	_	
163-29	30592-30597	study	_	
163-30	30598-30605	modeled	_	
163-31	30606-30610	each	_	
163-32	30611-30619	sequence	_	
163-33	30620-30622	of	_	
163-34	30623-30628	pumps	_	
163-35	30629-30631	as	_	
163-36	30632-30633	a	_	
163-37	30634-30640	single	_	
163-38	30641-30646	block	_	
163-39	30646-30647	.	_	

#Text=In addition, the current study used a consistent reward (i.e. 1 point), whereas Bogg et al. used increasing rewards for each pump.
164-1	30648-30650	In	_	
164-2	30651-30659	addition	_	
164-3	30659-30660	,	_	
164-4	30661-30664	the	_	
164-5	30665-30672	current	_	
164-6	30673-30678	study	_	
164-7	30679-30683	used	_	
164-8	30684-30685	a	_	
164-9	30686-30696	consistent	_	
164-10	30697-30703	reward	_	
164-11	30704-30705	(	_	
164-12	30705-30708	i.e	_	
164-13	30708-30709	.	_	
164-14	30710-30711	1	_	
164-15	30712-30717	point	_	
164-16	30717-30718	)	_	
164-17	30718-30719	,	_	
164-18	30720-30727	whereas	_	
164-19	30728-30732	Bogg	_	
164-20	30733-30735	et	_	
164-21	30736-30738	al	_	
164-22	30738-30739	.	_	
164-23	30740-30744	used	_	
164-24	30745-30755	increasing	_	
164-25	30756-30763	rewards	_	
164-26	30764-30767	for	_	
164-27	30768-30772	each	_	
164-28	30773-30777	pump	_	
164-29	30777-30778	.	_	

#Text=Either task difference could potentially account for the difference in observed empirical outcomes between these two studies.
165-1	30779-30785	Either	_	
165-2	30786-30790	task	_	
165-3	30791-30801	difference	_	
165-4	30802-30807	could	_	
165-5	30808-30819	potentially	_	
165-6	30820-30827	account	_	
165-7	30828-30831	for	_	
165-8	30832-30835	the	_	
165-9	30836-30846	difference	_	
165-10	30847-30849	in	_	
165-11	30850-30858	observed	_	
165-12	30859-30868	empirical	_	
165-13	30869-30877	outcomes	_	
165-14	30878-30885	between	_	
165-15	30886-30891	these	_	
165-16	30892-30895	two	_	
165-17	30896-30903	studies	_	
165-18	30903-30904	.	_	

#Text=Future studies that explcitly examine increasing versus constant rewards may clarify these results.
166-1	30905-30911	Future	_	
166-2	30912-30919	studies	_	
166-3	30920-30924	that	_	
166-4	30925-30934	explcitly	_	
166-5	30935-30942	examine	_	
166-6	30943-30953	increasing	_	
166-7	30954-30960	versus	_	
166-8	30961-30969	constant	_	
166-9	30970-30977	rewards	_	
166-10	30978-30981	may	_	
166-11	30982-30989	clarify	_	
166-12	30990-30995	these	_	
166-13	30996-31003	results	_	
166-14	31003-31004	.	_	

#Text=In addition to differences in the SMA, the adolescent alcohol+marijuana group showed a decreased relationship between pump number and response in the right insula/putamen compared to the non-using group, and in left PoCG/SPL compared to both the non-using and marijuana-only group.
167-1	31005-31007	In	_	
167-2	31008-31016	addition	_	
167-3	31017-31019	to	_	
167-4	31020-31031	differences	_	
167-5	31032-31034	in	_	
167-6	31035-31038	the	_	
167-7	31039-31042	SMA	_	
167-8	31042-31043	,	_	
167-9	31044-31047	the	_	
167-10	31048-31058	adolescent	_	
167-11	31059-31066	alcohol	_	
167-12	31066-31067	+	_	
167-13	31067-31076	marijuana	_	
167-14	31077-31082	group	_	
167-15	31083-31089	showed	_	
167-16	31090-31091	a	_	
167-17	31092-31101	decreased	_	
167-18	31102-31114	relationship	_	
167-19	31115-31122	between	_	
167-20	31123-31127	pump	_	
167-21	31128-31134	number	_	
167-22	31135-31138	and	_	
167-23	31139-31147	response	_	
167-24	31148-31150	in	_	
167-25	31151-31154	the	_	
167-26	31155-31160	right	_	
167-27	31161-31167	insula	_	
167-28	31167-31168	/	_	
167-29	31168-31175	putamen	_	
167-30	31176-31184	compared	_	
167-31	31185-31187	to	_	
167-32	31188-31191	the	_	
167-33	31192-31201	non-using	_	
167-34	31202-31207	group	_	
167-35	31207-31208	,	_	
167-36	31209-31212	and	_	
167-37	31213-31215	in	_	
167-38	31216-31220	left	_	
167-39	31221-31225	PoCG	_	
167-40	31225-31226	/	_	
167-41	31226-31229	SPL	_	
167-42	31230-31238	compared	_	
167-43	31239-31241	to	_	
167-44	31242-31246	both	_	
167-45	31247-31250	the	_	
167-46	31251-31260	non-using	_	
167-47	31261-31264	and	_	
167-48	31265-31279	marijuana-only	_	
167-49	31280-31285	group	_	
167-50	31285-31286	.	_	

#Text=The anterior insula plays a critical role in anticipating negative outcomes in adults and may serve as a stop signal to prevent risk-taking.
168-1	31287-31290	The	_	
168-2	31291-31299	anterior	_	
168-3	31300-31306	insula	_	
168-4	31307-31312	plays	_	
168-5	31313-31314	a	_	
168-6	31315-31323	critical	_	
168-7	31324-31328	role	_	
168-8	31329-31331	in	_	
168-9	31332-31344	anticipating	_	
168-10	31345-31353	negative	_	
168-11	31354-31362	outcomes	_	
168-12	31363-31365	in	_	
168-13	31366-31372	adults	_	
168-14	31373-31376	and	_	
168-15	31377-31380	may	_	
168-16	31381-31386	serve	_	
168-17	31387-31389	as	_	
168-18	31390-31391	a	_	
168-19	31392-31396	stop	_	
168-20	31397-31403	signal	_	
168-21	31404-31406	to	_	
168-22	31407-31414	prevent	_	
168-23	31415-31426	risk-taking	_	
168-24	31426-31427	.	_	

#Text=The SPL is an area whose response typically increases with degree of perceived uncertainty.
169-1	31428-31431	The	_	
169-2	31432-31435	SPL	_	
169-3	31436-31438	is	_	
169-4	31439-31441	an	_	
169-5	31442-31446	area	_	
169-6	31447-31452	whose	_	
169-7	31453-31461	response	_	
169-8	31462-31471	typically	_	
169-9	31472-31481	increases	_	
169-10	31482-31486	with	_	
169-11	31487-31493	degree	_	
169-12	31494-31496	of	_	
169-13	31497-31506	perceived	_	
169-14	31507-31518	uncertainty	_	
169-15	31518-31519	.	_	

#Text=The reduced parametric relationship between pump number and signal in these areas among the substance use groups thus may suggest less differentiation of varying levels of risk in the alcohol+marijuana group.
170-1	31520-31523	The	_	
170-2	31524-31531	reduced	_	
170-3	31532-31542	parametric	_	
170-4	31543-31555	relationship	_	
170-5	31556-31563	between	_	
170-6	31564-31568	pump	_	
170-7	31569-31575	number	_	
170-8	31576-31579	and	_	
170-9	31580-31586	signal	_	
170-10	31587-31589	in	_	
170-11	31590-31595	these	_	
170-12	31596-31601	areas	_	
170-13	31602-31607	among	_	
170-14	31608-31611	the	_	
170-15	31612-31621	substance	_	
170-16	31622-31625	use	_	
170-17	31626-31632	groups	_	
170-18	31633-31637	thus	_	
170-19	31638-31641	may	_	
170-20	31642-31649	suggest	_	
170-21	31650-31654	less	_	
170-22	31655-31670	differentiation	_	
170-23	31671-31673	of	_	
170-24	31674-31681	varying	_	
170-25	31682-31688	levels	_	
170-26	31689-31691	of	_	
170-27	31692-31696	risk	_	
170-28	31697-31699	in	_	
170-29	31700-31703	the	_	
170-30	31704-31711	alcohol	_	
170-31	31711-31712	+	_	
170-32	31712-31721	marijuana	_	
170-33	31722-31727	group	_	
170-34	31727-31728	.	_	

#Text=If reduced differentiation of levels of risk is the underlying mechanism that differentiates the substance users from non-users, it could then be expected that with a greater range of available pumps, a behavioral difference might be observed in future examinations.
171-1	31729-31731	If	_	
171-2	31732-31739	reduced	_	
171-3	31740-31755	differentiation	_	
171-4	31756-31758	of	_	
171-5	31759-31765	levels	_	
171-6	31766-31768	of	_	
171-7	31769-31773	risk	_	
171-8	31774-31776	is	_	
171-9	31777-31780	the	_	
171-10	31781-31791	underlying	_	
171-11	31792-31801	mechanism	_	
171-12	31802-31806	that	_	
171-13	31807-31821	differentiates	_	
171-14	31822-31825	the	_	
171-15	31826-31835	substance	_	
171-16	31836-31841	users	_	
171-17	31842-31846	from	_	
171-18	31847-31856	non-users	_	
171-19	31856-31857	,	_	
171-20	31858-31860	it	_	
171-21	31861-31866	could	_	
171-22	31867-31871	then	_	
171-23	31872-31874	be	_	
171-24	31875-31883	expected	_	
171-25	31884-31888	that	_	
171-26	31889-31893	with	_	
171-27	31894-31895	a	_	
171-28	31896-31903	greater	_	
171-29	31904-31909	range	_	
171-30	31910-31912	of	_	
171-31	31913-31922	available	_	
171-32	31923-31928	pumps	_	
171-33	31928-31929	,	_	
171-34	31930-31931	a	_	
171-35	31932-31942	behavioral	_	
171-36	31943-31953	difference	_	
171-37	31954-31959	might	_	
171-38	31960-31962	be	_	
171-39	31963-31971	observed	_	
171-40	31972-31974	in	_	
171-41	31975-31981	future	_	
171-42	31982-31994	examinations	_	
171-43	31994-31995	.	_	

#Text=Future studies that examine greater ranges of risk taking as well as those that specifically manipulate uncertainty processing will provide a stronger test of this differentiability hypothesis.
172-1	31996-32002	Future	_	
172-2	32003-32010	studies	_	
172-3	32011-32015	that	_	
172-4	32016-32023	examine	_	
172-5	32024-32031	greater	_	
172-6	32032-32038	ranges	_	
172-7	32039-32041	of	_	
172-8	32042-32046	risk	_	
172-9	32047-32053	taking	_	
172-10	32054-32056	as	_	
172-11	32057-32061	well	_	
172-12	32062-32064	as	_	
172-13	32065-32070	those	_	
172-14	32071-32075	that	_	
172-15	32076-32088	specifically	_	
172-16	32089-32099	manipulate	_	
172-17	32100-32111	uncertainty	_	
172-18	32112-32122	processing	_	
172-19	32123-32127	will	_	
172-20	32128-32135	provide	_	
172-21	32136-32137	a	_	
172-22	32138-32146	stronger	_	
172-23	32147-32151	test	_	
172-24	32152-32154	of	_	
172-25	32155-32159	this	_	
172-26	32160-32177	differentiability	_	
172-27	32178-32188	hypothesis	_	
172-28	32188-32189	.	_	

#Text=Interestingly, the difference in SPL/IPL is in the opposite direction to the results of a prior study of risky decision making in marijuana users.
173-1	32190-32203	Interestingly	_	
173-2	32203-32204	,	_	
173-3	32205-32208	the	_	
173-4	32209-32219	difference	_	
173-5	32220-32222	in	_	
173-6	32223-32226	SPL	_	
173-7	32226-32227	/	_	
173-8	32227-32230	IPL	_	
173-9	32231-32233	is	_	
173-10	32234-32236	in	_	
173-11	32237-32240	the	_	
173-12	32241-32249	opposite	_	
173-13	32250-32259	direction	_	
173-14	32260-32262	to	_	
173-15	32263-32266	the	_	
173-16	32267-32274	results	_	
173-17	32275-32277	of	_	
173-18	32278-32279	a	_	
173-19	32280-32285	prior	_	
173-20	32286-32291	study	_	
173-21	32292-32294	of	_	
173-22	32295-32300	risky	_	
173-23	32301-32309	decision	_	
173-24	32310-32316	making	_	
173-25	32317-32319	in	_	
173-26	32320-32329	marijuana	_	
173-27	32330-32335	users	_	
173-28	32335-32336	.	_	

#Text=Whether this reflects task differences or the different developmental stage of the adolescents examined herein is unclear; yet, future studies that specifically address the task and sample differences will shed light on these disparate results.
174-1	32337-32344	Whether	_	
174-2	32345-32349	this	_	
174-3	32350-32358	reflects	_	
174-4	32359-32363	task	_	
174-5	32364-32375	differences	_	
174-6	32376-32378	or	_	
174-7	32379-32382	the	_	
174-8	32383-32392	different	_	
174-9	32393-32406	developmental	_	
174-10	32407-32412	stage	_	
174-11	32413-32415	of	_	
174-12	32416-32419	the	_	
174-13	32420-32431	adolescents	_	
174-14	32432-32440	examined	_	
174-15	32441-32447	herein	_	
174-16	32448-32450	is	_	
174-17	32451-32458	unclear	_	
174-18	32458-32459	;	_	
174-19	32460-32463	yet	_	
174-20	32463-32464	,	_	
174-21	32465-32471	future	_	
174-22	32472-32479	studies	_	
174-23	32480-32484	that	_	
174-24	32485-32497	specifically	_	
174-25	32498-32505	address	_	
174-26	32506-32509	the	_	
174-27	32510-32514	task	_	
174-28	32515-32518	and	_	
174-29	32519-32525	sample	_	
174-30	32526-32537	differences	_	
174-31	32538-32542	will	_	
174-32	32543-32547	shed	_	
174-33	32548-32553	light	_	
174-34	32554-32556	on	_	
174-35	32557-32562	these	_	
174-36	32563-32572	disparate	_	
174-37	32573-32580	results	_	
174-38	32580-32581	.	_	

#Text=An important question that arises from the current study is the specificity of the results to substance use per se as opposed to more general proclivity toward risk taking during this developmental phase, and whether the differences observed could potentially be a marker of future drug use or the sequelae of prior drug use.
175-1	32582-32584	An	_	
175-2	32585-32594	important	_	
175-3	32595-32603	question	_	
175-4	32604-32608	that	_	
175-5	32609-32615	arises	_	
175-6	32616-32620	from	_	
175-7	32621-32624	the	_	
175-8	32625-32632	current	_	
175-9	32633-32638	study	_	
175-10	32639-32641	is	_	
175-11	32642-32645	the	_	
175-12	32646-32657	specificity	_	
175-13	32658-32660	of	_	
175-14	32661-32664	the	_	
175-15	32665-32672	results	_	
175-16	32673-32675	to	_	
175-17	32676-32685	substance	_	
175-18	32686-32689	use	_	
175-19	32690-32693	per	_	
175-20	32694-32696	se	_	
175-21	32697-32699	as	_	
175-22	32700-32707	opposed	_	
175-23	32708-32710	to	_	
175-24	32711-32715	more	_	
175-25	32716-32723	general	_	
175-26	32724-32734	proclivity	_	
175-27	32735-32741	toward	_	
175-28	32742-32746	risk	_	
175-29	32747-32753	taking	_	
175-30	32754-32760	during	_	
175-31	32761-32765	this	_	
175-32	32766-32779	developmental	_	
175-33	32780-32785	phase	_	
175-34	32785-32786	,	_	
175-35	32787-32790	and	_	
175-36	32791-32798	whether	_	
175-37	32799-32802	the	_	
175-38	32803-32814	differences	_	
175-39	32815-32823	observed	_	
175-40	32824-32829	could	_	
175-41	32830-32841	potentially	_	
175-42	32842-32844	be	_	
175-43	32845-32846	a	_	
175-44	32847-32853	marker	_	
175-45	32854-32856	of	_	
175-46	32857-32863	future	_	
175-47	32864-32868	drug	_	
175-48	32869-32872	use	_	
175-49	32873-32875	or	_	
175-50	32876-32879	the	_	
175-51	32880-32888	sequelae	_	
175-52	32889-32891	of	_	
175-53	32892-32897	prior	_	
175-54	32898-32902	drug	_	
175-55	32903-32906	use	_	
175-56	32906-32907	.	_	

#Text=First, the studied population is known to engage in greater levels of risk than individuals not involved in the juvenile justice system, and in this sense are a fairly homogenous group with regard to general propensity for risk-taking.
176-1	32908-32913	First	_	
176-2	32913-32914	,	_	
176-3	32915-32918	the	_	
176-4	32919-32926	studied	_	
176-5	32927-32937	population	_	
176-6	32938-32940	is	_	
176-7	32941-32946	known	_	
176-8	32947-32949	to	_	
176-9	32950-32956	engage	_	
176-10	32957-32959	in	_	
176-11	32960-32967	greater	_	
176-12	32968-32974	levels	_	
176-13	32975-32977	of	_	
176-14	32978-32982	risk	_	
176-15	32983-32987	than	_	
176-16	32988-32999	individuals	_	
176-17	33000-33003	not	_	
176-18	33004-33012	involved	_	
176-19	33013-33015	in	_	
176-20	33016-33019	the	_	
176-21	33020-33028	juvenile	_	
176-22	33029-33036	justice	_	
176-23	33037-33043	system	_	
176-24	33043-33044	,	_	
176-25	33045-33048	and	_	
176-26	33049-33051	in	_	
176-27	33052-33056	this	_	
176-28	33057-33062	sense	_	
176-29	33063-33066	are	_	
176-30	33067-33068	a	_	
176-31	33069-33075	fairly	_	
176-32	33076-33086	homogenous	_	
176-33	33087-33092	group	_	
176-34	33093-33097	with	_	
176-35	33098-33104	regard	_	
176-36	33105-33107	to	_	
176-37	33108-33115	general	_	
176-38	33116-33126	propensity	_	
176-39	33127-33130	for	_	
176-40	33131-33142	risk-taking	_	
176-41	33142-33143	.	_	

#Text=If it is true that there are patterns of activation that underlie risk-taking more generally, then of importance for interpretation, these patterns are, in fact, matched in our groups, and thus any observed differences could be viewed as specific to substance use.
177-1	33144-33146	If	_	
177-2	33147-33149	it	_	
177-3	33150-33152	is	_	
177-4	33153-33157	true	_	
177-5	33158-33162	that	_	
177-6	33163-33168	there	_	
177-7	33169-33172	are	_	
177-8	33173-33181	patterns	_	
177-9	33182-33184	of	_	
177-10	33185-33195	activation	_	
177-11	33196-33200	that	_	
177-12	33201-33209	underlie	_	
177-13	33210-33221	risk-taking	_	
177-14	33222-33226	more	_	
177-15	33227-33236	generally	_	
177-16	33236-33237	,	_	
177-17	33238-33242	then	_	
177-18	33243-33245	of	_	
177-19	33246-33256	importance	_	
177-20	33257-33260	for	_	
177-21	33261-33275	interpretation	_	
177-22	33275-33276	,	_	
177-23	33277-33282	these	_	
177-24	33283-33291	patterns	_	
177-25	33292-33295	are	_	
177-26	33295-33296	,	_	
177-27	33297-33299	in	_	
177-28	33300-33304	fact	_	
177-29	33304-33305	,	_	
177-30	33306-33313	matched	_	
177-31	33314-33316	in	_	
177-32	33317-33320	our	_	
177-33	33321-33327	groups	_	
177-34	33327-33328	,	_	
177-35	33329-33332	and	_	
177-36	33333-33337	thus	_	
177-37	33338-33341	any	_	
177-38	33342-33350	observed	_	
177-39	33351-33362	differences	_	
177-40	33363-33368	could	_	
177-41	33369-33371	be	_	
177-42	33372-33378	viewed	_	
177-43	33379-33381	as	_	
177-44	33382-33390	specific	_	
177-45	33391-33393	to	_	
177-46	33394-33403	substance	_	
177-47	33404-33407	use	_	
177-48	33407-33408	.	_	

#Text=Although our findings are likely specific to substance use, we are still unable with this design to determine whether the differences existed prior to the initiation of substance use or as a consequence of adolescent substance use.
178-1	33409-33417	Although	_	
178-2	33418-33421	our	_	
178-3	33422-33430	findings	_	
178-4	33431-33434	are	_	
178-5	33435-33441	likely	_	
178-6	33442-33450	specific	_	
178-7	33451-33453	to	_	
178-8	33454-33463	substance	_	
178-9	33464-33467	use	_	
178-10	33467-33468	,	_	
178-11	33469-33471	we	_	
178-12	33472-33475	are	_	
178-13	33476-33481	still	_	
178-14	33482-33488	unable	_	
178-15	33489-33493	with	_	
178-16	33494-33498	this	_	
178-17	33499-33505	design	_	
178-18	33506-33508	to	_	
178-19	33509-33518	determine	_	
178-20	33519-33526	whether	_	
178-21	33527-33530	the	_	
178-22	33531-33542	differences	_	
178-23	33543-33550	existed	_	
178-24	33551-33556	prior	_	
178-25	33557-33559	to	_	
178-26	33560-33563	the	_	
178-27	33564-33574	initiation	_	
178-28	33575-33577	of	_	
178-29	33578-33587	substance	_	
178-30	33588-33591	use	_	
178-31	33592-33594	or	_	
178-32	33595-33597	as	_	
178-33	33598-33599	a	_	
178-34	33600-33611	consequence	_	
178-35	33612-33614	of	_	
178-36	33615-33625	adolescent	_	
178-37	33626-33635	substance	_	
178-38	33636-33639	use	_	
178-39	33639-33640	.	_	

#Text=Future longitudinal studies will be well-positioned to answer this key question.
179-1	33641-33647	Future	_	
179-2	33648-33660	longitudinal	_	
179-3	33661-33668	studies	_	
179-4	33669-33673	will	_	
179-5	33674-33676	be	_	
179-6	33677-33692	well-positioned	_	
179-7	33693-33695	to	_	
179-8	33696-33702	answer	_	
179-9	33703-33707	this	_	
179-10	33708-33711	key	_	
179-11	33712-33720	question	_	
179-12	33720-33721	.	_	

#Text=Finally, one question that often emerges following fMRI analyses of adolescent task-based behavior is the potential applicability of the results to treatment.
180-1	33722-33729	Finally	_	
180-2	33729-33730	,	_	
180-3	33731-33734	one	_	
180-4	33735-33743	question	_	
180-5	33744-33748	that	_	
180-6	33749-33754	often	_	
180-7	33755-33762	emerges	_	
180-8	33763-33772	following	_	
180-9	33773-33777	fMRI	_	
180-10	33778-33786	analyses	_	
180-11	33787-33789	of	_	
180-12	33790-33800	adolescent	_	
180-13	33801-33811	task-based	_	
180-14	33812-33820	behavior	_	
180-15	33821-33823	is	_	
180-16	33824-33827	the	_	
180-17	33828-33837	potential	_	
180-18	33838-33851	applicability	_	
180-19	33852-33854	of	_	
180-20	33855-33858	the	_	
180-21	33859-33866	results	_	
180-22	33867-33869	to	_	
180-23	33870-33879	treatment	_	
180-24	33879-33880	.	_	

#Text=The field has been moving towards integration of basic biological metrics, including neuroimaging (MRI/fMRI) as indices of mechanisms of treatment response for adolescents, as well as increasing use of neuroimaging as a more sensitive metric to identify the nature of adolescent cognitive processing.
181-1	33881-33884	The	_	
181-2	33885-33890	field	_	
181-3	33891-33894	has	_	
181-4	33895-33899	been	_	
181-5	33900-33906	moving	_	
181-6	33907-33914	towards	_	
181-7	33915-33926	integration	_	
181-8	33927-33929	of	_	
181-9	33930-33935	basic	_	
181-10	33936-33946	biological	_	
181-11	33947-33954	metrics	_	
181-12	33954-33955	,	_	
181-13	33956-33965	including	_	
181-14	33966-33978	neuroimaging	_	
181-15	33979-33980	(	_	
181-16	33980-33983	MRI	_	
181-17	33983-33984	/	_	
181-18	33984-33988	fMRI	_	
181-19	33988-33989	)	_	
181-20	33990-33992	as	_	
181-21	33993-34000	indices	_	
181-22	34001-34003	of	_	
181-23	34004-34014	mechanisms	_	
181-24	34015-34017	of	_	
181-25	34018-34027	treatment	_	
181-26	34028-34036	response	_	
181-27	34037-34040	for	_	
181-28	34041-34052	adolescents	_	
181-29	34052-34053	,	_	
181-30	34054-34056	as	_	
181-31	34057-34061	well	_	
181-32	34062-34064	as	_	
181-33	34065-34075	increasing	_	
181-34	34076-34079	use	_	
181-35	34080-34082	of	_	
181-36	34083-34095	neuroimaging	_	
181-37	34096-34098	as	_	
181-38	34099-34100	a	_	
181-39	34101-34105	more	_	
181-40	34106-34115	sensitive	_	
181-41	34116-34122	metric	_	
181-42	34123-34125	to	_	
181-43	34126-34134	identify	_	
181-44	34135-34138	the	_	
181-45	34139-34145	nature	_	
181-46	34146-34148	of	_	
181-47	34149-34159	adolescent	_	
181-48	34160-34169	cognitive	_	
181-49	34170-34180	processing	_	
181-50	34180-34181	.	_	

#Text=While neuroimaging itself is unlikely to be a widely disseminated tool for day-to-day clinical settings, starting to understand how the adolescent brain processes risk information is critical to informing treatment development and tailoring of interventions so that they are more responsive and effective for this developmental phase.
182-1	34182-34187	While	_	
182-2	34188-34200	neuroimaging	_	
182-3	34201-34207	itself	_	
182-4	34208-34210	is	_	
182-5	34211-34219	unlikely	_	
182-6	34220-34222	to	_	
182-7	34223-34225	be	_	
182-8	34226-34227	a	_	
182-9	34228-34234	widely	_	
182-10	34235-34247	disseminated	_	
182-11	34248-34252	tool	_	
182-12	34253-34256	for	_	
182-13	34257-34267	day-to-day	_	
182-14	34268-34276	clinical	_	
182-15	34277-34285	settings	_	
182-16	34285-34286	,	_	
182-17	34287-34295	starting	_	
182-18	34296-34298	to	_	
182-19	34299-34309	understand	_	
182-20	34310-34313	how	_	
182-21	34314-34317	the	_	
182-22	34318-34328	adolescent	_	
182-23	34329-34334	brain	_	
182-24	34335-34344	processes	_	
182-25	34345-34349	risk	_	
182-26	34350-34361	information	_	
182-27	34362-34364	is	_	
182-28	34365-34373	critical	_	
182-29	34374-34376	to	_	
182-30	34377-34386	informing	_	
182-31	34387-34396	treatment	_	
182-32	34397-34408	development	_	
182-33	34409-34412	and	_	
182-34	34413-34422	tailoring	_	
182-35	34423-34425	of	_	
182-36	34426-34439	interventions	_	
182-37	34440-34442	so	_	
182-38	34443-34447	that	_	
182-39	34448-34452	they	_	
182-40	34453-34456	are	_	
182-41	34457-34461	more	_	
182-42	34462-34472	responsive	_	
182-43	34473-34476	and	_	
182-44	34477-34486	effective	_	
182-45	34487-34490	for	_	
182-46	34491-34495	this	_	
182-47	34496-34509	developmental	_	
182-48	34510-34515	phase	_	
182-49	34515-34516	.	_	

#Text=This is particularly critical at this time, when interventions for adolescent alcohol and cannabis use have much lower effect sizes for adolescents, as compared with adults.
183-1	34517-34521	This	_	
183-2	34522-34524	is	_	
183-3	34525-34537	particularly	_	
183-4	34538-34546	critical	_	
183-5	34547-34549	at	_	
183-6	34550-34554	this	_	
183-7	34555-34559	time	_	
183-8	34559-34560	,	_	
183-9	34561-34565	when	_	
183-10	34566-34579	interventions	_	
183-11	34580-34583	for	_	
183-12	34584-34594	adolescent	_	
183-13	34595-34602	alcohol	_	
183-14	34603-34606	and	_	
183-15	34607-34615	cannabis	_	
183-16	34616-34619	use	_	
183-17	34620-34624	have	_	
183-18	34625-34629	much	_	
183-19	34630-34635	lower	_	
183-20	34636-34642	effect	_	
183-21	34643-34648	sizes	_	
183-22	34649-34652	for	_	
183-23	34653-34664	adolescents	_	
183-24	34664-34665	,	_	
183-25	34666-34668	as	_	
183-26	34669-34677	compared	_	
183-27	34678-34682	with	_	
183-28	34683-34689	adults	_	
183-29	34689-34690	.	_	

#Text=Concretely, brain-based differences may play a critical role in helping interventionists determine which factors to address and enhance within the context of intervention efforts.
184-1	34691-34701	Concretely	_	
184-2	34701-34702	,	_	
184-3	34703-34714	brain-based	_	
184-4	34715-34726	differences	_	
184-5	34727-34730	may	_	
184-6	34731-34735	play	_	
184-7	34736-34737	a	_	
184-8	34738-34746	critical	_	
184-9	34747-34751	role	_	
184-10	34752-34754	in	_	
184-11	34755-34762	helping	_	
184-12	34763-34779	interventionists	_	
184-13	34780-34789	determine	_	
184-14	34790-34795	which	_	
184-15	34796-34803	factors	_	
184-16	34804-34806	to	_	
184-17	34807-34814	address	_	
184-18	34815-34818	and	_	
184-19	34819-34826	enhance	_	
184-20	34827-34833	within	_	
184-21	34834-34837	the	_	
184-22	34838-34845	context	_	
184-23	34846-34848	of	_	
184-24	34849-34861	intervention	_	
184-25	34862-34869	efforts	_	
184-26	34869-34870	.	_	

#Text=For example, results from the current study may suggest that it may be fruitful to target cognitive processes such as reward valuation or risk assessment in individuals who use alcohol+marijuana.
185-1	34871-34874	For	_	
185-2	34875-34882	example	_	
185-3	34882-34883	,	_	
185-4	34884-34891	results	_	
185-5	34892-34896	from	_	
185-6	34897-34900	the	_	
185-7	34901-34908	current	_	
185-8	34909-34914	study	_	
185-9	34915-34918	may	_	
185-10	34919-34926	suggest	_	
185-11	34927-34931	that	_	
185-12	34932-34934	it	_	
185-13	34935-34938	may	_	
185-14	34939-34941	be	_	
185-15	34942-34950	fruitful	_	
185-16	34951-34953	to	_	
185-17	34954-34960	target	_	
185-18	34961-34970	cognitive	_	
185-19	34971-34980	processes	_	
185-20	34981-34985	such	_	
185-21	34986-34988	as	_	
185-22	34989-34995	reward	_	
185-23	34996-35005	valuation	_	
185-24	35006-35008	or	_	
185-25	35009-35013	risk	_	
185-26	35014-35024	assessment	_	
185-27	35025-35027	in	_	
185-28	35028-35039	individuals	_	
185-29	35040-35043	who	_	
185-30	35044-35047	use	_	
185-31	35048-35055	alcohol	_	
185-32	35055-35056	+	_	
185-33	35056-35065	marijuana	_	
185-34	35065-35066	.	_	

#Text=The next step would be to examine the degree to which interventions that incorporate reward valuation and risk assessment (e.g., contingency management; cognitive behavioral therapy) change response in these regions, and whether those modulations of brain response predict subsequent reductions in adolescent drug use and/or risk taking.
186-1	35067-35070	The	_	
186-2	35071-35075	next	_	
186-3	35076-35080	step	_	
186-4	35081-35086	would	_	
186-5	35087-35089	be	_	
186-6	35090-35092	to	_	
186-7	35093-35100	examine	_	
186-8	35101-35104	the	_	
186-9	35105-35111	degree	_	
186-10	35112-35114	to	_	
186-11	35115-35120	which	_	
186-12	35121-35134	interventions	_	
186-13	35135-35139	that	_	
186-14	35140-35151	incorporate	_	
186-15	35152-35158	reward	_	
186-16	35159-35168	valuation	_	
186-17	35169-35172	and	_	
186-18	35173-35177	risk	_	
186-19	35178-35188	assessment	_	
186-20	35189-35190	(	_	
186-21	35190-35193	e.g	_	
186-22	35193-35194	.	_	
186-23	35194-35195	,	_	
186-24	35196-35207	contingency	_	
186-25	35208-35218	management	_	
186-26	35218-35219	;	_	
186-27	35220-35229	cognitive	_	
186-28	35230-35240	behavioral	_	
186-29	35241-35248	therapy	_	
186-30	35248-35249	)	_	
186-31	35250-35256	change	_	
186-32	35257-35265	response	_	
186-33	35266-35268	in	_	
186-34	35269-35274	these	_	
186-35	35275-35282	regions	_	
186-36	35282-35283	,	_	
186-37	35284-35287	and	_	
186-38	35288-35295	whether	_	
186-39	35296-35301	those	_	
186-40	35302-35313	modulations	_	
186-41	35314-35316	of	_	
186-42	35317-35322	brain	_	
186-43	35323-35331	response	_	
186-44	35332-35339	predict	_	
186-45	35340-35350	subsequent	_	
186-46	35351-35361	reductions	_	
186-47	35362-35364	in	_	
186-48	35365-35375	adolescent	_	
186-49	35376-35380	drug	_	
186-50	35381-35384	use	_	
186-51	35385-35388	and	_	
186-52	35388-35389	/	_	
186-53	35389-35391	or	_	
186-54	35392-35396	risk	_	
186-55	35397-35403	taking	_	
186-56	35403-35404	.	_	

#Text=Limitations and Future Directions
#Text=While the current study has many strengths, some limitations must also be acknowledged.
187-1	35405-35416	Limitations	_	
187-2	35417-35420	and	_	
187-3	35421-35427	Future	_	
187-4	35428-35438	Directions	_	
187-5	35439-35444	While	_	
187-6	35445-35448	the	_	
187-7	35449-35456	current	_	
187-8	35457-35462	study	_	
187-9	35463-35466	has	_	
187-10	35467-35471	many	_	
187-11	35472-35481	strengths	_	
187-12	35481-35482	,	_	
187-13	35483-35487	some	_	
187-14	35488-35499	limitations	_	
187-15	35500-35504	must	_	
187-16	35505-35509	also	_	
187-17	35510-35512	be	_	
187-18	35513-35525	acknowledged	_	
187-19	35525-35526	.	_	

#Text=First, the groups differed in the use of hard drugs and proportion of males, both of which could have influenced group differences.
188-1	35527-35532	First	_	
188-2	35532-35533	,	_	
188-3	35534-35537	the	_	
188-4	35538-35544	groups	_	
188-5	35545-35553	differed	_	
188-6	35554-35556	in	_	
188-7	35557-35560	the	_	
188-8	35561-35564	use	_	
188-9	35565-35567	of	_	
188-10	35568-35572	hard	_	
188-11	35573-35578	drugs	_	
188-12	35579-35582	and	_	
188-13	35583-35593	proportion	_	
188-14	35594-35596	of	_	
188-15	35597-35602	males	_	
188-16	35602-35603	,	_	
188-17	35604-35608	both	_	
188-18	35609-35611	of	_	
188-19	35612-35617	which	_	
188-20	35618-35623	could	_	
188-21	35624-35628	have	_	
188-22	35629-35639	influenced	_	
188-23	35640-35645	group	_	
188-24	35646-35657	differences	_	
188-25	35657-35658	.	_	

#Text=However, when controlling for these variables, clusters showing group differences either increased in extent or decreased slightly, but remained significant suggesting that group differences were not driven solely by these variables.
189-1	35659-35666	However	_	
189-2	35666-35667	,	_	
189-3	35668-35672	when	_	
189-4	35673-35684	controlling	_	
189-5	35685-35688	for	_	
189-6	35689-35694	these	_	
189-7	35695-35704	variables	_	
189-8	35704-35705	,	_	
189-9	35706-35714	clusters	_	
189-10	35715-35722	showing	_	
189-11	35723-35728	group	_	
189-12	35729-35740	differences	_	
189-13	35741-35747	either	_	
189-14	35748-35757	increased	_	
189-15	35758-35760	in	_	
189-16	35761-35767	extent	_	
189-17	35768-35770	or	_	
189-18	35771-35780	decreased	_	
189-19	35781-35789	slightly	_	
189-20	35789-35790	,	_	
189-21	35791-35794	but	_	
189-22	35795-35803	remained	_	
189-23	35804-35815	significant	_	
189-24	35816-35826	suggesting	_	
189-25	35827-35831	that	_	
189-26	35832-35837	group	_	
189-27	35838-35849	differences	_	
189-28	35850-35854	were	_	
189-29	35855-35858	not	_	
189-30	35859-35865	driven	_	
189-31	35866-35872	solely	_	
189-32	35873-35875	by	_	
189-33	35876-35881	these	_	
189-34	35882-35891	variables	_	
189-35	35891-35892	.	_	

#Text=Next, abstinence from alcohol/marijuana at the time of scanning was confirmed using only self-report.
190-1	35893-35897	Next	_	
190-2	35897-35898	,	_	
190-3	35899-35909	abstinence	_	
190-4	35910-35914	from	_	
190-5	35915-35922	alcohol	_	
190-6	35922-35923	/	_	
190-7	35923-35932	marijuana	_	
190-8	35933-35935	at	_	
190-9	35936-35939	the	_	
190-10	35940-35944	time	_	
190-11	35945-35947	of	_	
190-12	35948-35956	scanning	_	
190-13	35957-35960	was	_	
190-14	35961-35970	confirmed	_	
190-15	35971-35976	using	_	
190-16	35977-35981	only	_	
190-17	35982-35993	self-report	_	
190-18	35993-35994	.	_	

#Text=Thus there is some possiblility that a portion of the group differences may have emerged from acute drug effects from past 24-hour use.
191-1	35995-35999	Thus	_	
191-2	36000-36005	there	_	
191-3	36006-36008	is	_	
191-4	36009-36013	some	_	
191-5	36014-36026	possiblility	_	
191-6	36027-36031	that	_	
191-7	36032-36033	a	_	
191-8	36034-36041	portion	_	
191-9	36042-36044	of	_	
191-10	36045-36048	the	_	
191-11	36049-36054	group	_	
191-12	36055-36066	differences	_	
191-13	36067-36070	may	_	
191-14	36071-36075	have	_	
191-15	36076-36083	emerged	_	
191-16	36084-36088	from	_	
191-17	36089-36094	acute	_	
191-18	36095-36099	drug	_	
191-19	36100-36107	effects	_	
191-20	36108-36112	from	_	
191-21	36113-36117	past	_	
191-22	36118-36120	24	_	
191-23	36120-36121	-	_	
191-24	36121-36125	hour	_	
191-25	36126-36129	use	_	
191-26	36129-36130	.	_	

#Text=Finally, the variant of the BART used in the current study had some limitations.
192-1	36131-36138	Finally	_	
192-2	36138-36139	,	_	
192-3	36140-36143	the	_	
192-4	36144-36151	variant	_	
192-5	36152-36154	of	_	
192-6	36155-36158	the	_	
192-7	36159-36163	BART	_	
192-8	36164-36168	used	_	
192-9	36169-36171	in	_	
192-10	36172-36175	the	_	
192-11	36176-36183	current	_	
192-12	36184-36189	study	_	
192-13	36190-36193	had	_	
192-14	36194-36198	some	_	
192-15	36199-36210	limitations	_	
192-16	36210-36211	.	_	

#Text=First, we failed to observe any group differences in behavior on the BART, which may have been the result of the reduced range of pumps required to cause an explosion; this limited range may have placed artificial constraints on risk taking.
193-1	36212-36217	First	_	
193-2	36217-36218	,	_	
193-3	36219-36221	we	_	
193-4	36222-36228	failed	_	
193-5	36229-36231	to	_	
193-6	36232-36239	observe	_	
193-7	36240-36243	any	_	
193-8	36244-36249	group	_	
193-9	36250-36261	differences	_	
193-10	36262-36264	in	_	
193-11	36265-36273	behavior	_	
193-12	36274-36276	on	_	
193-13	36277-36280	the	_	
193-14	36281-36285	BART	_	
193-15	36285-36286	,	_	
193-16	36287-36292	which	_	
193-17	36293-36296	may	_	
193-18	36297-36301	have	_	
193-19	36302-36306	been	_	
193-20	36307-36310	the	_	
193-21	36311-36317	result	_	
193-22	36318-36320	of	_	
193-23	36321-36324	the	_	
193-24	36325-36332	reduced	_	
193-25	36333-36338	range	_	
193-26	36339-36341	of	_	
193-27	36342-36347	pumps	_	
193-28	36348-36356	required	_	
193-29	36357-36359	to	_	
193-30	36360-36365	cause	_	
193-31	36366-36368	an	_	
193-32	36369-36378	explosion	_	
193-33	36378-36379	;	_	
193-34	36380-36384	this	_	
193-35	36385-36392	limited	_	
193-36	36393-36398	range	_	
193-37	36399-36402	may	_	
193-38	36403-36407	have	_	
193-39	36408-36414	placed	_	
193-40	36415-36425	artificial	_	
193-41	36426-36437	constraints	_	
193-42	36438-36440	on	_	
193-43	36441-36445	risk	_	
193-44	36446-36452	taking	_	
193-45	36452-36453	.	_	

#Text=In addition to a lack of group differences, the limited range of available pumps on color balloons caused participants to pump significantly less on color balloons than the control balloons, a difference that could contribute to group differences in BOLD response.
194-1	36454-36456	In	_	
194-2	36457-36465	addition	_	
194-3	36466-36468	to	_	
194-4	36469-36470	a	_	
194-5	36471-36475	lack	_	
194-6	36476-36478	of	_	
194-7	36479-36484	group	_	
194-8	36485-36496	differences	_	
194-9	36496-36497	,	_	
194-10	36498-36501	the	_	
194-11	36502-36509	limited	_	
194-12	36510-36515	range	_	
194-13	36516-36518	of	_	
194-14	36519-36528	available	_	
194-15	36529-36534	pumps	_	
194-16	36535-36537	on	_	
194-17	36538-36543	color	_	
194-18	36544-36552	balloons	_	
194-19	36553-36559	caused	_	
194-20	36560-36572	participants	_	
194-21	36573-36575	to	_	
194-22	36576-36580	pump	_	
194-23	36581-36594	significantly	_	
194-24	36595-36599	less	_	
194-25	36600-36602	on	_	
194-26	36603-36608	color	_	
194-27	36609-36617	balloons	_	
194-28	36618-36622	than	_	
194-29	36623-36626	the	_	
194-30	36627-36634	control	_	
194-31	36635-36643	balloons	_	
194-32	36643-36644	,	_	
194-33	36645-36646	a	_	
194-34	36647-36657	difference	_	
194-35	36658-36662	that	_	
194-36	36663-36668	could	_	
194-37	36669-36679	contribute	_	
194-38	36680-36682	to	_	
194-39	36683-36688	group	_	
194-40	36689-36700	differences	_	
194-41	36701-36703	in	_	
194-42	36704-36708	BOLD	_	
194-43	36709-36717	response	_	
194-44	36717-36718	.	_	

#Text=However, examination of the percent signal change across regions that demonstrated group differences suggests that variation in BOLD reponse occurred primarily in the color balloon condition, suggesting our results are not merely the result of an imperfect control condition.
195-1	36719-36726	However	_	
195-2	36726-36727	,	_	
195-3	36728-36739	examination	_	
195-4	36740-36742	of	_	
195-5	36743-36746	the	_	
195-6	36747-36754	percent	_	
195-7	36755-36761	signal	_	
195-8	36762-36768	change	_	
195-9	36769-36775	across	_	
195-10	36776-36783	regions	_	
195-11	36784-36788	that	_	
195-12	36789-36801	demonstrated	_	
195-13	36802-36807	group	_	
195-14	36808-36819	differences	_	
195-15	36820-36828	suggests	_	
195-16	36829-36833	that	_	
195-17	36834-36843	variation	_	
195-18	36844-36846	in	_	
195-19	36847-36851	BOLD	_	
195-20	36852-36859	reponse	_	
195-21	36860-36868	occurred	_	
195-22	36869-36878	primarily	_	
195-23	36879-36881	in	_	
195-24	36882-36885	the	_	
195-25	36886-36891	color	_	
195-26	36892-36899	balloon	_	
195-27	36900-36909	condition	_	
195-28	36909-36910	,	_	
195-29	36911-36921	suggesting	_	
195-30	36922-36925	our	_	
195-31	36926-36933	results	_	
195-32	36934-36937	are	_	
195-33	36938-36941	not	_	
195-34	36942-36948	merely	_	
195-35	36949-36952	the	_	
195-36	36953-36959	result	_	
195-37	36960-36962	of	_	
195-38	36963-36965	an	_	
195-39	36966-36975	imperfect	_	
195-40	36976-36983	control	_	
195-41	36984-36993	condition	_	
195-42	36993-36994	.	_	

#Text=Finally, we acknowledge that the variant of the BART used in the current study is limited in its ablity to parse specific cognitive functions.
196-1	36995-37002	Finally	_	
196-2	37002-37003	,	_	
196-3	37004-37006	we	_	
196-4	37007-37018	acknowledge	_	
196-5	37019-37023	that	_	
196-6	37024-37027	the	_	
196-7	37028-37035	variant	_	
196-8	37036-37038	of	_	
196-9	37039-37042	the	_	
196-10	37043-37047	BART	_	
196-11	37048-37052	used	_	
196-12	37053-37055	in	_	
196-13	37056-37059	the	_	
196-14	37060-37067	current	_	
196-15	37068-37073	study	_	
196-16	37074-37076	is	_	
196-17	37077-37084	limited	_	
196-18	37085-37087	in	_	
196-19	37088-37091	its	_	
196-20	37092-37098	ablity	_	
196-21	37099-37101	to	_	
196-22	37102-37107	parse	_	
196-23	37108-37116	specific	_	
196-24	37117-37126	cognitive	_	
196-25	37127-37136	functions	_	
196-26	37136-37137	.	_	

#Text=Although we have attempted to control for some of the more obvious motor related activity, the contrasts included in the study are unlikley to control for factors such as executive control, working memory, and attention.
197-1	37138-37146	Although	_	
197-2	37147-37149	we	_	
197-3	37150-37154	have	_	
197-4	37155-37164	attempted	_	
197-5	37165-37167	to	_	
197-6	37168-37175	control	_	
197-7	37176-37179	for	_	
197-8	37180-37184	some	_	
197-9	37185-37187	of	_	
197-10	37188-37191	the	_	
197-11	37192-37196	more	_	
197-12	37197-37204	obvious	_	
197-13	37205-37210	motor	_	
197-14	37211-37218	related	_	
197-15	37219-37227	activity	_	
197-16	37227-37228	,	_	
197-17	37229-37232	the	_	
197-18	37233-37242	contrasts	_	
197-19	37243-37251	included	_	
197-20	37252-37254	in	_	
197-21	37255-37258	the	_	
197-22	37259-37264	study	_	
197-23	37265-37268	are	_	
197-24	37269-37277	unlikley	_	
197-25	37278-37280	to	_	
197-26	37281-37288	control	_	
197-27	37289-37292	for	_	
197-28	37293-37300	factors	_	
197-29	37301-37305	such	_	
197-30	37306-37308	as	_	
197-31	37309-37318	executive	_	
197-32	37319-37326	control	_	
197-33	37326-37327	,	_	
197-34	37328-37335	working	_	
197-35	37336-37342	memory	_	
197-36	37342-37343	,	_	
197-37	37344-37347	and	_	
197-38	37348-37357	attention	_	
197-39	37357-37358	.	_	

#Text=Given that we do not have any estimate of intelligence or school performance in our participants, the possibility of group differences in overall executive ablility could be driving some of the group differences noted in the task.
198-1	37359-37364	Given	_	
198-2	37365-37369	that	_	
198-3	37370-37372	we	_	
198-4	37373-37375	do	_	
198-5	37376-37379	not	_	
198-6	37380-37384	have	_	
198-7	37385-37388	any	_	
198-8	37389-37397	estimate	_	
198-9	37398-37400	of	_	
198-10	37401-37413	intelligence	_	
198-11	37414-37416	or	_	
198-12	37417-37423	school	_	
198-13	37424-37435	performance	_	
198-14	37436-37438	in	_	
198-15	37439-37442	our	_	
198-16	37443-37455	participants	_	
198-17	37455-37456	,	_	
198-18	37457-37460	the	_	
198-19	37461-37472	possibility	_	
198-20	37473-37475	of	_	
198-21	37476-37481	group	_	
198-22	37482-37493	differences	_	
198-23	37494-37496	in	_	
198-24	37497-37504	overall	_	
198-25	37505-37514	executive	_	
198-26	37515-37523	ablility	_	
198-27	37524-37529	could	_	
198-28	37530-37532	be	_	
198-29	37533-37540	driving	_	
198-30	37541-37545	some	_	
198-31	37546-37548	of	_	
198-32	37549-37552	the	_	
198-33	37553-37558	group	_	
198-34	37559-37570	differences	_	
198-35	37571-37576	noted	_	
198-36	37577-37579	in	_	
198-37	37580-37583	the	_	
198-38	37584-37588	task	_	
198-39	37588-37589	.	_	

#Text=Future studies that carefully assess risk taking in more controlled tasks alongside assessment of general cognitive ability will be key for further advancing our understanding of risk taking mechanisms among substance using groups.
199-1	37590-37596	Future	_	
199-2	37597-37604	studies	_	
199-3	37605-37609	that	_	
199-4	37610-37619	carefully	_	
199-5	37620-37626	assess	_	
199-6	37627-37631	risk	_	
199-7	37632-37638	taking	_	
199-8	37639-37641	in	_	
199-9	37642-37646	more	_	
199-10	37647-37657	controlled	_	
199-11	37658-37663	tasks	_	
199-12	37664-37673	alongside	_	
199-13	37674-37684	assessment	_	
199-14	37685-37687	of	_	
199-15	37688-37695	general	_	
199-16	37696-37705	cognitive	_	
199-17	37706-37713	ability	_	
199-18	37714-37718	will	_	
199-19	37719-37721	be	_	
199-20	37722-37725	key	_	
199-21	37726-37729	for	_	
199-22	37730-37737	further	_	
199-23	37738-37747	advancing	_	
199-24	37748-37751	our	_	
199-25	37752-37765	understanding	_	
199-26	37766-37768	of	_	
199-27	37769-37773	risk	_	
199-28	37774-37780	taking	_	
199-29	37781-37791	mechanisms	_	
199-30	37792-37797	among	_	
199-31	37798-37807	substance	_	
199-32	37808-37813	using	_	
199-33	37814-37820	groups	_	
199-34	37820-37821	.	_	

#Text=While several group differences emerged between non-using and substance-using individuals at the neural level, the precise cognitive process contributing to these differences remains unclear.
200-1	37822-37827	While	_	
200-2	37828-37835	several	_	
200-3	37836-37841	group	_	
200-4	37842-37853	differences	_	
200-5	37854-37861	emerged	_	
200-6	37862-37869	between	_	
200-7	37870-37879	non-using	_	
200-8	37880-37883	and	_	
200-9	37884-37899	substance-using	_	
200-10	37900-37911	individuals	_	
200-11	37912-37914	at	_	
200-12	37915-37918	the	_	
200-13	37919-37925	neural	_	
200-14	37926-37931	level	_	
200-15	37931-37932	,	_	
200-16	37933-37936	the	_	
200-17	37937-37944	precise	_	
200-18	37945-37954	cognitive	_	
200-19	37955-37962	process	_	
200-20	37963-37975	contributing	_	
200-21	37976-37978	to	_	
200-22	37979-37984	these	_	
200-23	37985-37996	differences	_	
200-24	37997-38004	remains	_	
200-25	38005-38012	unclear	_	
200-26	38012-38013	.	_	

#Text=Futher studies that manipulate reward expectancy, choice conflict, and risk assessment may provide further clues about the underlying cognitive differences in substance using adolescents.
201-1	38014-38020	Futher	_	
201-2	38021-38028	studies	_	
201-3	38029-38033	that	_	
201-4	38034-38044	manipulate	_	
201-5	38045-38051	reward	_	
201-6	38052-38062	expectancy	_	
201-7	38062-38063	,	_	
201-8	38064-38070	choice	_	
201-9	38071-38079	conflict	_	
201-10	38079-38080	,	_	
201-11	38081-38084	and	_	
201-12	38085-38089	risk	_	
201-13	38090-38100	assessment	_	
201-14	38101-38104	may	_	
201-15	38105-38112	provide	_	
201-16	38113-38120	further	_	
201-17	38121-38126	clues	_	
201-18	38127-38132	about	_	
201-19	38133-38136	the	_	
201-20	38137-38147	underlying	_	
201-21	38148-38157	cognitive	_	
201-22	38158-38169	differences	_	
201-23	38170-38172	in	_	
201-24	38173-38182	substance	_	
201-25	38183-38188	using	_	
201-26	38189-38200	adolescents	_	
201-27	38200-38201	.	_	

#Text=In addition, future studies should examine how neurocognitive functioning changes throughout the course of interventions targeting reductions in substance use, and whether an increase in response over the course of treatment corresponds to a decrease in substance use outside the laboratory.
202-1	38202-38204	In	_	
202-2	38205-38213	addition	_	
202-3	38213-38214	,	_	
202-4	38215-38221	future	_	
202-5	38222-38229	studies	_	
202-6	38230-38236	should	_	
202-7	38237-38244	examine	_	
202-8	38245-38248	how	_	
202-9	38249-38263	neurocognitive	_	
202-10	38264-38275	functioning	_	
202-11	38276-38283	changes	_	
202-12	38284-38294	throughout	_	
202-13	38295-38298	the	_	
202-14	38299-38305	course	_	
202-15	38306-38308	of	_	
202-16	38309-38322	interventions	_	
202-17	38323-38332	targeting	_	
202-18	38333-38343	reductions	_	
202-19	38344-38346	in	_	
202-20	38347-38356	substance	_	
202-21	38357-38360	use	_	
202-22	38360-38361	,	_	
202-23	38362-38365	and	_	
202-24	38366-38373	whether	_	
202-25	38374-38376	an	_	
202-26	38377-38385	increase	_	
202-27	38386-38388	in	_	
202-28	38389-38397	response	_	
202-29	38398-38402	over	_	
202-30	38403-38406	the	_	
202-31	38407-38413	course	_	
202-32	38414-38416	of	_	
202-33	38417-38426	treatment	_	
202-34	38427-38438	corresponds	_	
202-35	38439-38441	to	_	
202-36	38442-38443	a	_	
202-37	38444-38452	decrease	_	
202-38	38453-38455	in	_	
202-39	38456-38465	substance	_	
202-40	38466-38469	use	_	
202-41	38470-38477	outside	_	
202-42	38478-38481	the	_	
202-43	38482-38492	laboratory	_	
202-44	38492-38493	.	_	

#Text=Supplementary Material
#Text=           Compliance with Ethical Standards         
#Text=Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of Univesrity of New Mexico Human Research Protection Office and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
203-1	38494-38507	Supplementary	_	
203-2	38508-38516	Material	_	
203-3	38528-38538	Compliance	_	
203-4	38539-38543	with	_	
203-5	38544-38551	Ethical	_	
203-6	38552-38561	Standards	_	
203-7	38571-38578	Ethical	_	
203-8	38579-38587	approval	_	
203-9	38587-38588	:	_	
203-10	38589-38592	All	_	
203-11	38593-38603	procedures	_	
203-12	38604-38613	performed	_	
203-13	38614-38616	in	_	
203-14	38617-38624	studies	_	
203-15	38625-38634	involving	_	
203-16	38635-38640	human	_	
203-17	38641-38653	participants	_	
203-18	38654-38658	were	_	
203-19	38659-38661	in	_	
203-20	38662-38672	accordance	_	
203-21	38673-38677	with	_	
203-22	38678-38681	the	_	
203-23	38682-38689	ethical	_	
203-24	38690-38699	standards	_	
203-25	38700-38702	of	_	
203-26	38703-38713	Univesrity	_	
203-27	38714-38716	of	_	
203-28	38717-38720	New	_	
203-29	38721-38727	Mexico	_	
203-30	38728-38733	Human	_	
203-31	38734-38742	Research	_	
203-32	38743-38753	Protection	_	
203-33	38754-38760	Office	_	
203-34	38761-38764	and	_	
203-35	38765-38769	with	_	
203-36	38770-38773	the	_	
203-37	38774-38778	1964	_	
203-38	38779-38787	Helsinki	_	
203-39	38788-38799	declaration	_	
203-40	38800-38803	and	_	
203-41	38804-38807	its	_	
203-42	38808-38813	later	_	
203-43	38814-38824	amendments	_	
203-44	38825-38827	or	_	
203-45	38828-38838	comparable	_	
203-46	38839-38846	ethical	_	
203-47	38847-38856	standards	_	
203-48	38856-38857	.	_	

#Text=Conflict of Interest: The authors declare no conflicts of interest.
204-1	38858-38866	Conflict	_	
204-2	38867-38869	of	_	
204-3	38870-38878	Interest	_	
204-4	38878-38879	:	_	
204-5	38880-38883	The	_	
204-6	38884-38891	authors	_	
204-7	38892-38899	declare	_	
204-8	38900-38902	no	_	
204-9	38903-38912	conflicts	_	
204-10	38913-38915	of	_	
204-11	38916-38924	interest	_	
204-12	38924-38925	.	_	

#Text=Informed consent: Informed assent (written) and informed parental/guardian consent (audiorecorded) were obtained for all individual participants included in the study.
205-1	38926-38934	Informed	_	
205-2	38935-38942	consent	_	
205-3	38942-38943	:	_	
205-4	38944-38952	Informed	_	
205-5	38953-38959	assent	_	
205-6	38960-38961	(	_	
205-7	38961-38968	written	_	
205-8	38968-38969	)	_	
205-9	38970-38973	and	_	
205-10	38974-38982	informed	_	
205-11	38983-38991	parental	_	
205-12	38991-38992	/	_	
205-13	38992-39000	guardian	_	
205-14	39001-39008	consent	_	
205-15	39009-39010	(	_	
205-16	39010-39023	audiorecorded	_	
205-17	39023-39024	)	_	
205-18	39025-39029	were	_	
205-19	39030-39038	obtained	_	
205-20	39039-39042	for	_	
205-21	39043-39046	all	_	
205-22	39047-39057	individual	_	
205-23	39058-39070	participants	_	
205-24	39071-39079	included	_	
205-25	39080-39082	in	_	
205-26	39083-39086	the	_	
205-27	39087-39092	study	_	
205-28	39092-39093	.	_	

#Text=Evaluation of behavioral measures of risk taking propensity with inner city adolescents
#Text=Functional architecture of basal ganglia circuits: neural substrates of parallel processing
#Text=Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions
#Text=Competition between learned reward and error outcome predictions in anterior cingulate cortex
#Text=Medial prefrontal cortex as an action-outcome predictor
#Text=Cortical and subcortical contributions to Stop signal response inhibition: role of the subthalamic nucleus
#Text=Developmental Differences in Posterior Mesofrontal Cortex Recruitment by Risky Rewards
#Text=Cognitive control links alcohol use, trait disinhibition, and reduced cognitive capacity: Evidence for medial prefrontal cortex dysregulation during reward-seeking behavior
#Text=Risk taking differences on a behavioral task as a function of potential reward/loss magnitude and individual differences in impulsivity and sensation seeking
#Text=Neural mechanisms of risk taking and relationships with hazardous drinking
#Text=A new self-report scale for the assessment of adolescent psychopathology: factor structure, reliability, validity and diagnostic sensitivity
#Text=Risky Decisions and Their Consequences: Neural Processing by Boys with Antisocial Substance Disorder
#Text=A Risk-Taking “Set” in a Novel Task Among Adolescents With Serious Conduct and Substance Problems
#Text=Neural mechanisms of risky decision-making and reward response in adolescent onset cannabis use disorder
#Text=Optimized EPI for fMRI studies of the orbitofrontal cortex
#Text=Neuroimaging mechanisms of change in psychotherapy for addictive behaviors: emerging translational approaches that bridge biology and behavior
#Text=Ambivalence: Prerequisite for success in motivational interviewing with adolescents?
206-1	39095-39105	Evaluation	_	
206-2	39106-39108	of	_	
206-3	39109-39119	behavioral	_	
206-4	39120-39128	measures	_	
206-5	39129-39131	of	_	
206-6	39132-39136	risk	_	
206-7	39137-39143	taking	_	
206-8	39144-39154	propensity	_	
206-9	39155-39159	with	_	
206-10	39160-39165	inner	_	
206-11	39166-39170	city	_	
206-12	39171-39182	adolescents	_	
206-13	39183-39193	Functional	_	
206-14	39194-39206	architecture	_	
206-15	39207-39209	of	_	
206-16	39210-39215	basal	_	
206-17	39216-39223	ganglia	_	
206-18	39224-39232	circuits	_	
206-19	39232-39233	:	_	
206-20	39234-39240	neural	_	
206-21	39241-39251	substrates	_	
206-22	39252-39254	of	_	
206-23	39255-39263	parallel	_	
206-24	39264-39274	processing	_	
206-25	39275-39280	Basal	_	
206-26	39281-39304	ganglia-thalamocortical	_	
206-27	39305-39313	circuits	_	
206-28	39313-39314	:	_	
206-29	39315-39323	parallel	_	
206-30	39324-39334	substrates	_	
206-31	39335-39338	for	_	
206-32	39339-39344	motor	_	
206-33	39344-39345	,	_	
206-34	39346-39356	oculomotor	_	
206-35	39356-39357	,	_	
206-36	39358-39359	“	_	
206-37	39359-39369	prefrontal	_	
206-38	39369-39370	”	_	
206-39	39371-39374	and	_	
206-40	39375-39376	“	_	
206-41	39376-39382	limbic	_	
206-42	39382-39383	”	_	
206-43	39384-39393	functions	_	
206-44	39394-39405	Competition	_	
206-45	39406-39413	between	_	
206-46	39414-39421	learned	_	
206-47	39422-39428	reward	_	
206-48	39429-39432	and	_	
206-49	39433-39438	error	_	
206-50	39439-39446	outcome	_	
206-51	39447-39458	predictions	_	
206-52	39459-39461	in	_	
206-53	39462-39470	anterior	_	
206-54	39471-39480	cingulate	_	
206-55	39481-39487	cortex	_	
206-56	39488-39494	Medial	_	
206-57	39495-39505	prefrontal	_	
206-58	39506-39512	cortex	_	
206-59	39513-39515	as	_	
206-60	39516-39518	an	_	
206-61	39519-39533	action-outcome	_	
206-62	39534-39543	predictor	_	
206-63	39544-39552	Cortical	_	
206-64	39553-39556	and	_	
206-65	39557-39568	subcortical	_	
206-66	39569-39582	contributions	_	
206-67	39583-39585	to	_	
206-68	39586-39590	Stop	_	
206-69	39591-39597	signal	_	
206-70	39598-39606	response	_	
206-71	39607-39617	inhibition	_	
206-72	39617-39618	:	_	
206-73	39619-39623	role	_	
206-74	39624-39626	of	_	
206-75	39627-39630	the	_	
206-76	39631-39642	subthalamic	_	
206-77	39643-39650	nucleus	_	
206-78	39651-39664	Developmental	_	
206-79	39665-39676	Differences	_	
206-80	39677-39679	in	_	
206-81	39680-39689	Posterior	_	
206-82	39690-39701	Mesofrontal	_	
206-83	39702-39708	Cortex	_	
206-84	39709-39720	Recruitment	_	
206-85	39721-39723	by	_	
206-86	39724-39729	Risky	_	
206-87	39730-39737	Rewards	_	
206-88	39738-39747	Cognitive	_	
206-89	39748-39755	control	_	
206-90	39756-39761	links	_	
206-91	39762-39769	alcohol	_	
206-92	39770-39773	use	_	
206-93	39773-39774	,	_	
206-94	39775-39780	trait	_	
206-95	39781-39794	disinhibition	_	
206-96	39794-39795	,	_	
206-97	39796-39799	and	_	
206-98	39800-39807	reduced	_	
206-99	39808-39817	cognitive	_	
206-100	39818-39826	capacity	_	
206-101	39826-39827	:	_	
206-102	39828-39836	Evidence	_	
206-103	39837-39840	for	_	
206-104	39841-39847	medial	_	
206-105	39848-39858	prefrontal	_	
206-106	39859-39865	cortex	_	
206-107	39866-39879	dysregulation	_	
206-108	39880-39886	during	_	
206-109	39887-39901	reward-seeking	_	
206-110	39902-39910	behavior	_	
206-111	39911-39915	Risk	_	
206-112	39916-39922	taking	_	
206-113	39923-39934	differences	_	
206-114	39935-39937	on	_	
206-115	39938-39939	a	_	
206-116	39940-39950	behavioral	_	
206-117	39951-39955	task	_	
206-118	39956-39958	as	_	
206-119	39959-39960	a	_	
206-120	39961-39969	function	_	
206-121	39970-39972	of	_	
206-122	39973-39982	potential	_	
206-123	39983-39989	reward	_	
206-124	39989-39990	/	_	
206-125	39990-39994	loss	_	
206-126	39995-40004	magnitude	_	
206-127	40005-40008	and	_	
206-128	40009-40019	individual	_	
206-129	40020-40031	differences	_	
206-130	40032-40034	in	_	
206-131	40035-40046	impulsivity	_	
206-132	40047-40050	and	_	
206-133	40051-40060	sensation	_	
206-134	40061-40068	seeking	_	
206-135	40069-40075	Neural	_	
206-136	40076-40086	mechanisms	_	
206-137	40087-40089	of	_	
206-138	40090-40094	risk	_	
206-139	40095-40101	taking	_	
206-140	40102-40105	and	_	
206-141	40106-40119	relationships	_	
206-142	40120-40124	with	_	
206-143	40125-40134	hazardous	_	
206-144	40135-40143	drinking	_	
206-145	40144-40145	A	_	
206-146	40146-40149	new	_	
206-147	40150-40161	self-report	_	
206-148	40162-40167	scale	_	
206-149	40168-40171	for	_	
206-150	40172-40175	the	_	
206-151	40176-40186	assessment	_	
206-152	40187-40189	of	_	
206-153	40190-40200	adolescent	_	
206-154	40201-40216	psychopathology	_	
206-155	40216-40217	:	_	
206-156	40218-40224	factor	_	
206-157	40225-40234	structure	_	
206-158	40234-40235	,	_	
206-159	40236-40247	reliability	_	
206-160	40247-40248	,	_	
206-161	40249-40257	validity	_	
206-162	40258-40261	and	_	
206-163	40262-40272	diagnostic	_	
206-164	40273-40284	sensitivity	_	
206-165	40285-40290	Risky	_	
206-166	40291-40300	Decisions	_	
206-167	40301-40304	and	_	
206-168	40305-40310	Their	_	
206-169	40311-40323	Consequences	_	
206-170	40323-40324	:	_	
206-171	40325-40331	Neural	_	
206-172	40332-40342	Processing	_	
206-173	40343-40345	by	_	
206-174	40346-40350	Boys	_	
206-175	40351-40355	with	_	
206-176	40356-40366	Antisocial	_	
206-177	40367-40376	Substance	_	
206-178	40377-40385	Disorder	_	
206-179	40386-40387	A	_	
206-180	40388-40399	Risk-Taking	_	
206-181	40400-40401	“	_	
206-182	40401-40404	Set	_	
206-183	40404-40405	”	_	
206-184	40406-40408	in	_	
206-185	40409-40410	a	_	
206-186	40411-40416	Novel	_	
206-187	40417-40421	Task	_	
206-188	40422-40427	Among	_	
206-189	40428-40439	Adolescents	_	
206-190	40440-40444	With	_	
206-191	40445-40452	Serious	_	
206-192	40453-40460	Conduct	_	
206-193	40461-40464	and	_	
206-194	40465-40474	Substance	_	
206-195	40475-40483	Problems	_	
206-196	40484-40490	Neural	_	
206-197	40491-40501	mechanisms	_	
206-198	40502-40504	of	_	
206-199	40505-40510	risky	_	
206-200	40511-40526	decision-making	_	
206-201	40527-40530	and	_	
206-202	40531-40537	reward	_	
206-203	40538-40546	response	_	
206-204	40547-40549	in	_	
206-205	40550-40560	adolescent	_	
206-206	40561-40566	onset	_	
206-207	40567-40575	cannabis	_	
206-208	40576-40579	use	_	
206-209	40580-40588	disorder	_	
206-210	40589-40598	Optimized	_	
206-211	40599-40602	EPI	_	
206-212	40603-40606	for	_	
206-213	40607-40611	fMRI	_	
206-214	40612-40619	studies	_	
206-215	40620-40622	of	_	
206-216	40623-40626	the	_	
206-217	40627-40640	orbitofrontal	_	
206-218	40641-40647	cortex	_	
206-219	40648-40660	Neuroimaging	_	
206-220	40661-40671	mechanisms	_	
206-221	40672-40674	of	_	
206-222	40675-40681	change	_	
206-223	40682-40684	in	_	
206-224	40685-40698	psychotherapy	_	
206-225	40699-40702	for	_	
206-226	40703-40712	addictive	_	
206-227	40713-40722	behaviors	_	
206-228	40722-40723	:	_	
206-229	40724-40732	emerging	_	
206-230	40733-40746	translational	_	
206-231	40747-40757	approaches	_	
206-232	40758-40762	that	_	
206-233	40763-40769	bridge	_	
206-234	40770-40777	biology	_	
206-235	40778-40781	and	_	
206-236	40782-40790	behavior	_	
206-237	40791-40802	Ambivalence	_	
206-238	40802-40803	:	_	
206-239	40804-40816	Prerequisite	_	
206-240	40817-40820	for	_	
206-241	40821-40828	success	_	
206-242	40829-40831	in	_	
206-243	40832-40844	motivational	_	
206-244	40845-40857	interviewing	_	
206-245	40858-40862	with	_	
206-246	40863-40874	adolescents	_	
206-247	40874-40875	?	_	

#Text=Uniting adolescent neuroimaging and treatment research: Recommendations in pursuit of improved integration
#Text=The effect of alcohol consumption on the adolescent brain: A systematic review of MRI and fMRI studies of alcohol-using youth
#Text=Exploring racial/ethnic differences in substance use: a preliminary theory-based investigation with juvenile justice-involved youth
#Text=Cannabis use and psychosocial adjustment in adolescence and young adulthood
#Text=Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity
#Text=Adolescent marijuana users have elevated risk-taking on the balloon analog risk task
#Text=Striatal Dysfunction Marks Preexisting Risk and Medial Prefrontal Dysfunction Is Related to Problem Drinking in Children of Alcoholics
#Text=Neural Response to Reward Anticipation under Risk Is Nonlinear in Probabilities
#Text=
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=Youth risk behavior surveillance--United States, 2013
#Text=Anticipation of increasing monetary reward selectively recruits nucleus accumbens
#Text=
#Text=Evaluation of a behavioral measure of risk taking: The Balloon Analogue Risk Task (BART)
#Text=Dare to delay?
207-1	40876-40883	Uniting	_	
207-2	40884-40894	adolescent	_	
207-3	40895-40907	neuroimaging	_	
207-4	40908-40911	and	_	
207-5	40912-40921	treatment	_	
207-6	40922-40930	research	_	
207-7	40930-40931	:	_	
207-8	40932-40947	Recommendations	_	
207-9	40948-40950	in	_	
207-10	40951-40958	pursuit	_	
207-11	40959-40961	of	_	
207-12	40962-40970	improved	_	
207-13	40971-40982	integration	_	
207-14	40983-40986	The	_	
207-15	40987-40993	effect	_	
207-16	40994-40996	of	_	
207-17	40997-41004	alcohol	_	
207-18	41005-41016	consumption	_	
207-19	41017-41019	on	_	
207-20	41020-41023	the	_	
207-21	41024-41034	adolescent	_	
207-22	41035-41040	brain	_	
207-23	41040-41041	:	_	
207-24	41042-41043	A	_	
207-25	41044-41054	systematic	_	
207-26	41055-41061	review	_	
207-27	41062-41064	of	_	
207-28	41065-41068	MRI	_	
207-29	41069-41072	and	_	
207-30	41073-41077	fMRI	_	
207-31	41078-41085	studies	_	
207-32	41086-41088	of	_	
207-33	41089-41102	alcohol-using	_	
207-34	41103-41108	youth	_	
207-35	41109-41118	Exploring	_	
207-36	41119-41125	racial	_	
207-37	41125-41126	/	_	
207-38	41126-41132	ethnic	_	
207-39	41133-41144	differences	_	
207-40	41145-41147	in	_	
207-41	41148-41157	substance	_	
207-42	41158-41161	use	_	
207-43	41161-41162	:	_	
207-44	41163-41164	a	_	
207-45	41165-41176	preliminary	_	
207-46	41177-41189	theory-based	_	
207-47	41190-41203	investigation	_	
207-48	41204-41208	with	_	
207-49	41209-41217	juvenile	_	
207-50	41218-41234	justice-involved	_	
207-51	41235-41240	youth	_	
207-52	41241-41249	Cannabis	_	
207-53	41250-41253	use	_	
207-54	41254-41257	and	_	
207-55	41258-41270	psychosocial	_	
207-56	41271-41281	adjustment	_	
207-57	41282-41284	in	_	
207-58	41285-41296	adolescence	_	
207-59	41297-41300	and	_	
207-60	41301-41306	young	_	
207-61	41307-41316	adulthood	_	
207-62	41317-41322	Worth	_	
207-63	41323-41326	the	_	
207-64	41327-41331	wait	_	
207-65	41331-41332	:	_	
207-66	41333-41340	effects	_	
207-67	41341-41343	of	_	
207-68	41344-41347	age	_	
207-69	41348-41350	of	_	
207-70	41351-41356	onset	_	
207-71	41357-41359	of	_	
207-72	41360-41369	marijuana	_	
207-73	41370-41373	use	_	
207-74	41374-41376	on	_	
207-75	41377-41382	white	_	
207-76	41383-41389	matter	_	
207-77	41390-41393	and	_	
207-78	41394-41405	impulsivity	_	
207-79	41406-41416	Adolescent	_	
207-80	41417-41426	marijuana	_	
207-81	41427-41432	users	_	
207-82	41433-41437	have	_	
207-83	41438-41446	elevated	_	
207-84	41447-41458	risk-taking	_	
207-85	41459-41461	on	_	
207-86	41462-41465	the	_	
207-87	41466-41473	balloon	_	
207-88	41474-41480	analog	_	
207-89	41481-41485	risk	_	
207-90	41486-41490	task	_	
207-91	41491-41499	Striatal	_	
207-92	41500-41511	Dysfunction	_	
207-93	41512-41517	Marks	_	
207-94	41518-41529	Preexisting	_	
207-95	41530-41534	Risk	_	
207-96	41535-41538	and	_	
207-97	41539-41545	Medial	_	
207-98	41546-41556	Prefrontal	_	
207-99	41557-41568	Dysfunction	_	
207-100	41569-41571	Is	_	
207-101	41572-41579	Related	_	
207-102	41580-41582	to	_	
207-103	41583-41590	Problem	_	
207-104	41591-41599	Drinking	_	
207-105	41600-41602	in	_	
207-106	41603-41611	Children	_	
207-107	41612-41614	of	_	
207-108	41615-41625	Alcoholics	_	
207-109	41626-41632	Neural	_	
207-110	41633-41641	Response	_	
207-111	41642-41644	to	_	
207-112	41645-41651	Reward	_	
207-113	41652-41664	Anticipation	_	
207-114	41665-41670	under	_	
207-115	41671-41675	Risk	_	
207-116	41676-41678	Is	_	
207-117	41679-41688	Nonlinear	_	
207-118	41689-41691	in	_	
207-119	41692-41705	Probabilities	_	
207-120	41707-41715	Improved	_	
207-121	41716-41728	optimization	_	
207-122	41729-41732	for	_	
207-123	41733-41736	the	_	
207-124	41737-41743	robust	_	
207-125	41744-41747	and	_	
207-126	41748-41756	accurate	_	
207-127	41757-41763	linear	_	
207-128	41764-41776	registration	_	
207-129	41777-41780	and	_	
207-130	41781-41787	motion	_	
207-131	41788-41798	correction	_	
207-132	41799-41801	of	_	
207-133	41802-41807	brain	_	
207-134	41808-41814	images	_	
207-135	41815-41820	Youth	_	
207-136	41821-41825	risk	_	
207-137	41826-41834	behavior	_	
207-138	41835-41847	surveillance	_	
207-139	41847-41848	-	_	
207-140	41848-41849	-	_	
207-141	41849-41855	United	_	
207-142	41856-41862	States	_	
207-143	41862-41863	,	_	
207-144	41864-41868	2013	_	
207-145	41869-41881	Anticipation	_	
207-146	41882-41884	of	_	
207-147	41885-41895	increasing	_	
207-148	41896-41904	monetary	_	
207-149	41905-41911	reward	_	
207-150	41912-41923	selectively	_	
207-151	41924-41932	recruits	_	
207-152	41933-41940	nucleus	_	
207-153	41941-41950	accumbens	_	
207-154	41952-41962	Evaluation	_	
207-155	41963-41965	of	_	
207-156	41966-41967	a	_	
207-157	41968-41978	behavioral	_	
207-158	41979-41986	measure	_	
207-159	41987-41989	of	_	
207-160	41990-41994	risk	_	
207-161	41995-42001	taking	_	
207-162	42001-42002	:	_	
207-163	42003-42006	The	_	
207-164	42007-42014	Balloon	_	
207-165	42015-42023	Analogue	_	
207-166	42024-42028	Risk	_	
207-167	42029-42033	Task	_	
207-168	42034-42035	(	_	
207-169	42035-42039	BART	_	
207-170	42039-42040	)	_	
207-171	42041-42045	Dare	_	
207-172	42046-42048	to	_	
207-173	42049-42054	delay	_	
207-174	42054-42055	?	_	

#Text=The impacts of adolescent alcohol and marijuana use onset on cognition, brain structure, and function
#Text=Functional dissociation in frontal and striatal areas for processing of positive and negative reward information
#Text=Anterior insular cortex anticipates impending stimulus significance
#Text=Evaluating an integrative theoretical framework for HIV sexual risk among juvenile justice involved adolescents
#Text=Persistent cannabis users show neuropsychological decline from childhood to midlife
#Text=Neural activation during inhibition predicts initiation of substance use in adolescence
#Text=Increased activation in the right insula during risk-taking decision making is related to harm avoidance and neuroticism
#Text=
#Text=Relationships Between Future Orientation, Impulsive Sensation Seeking, and Risk Behavior among Adjudicated Adolescents
#Text=Expected Value, Reward Outcome, and Temporal Difference Error Representations in a Probabilistic Decision Task
#Text=Risk taking and the adolescent reward system: a potential common link to substance abuse
#Text=Decreasing Ventromedial Prefrontal Cortex Activity During Sequential Risk-Taking: An fMRI Investigation of the Balloon Analog Risk Task
#Text=Age-varying associations between substance use behaviors and depressive symptoms during adolescence and young adulthood
#Text=An FMRI study of response inhibition in youths with a family history of alcoholism
#Text=Adolescent drug use and psychological health.
208-1	42056-42059	The	_	
208-2	42060-42067	impacts	_	
208-3	42068-42070	of	_	
208-4	42071-42081	adolescent	_	
208-5	42082-42089	alcohol	_	
208-6	42090-42093	and	_	
208-7	42094-42103	marijuana	_	
208-8	42104-42107	use	_	
208-9	42108-42113	onset	_	
208-10	42114-42116	on	_	
208-11	42117-42126	cognition	_	
208-12	42126-42127	,	_	
208-13	42128-42133	brain	_	
208-14	42134-42143	structure	_	
208-15	42143-42144	,	_	
208-16	42145-42148	and	_	
208-17	42149-42157	function	_	
208-18	42158-42168	Functional	_	
208-19	42169-42181	dissociation	_	
208-20	42182-42184	in	_	
208-21	42185-42192	frontal	_	
208-22	42193-42196	and	_	
208-23	42197-42205	striatal	_	
208-24	42206-42211	areas	_	
208-25	42212-42215	for	_	
208-26	42216-42226	processing	_	
208-27	42227-42229	of	_	
208-28	42230-42238	positive	_	
208-29	42239-42242	and	_	
208-30	42243-42251	negative	_	
208-31	42252-42258	reward	_	
208-32	42259-42270	information	_	
208-33	42271-42279	Anterior	_	
208-34	42280-42287	insular	_	
208-35	42288-42294	cortex	_	
208-36	42295-42306	anticipates	_	
208-37	42307-42316	impending	_	
208-38	42317-42325	stimulus	_	
208-39	42326-42338	significance	_	
208-40	42339-42349	Evaluating	_	
208-41	42350-42352	an	_	
208-42	42353-42364	integrative	_	
208-43	42365-42376	theoretical	_	
208-44	42377-42386	framework	_	
208-45	42387-42390	for	_	
208-46	42391-42394	HIV	_	
208-47	42395-42401	sexual	_	
208-48	42402-42406	risk	_	
208-49	42407-42412	among	_	
208-50	42413-42421	juvenile	_	
208-51	42422-42429	justice	_	
208-52	42430-42438	involved	_	
208-53	42439-42450	adolescents	_	
208-54	42451-42461	Persistent	_	
208-55	42462-42470	cannabis	_	
208-56	42471-42476	users	_	
208-57	42477-42481	show	_	
208-58	42482-42500	neuropsychological	_	
208-59	42501-42508	decline	_	
208-60	42509-42513	from	_	
208-61	42514-42523	childhood	_	
208-62	42524-42526	to	_	
208-63	42527-42534	midlife	_	
208-64	42535-42541	Neural	_	
208-65	42542-42552	activation	_	
208-66	42553-42559	during	_	
208-67	42560-42570	inhibition	_	
208-68	42571-42579	predicts	_	
208-69	42580-42590	initiation	_	
208-70	42591-42593	of	_	
208-71	42594-42603	substance	_	
208-72	42604-42607	use	_	
208-73	42608-42610	in	_	
208-74	42611-42622	adolescence	_	
208-75	42623-42632	Increased	_	
208-76	42633-42643	activation	_	
208-77	42644-42646	in	_	
208-78	42647-42650	the	_	
208-79	42651-42656	right	_	
208-80	42657-42663	insula	_	
208-81	42664-42670	during	_	
208-82	42671-42682	risk-taking	_	
208-83	42683-42691	decision	_	
208-84	42692-42698	making	_	
208-85	42699-42701	is	_	
208-86	42702-42709	related	_	
208-87	42710-42712	to	_	
208-88	42713-42717	harm	_	
208-89	42718-42727	avoidance	_	
208-90	42728-42731	and	_	
208-91	42732-42743	neuroticism	_	
208-92	42745-42758	Relationships	_	
208-93	42759-42766	Between	_	
208-94	42767-42773	Future	_	
208-95	42774-42785	Orientation	_	
208-96	42785-42786	,	_	
208-97	42787-42796	Impulsive	_	
208-98	42797-42806	Sensation	_	
208-99	42807-42814	Seeking	_	
208-100	42814-42815	,	_	
208-101	42816-42819	and	_	
208-102	42820-42824	Risk	_	
208-103	42825-42833	Behavior	_	
208-104	42834-42839	among	_	
208-105	42840-42851	Adjudicated	_	
208-106	42852-42863	Adolescents	_	
208-107	42864-42872	Expected	_	
208-108	42873-42878	Value	_	
208-109	42878-42879	,	_	
208-110	42880-42886	Reward	_	
208-111	42887-42894	Outcome	_	
208-112	42894-42895	,	_	
208-113	42896-42899	and	_	
208-114	42900-42908	Temporal	_	
208-115	42909-42919	Difference	_	
208-116	42920-42925	Error	_	
208-117	42926-42941	Representations	_	
208-118	42942-42944	in	_	
208-119	42945-42946	a	_	
208-120	42947-42960	Probabilistic	_	
208-121	42961-42969	Decision	_	
208-122	42970-42974	Task	_	
208-123	42975-42979	Risk	_	
208-124	42980-42986	taking	_	
208-125	42987-42990	and	_	
208-126	42991-42994	the	_	
208-127	42995-43005	adolescent	_	
208-128	43006-43012	reward	_	
208-129	43013-43019	system	_	
208-130	43019-43020	:	_	
208-131	43021-43022	a	_	
208-132	43023-43032	potential	_	
208-133	43033-43039	common	_	
208-134	43040-43044	link	_	
208-135	43045-43047	to	_	
208-136	43048-43057	substance	_	
208-137	43058-43063	abuse	_	
208-138	43064-43074	Decreasing	_	
208-139	43075-43087	Ventromedial	_	
208-140	43088-43098	Prefrontal	_	
208-141	43099-43105	Cortex	_	
208-142	43106-43114	Activity	_	
208-143	43115-43121	During	_	
208-144	43122-43132	Sequential	_	
208-145	43133-43144	Risk-Taking	_	
208-146	43144-43145	:	_	
208-147	43146-43148	An	_	
208-148	43149-43153	fMRI	_	
208-149	43154-43167	Investigation	_	
208-150	43168-43170	of	_	
208-151	43171-43174	the	_	
208-152	43175-43182	Balloon	_	
208-153	43183-43189	Analog	_	
208-154	43190-43194	Risk	_	
208-155	43195-43199	Task	_	
208-156	43200-43211	Age-varying	_	
208-157	43212-43224	associations	_	
208-158	43225-43232	between	_	
208-159	43233-43242	substance	_	
208-160	43243-43246	use	_	
208-161	43247-43256	behaviors	_	
208-162	43257-43260	and	_	
208-163	43261-43271	depressive	_	
208-164	43272-43280	symptoms	_	
208-165	43281-43287	during	_	
208-166	43288-43299	adolescence	_	
208-167	43300-43303	and	_	
208-168	43304-43309	young	_	
208-169	43310-43319	adulthood	_	
208-170	43320-43322	An	_	
208-171	43323-43327	FMRI	_	
208-172	43328-43333	study	_	
208-173	43334-43336	of	_	
208-174	43337-43345	response	_	
208-175	43346-43356	inhibition	_	
208-176	43357-43359	in	_	
208-177	43360-43366	youths	_	
208-178	43367-43371	with	_	
208-179	43372-43373	a	_	
208-180	43374-43380	family	_	
208-181	43381-43388	history	_	
208-182	43389-43391	of	_	
208-183	43392-43402	alcoholism	_	
208-184	43403-43413	Adolescent	_	
208-185	43414-43418	drug	_	
208-186	43419-43422	use	_	
208-187	43423-43426	and	_	
208-188	43427-43440	psychological	_	
208-189	43441-43447	health	_	
208-190	43447-43448	.	_	

#Text=A longitudinal inquiry
#Text=Advances in functional and structural MR image analysis and implementation as FSL
#Text=Fast robust automated brain extraction
#Text=Timeline follow-back: A technique for assessing self-reported alcohol consumption
#Text=Developmental neurobiology of cognitive control and motivational systems
#Text=Brain volume reductions in adolescent heavy drinkers
#Text=Are Drug Experimenters Better Adjusted Than Abstainers and Users?
209-1	43449-43450	A	_	
209-2	43451-43463	longitudinal	_	
209-3	43464-43471	inquiry	_	
209-4	43472-43480	Advances	_	
209-5	43481-43483	in	_	
209-6	43484-43494	functional	_	
209-7	43495-43498	and	_	
209-8	43499-43509	structural	_	
209-9	43510-43512	MR	_	
209-10	43513-43518	image	_	
209-11	43519-43527	analysis	_	
209-12	43528-43531	and	_	
209-13	43532-43546	implementation	_	
209-14	43547-43549	as	_	
209-15	43550-43553	FSL	_	
209-16	43554-43558	Fast	_	
209-17	43559-43565	robust	_	
209-18	43566-43575	automated	_	
209-19	43576-43581	brain	_	
209-20	43582-43592	extraction	_	
209-21	43593-43601	Timeline	_	
209-22	43602-43613	follow-back	_	
209-23	43613-43614	:	_	
209-24	43615-43616	A	_	
209-25	43617-43626	technique	_	
209-26	43627-43630	for	_	
209-27	43631-43640	assessing	_	
209-28	43641-43654	self-reported	_	
209-29	43655-43662	alcohol	_	
209-30	43663-43674	consumption	_	
209-31	43675-43688	Developmental	_	
209-32	43689-43701	neurobiology	_	
209-33	43702-43704	of	_	
209-34	43705-43714	cognitive	_	
209-35	43715-43722	control	_	
209-36	43723-43726	and	_	
209-37	43727-43739	motivational	_	
209-38	43740-43747	systems	_	
209-39	43748-43753	Brain	_	
209-40	43754-43760	volume	_	
209-41	43761-43771	reductions	_	
209-42	43772-43774	in	_	
209-43	43775-43785	adolescent	_	
209-44	43786-43791	heavy	_	
209-45	43792-43800	drinkers	_	
209-46	43801-43804	Are	_	
209-47	43805-43809	Drug	_	
209-48	43810-43823	Experimenters	_	
209-49	43824-43830	Better	_	
209-50	43831-43839	Adjusted	_	
209-51	43840-43844	Than	_	
209-52	43845-43855	Abstainers	_	
209-53	43856-43859	and	_	
209-54	43860-43865	Users	_	
209-55	43865-43866	?	_	

#Text=: A Longitudinal Study of Adolescent Marijuana Use
#Text=Neural correlates of developmental differences in risk estimation and feedback processing
#Text=Inferior Parietal Lobule Supports Decision Making under Uncertainty in Humans
#Text=Daily marijuana use is not associated with brain morphometric measures in adolescents or adults
#Text=A longitudinal examination of adolescent response inhibition: neural differences before and after the initiation of heavy drinking
#Text=Associations Between Heavy Drinking and Changes in Impulsive Behavior Among Adolescent Boys
#Text=Multilevel linear modelling for FMRI group analysis using Bayesian inference
#Text=A unified statistical approach for determining significant signals in images of cerebral activation
#Text=A comparison of three structural models for personality: The Big Three, the Big Five, and the Alternative Five
#Text=fMRI results of main effect contrast of risky decision making across all participants in the (a) mean risk contrast (Mean Color > Mean White (orange) and Mean Color < Mean White (blue)) and (b) linear risk contrast (Linear Color > Linear White (orange) and Linear Color < Linear White (blue)).
210-1	43866-43867	:	_	
210-2	43868-43869	A	_	
210-3	43870-43882	Longitudinal	_	
210-4	43883-43888	Study	_	
210-5	43889-43891	of	_	
210-6	43892-43902	Adolescent	_	
210-7	43903-43912	Marijuana	_	
210-8	43913-43916	Use	_	
210-9	43917-43923	Neural	_	
210-10	43924-43934	correlates	_	
210-11	43935-43937	of	_	
210-12	43938-43951	developmental	_	
210-13	43952-43963	differences	_	
210-14	43964-43966	in	_	
210-15	43967-43971	risk	_	
210-16	43972-43982	estimation	_	
210-17	43983-43986	and	_	
210-18	43987-43995	feedback	_	
210-19	43996-44006	processing	_	
210-20	44007-44015	Inferior	_	
210-21	44016-44024	Parietal	_	
210-22	44025-44031	Lobule	_	
210-23	44032-44040	Supports	_	
210-24	44041-44049	Decision	_	
210-25	44050-44056	Making	_	
210-26	44057-44062	under	_	
210-27	44063-44074	Uncertainty	_	
210-28	44075-44077	in	_	
210-29	44078-44084	Humans	_	
210-30	44085-44090	Daily	_	
210-31	44091-44100	marijuana	_	
210-32	44101-44104	use	_	
210-33	44105-44107	is	_	
210-34	44108-44111	not	_	
210-35	44112-44122	associated	_	
210-36	44123-44127	with	_	
210-37	44128-44133	brain	_	
210-38	44134-44146	morphometric	_	
210-39	44147-44155	measures	_	
210-40	44156-44158	in	_	
210-41	44159-44170	adolescents	_	
210-42	44171-44173	or	_	
210-43	44174-44180	adults	_	
210-44	44181-44182	A	_	
210-45	44183-44195	longitudinal	_	
210-46	44196-44207	examination	_	
210-47	44208-44210	of	_	
210-48	44211-44221	adolescent	_	
210-49	44222-44230	response	_	
210-50	44231-44241	inhibition	_	
210-51	44241-44242	:	_	
210-52	44243-44249	neural	_	
210-53	44250-44261	differences	_	
210-54	44262-44268	before	_	
210-55	44269-44272	and	_	
210-56	44273-44278	after	_	
210-57	44279-44282	the	_	
210-58	44283-44293	initiation	_	
210-59	44294-44296	of	_	
210-60	44297-44302	heavy	_	
210-61	44303-44311	drinking	_	
210-62	44312-44324	Associations	_	
210-63	44325-44332	Between	_	
210-64	44333-44338	Heavy	_	
210-65	44339-44347	Drinking	_	
210-66	44348-44351	and	_	
210-67	44352-44359	Changes	_	
210-68	44360-44362	in	_	
210-69	44363-44372	Impulsive	_	
210-70	44373-44381	Behavior	_	
210-71	44382-44387	Among	_	
210-72	44388-44398	Adolescent	_	
210-73	44399-44403	Boys	_	
210-74	44404-44414	Multilevel	_	
210-75	44415-44421	linear	_	
210-76	44422-44431	modelling	_	
210-77	44432-44435	for	_	
210-78	44436-44440	FMRI	_	
210-79	44441-44446	group	_	
210-80	44447-44455	analysis	_	
210-81	44456-44461	using	_	
210-82	44462-44470	Bayesian	_	
210-83	44471-44480	inference	_	
210-84	44481-44482	A	_	
210-85	44483-44490	unified	_	
210-86	44491-44502	statistical	_	
210-87	44503-44511	approach	_	
210-88	44512-44515	for	_	
210-89	44516-44527	determining	_	
210-90	44528-44539	significant	_	
210-91	44540-44547	signals	_	
210-92	44548-44550	in	_	
210-93	44551-44557	images	_	
210-94	44558-44560	of	_	
210-95	44561-44569	cerebral	_	
210-96	44570-44580	activation	_	
210-97	44581-44582	A	_	
210-98	44583-44593	comparison	_	
210-99	44594-44596	of	_	
210-100	44597-44602	three	_	
210-101	44603-44613	structural	_	
210-102	44614-44620	models	_	
210-103	44621-44624	for	_	
210-104	44625-44636	personality	_	
210-105	44636-44637	:	_	
210-106	44638-44641	The	_	
210-107	44642-44645	Big	_	
210-108	44646-44651	Three	_	
210-109	44651-44652	,	_	
210-110	44653-44656	the	_	
210-111	44657-44660	Big	_	
210-112	44661-44665	Five	_	
210-113	44665-44666	,	_	
210-114	44667-44670	and	_	
210-115	44671-44674	the	_	
210-116	44675-44686	Alternative	_	
210-117	44687-44691	Five	_	
210-118	44692-44696	fMRI	_	
210-119	44697-44704	results	_	
210-120	44705-44707	of	_	
210-121	44708-44712	main	_	
210-122	44713-44719	effect	_	
210-123	44720-44728	contrast	_	
210-124	44729-44731	of	_	
210-125	44732-44737	risky	_	
210-126	44738-44746	decision	_	
210-127	44747-44753	making	_	
210-128	44754-44760	across	_	
210-129	44761-44764	all	_	
210-130	44765-44777	participants	_	
210-131	44778-44780	in	_	
210-132	44781-44784	the	_	
210-133	44785-44786	(	_	
210-134	44786-44787	a	_	
210-135	44787-44788	)	_	
210-136	44789-44793	mean	_	
210-137	44794-44798	risk	_	
210-138	44799-44807	contrast	_	
210-139	44808-44809	(	_	
210-140	44809-44813	Mean	_	
210-141	44814-44819	Color	_	
210-142	44820-44821	>	_	
210-143	44822-44826	Mean	_	
210-144	44827-44832	White	_	
210-145	44833-44834	(	_	
210-146	44834-44840	orange	_	
210-147	44840-44841	)	_	
210-148	44842-44845	and	_	
210-149	44846-44850	Mean	_	
210-150	44851-44856	Color	_	
210-151	44857-44858	<	_	
210-152	44859-44863	Mean	_	
210-153	44864-44869	White	_	
210-154	44870-44871	(	_	
210-155	44871-44875	blue	_	
210-156	44875-44876	)	_	
210-157	44876-44877	)	_	
210-158	44878-44881	and	_	
210-159	44882-44883	(	_	
210-160	44883-44884	b	_	
210-161	44884-44885	)	_	
210-162	44886-44892	linear	_	
210-163	44893-44897	risk	_	
210-164	44898-44906	contrast	_	
210-165	44907-44908	(	_	
210-166	44908-44914	Linear	_	
210-167	44915-44920	Color	_	
210-168	44921-44922	>	_	
210-169	44923-44929	Linear	_	
210-170	44930-44935	White	_	
210-171	44936-44937	(	_	
210-172	44937-44943	orange	_	
210-173	44943-44944	)	_	
210-174	44945-44948	and	_	
210-175	44949-44955	Linear	_	
210-176	44956-44961	Color	_	
210-177	44962-44963	<	_	
210-178	44964-44970	Linear	_	
210-179	44971-44976	White	_	
210-180	44977-44978	(	_	
210-181	44978-44982	blue	_	
210-182	44982-44983	)	_	
210-183	44983-44984	)	_	
210-184	44984-44985	.	_	

#Text=Images are cluster corrected using a voxel threshold of z > 3.72 and cluster p level of .05.
211-1	44986-44992	Images	_	
211-2	44993-44996	are	_	
211-3	44997-45004	cluster	_	
211-4	45005-45014	corrected	_	
211-5	45015-45020	using	_	
211-6	45021-45022	a	_	
211-7	45023-45028	voxel	_	
211-8	45029-45038	threshold	_	
211-9	45039-45041	of	_	
211-10	45042-45043	z	_	
211-11	45044-45045	>	_	
211-12	45046-45050	3.72	_	
211-13	45051-45054	and	_	
211-14	45055-45062	cluster	_	
211-15	45063-45064	p	_	
211-16	45065-45070	level	_	
211-17	45071-45073	of	_	
211-18	45074-45077	.05	_	
211-19	45077-45078	.	_	

#Text=Regions that showed differences in the omnibus test across group for the mean risk contrast (a) and the linear risk contrast (b).
212-1	45079-45086	Regions	_	
212-2	45087-45091	that	_	
212-3	45092-45098	showed	_	
212-4	45099-45110	differences	_	
212-5	45111-45113	in	_	
212-6	45114-45117	the	_	
212-7	45118-45125	omnibus	_	
212-8	45126-45130	test	_	
212-9	45131-45137	across	_	
212-10	45138-45143	group	_	
212-11	45144-45147	for	_	
212-12	45148-45151	the	_	
212-13	45152-45156	mean	_	
212-14	45157-45161	risk	_	
212-15	45162-45170	contrast	_	
212-16	45171-45172	(	_	
212-17	45172-45173	a	_	
212-18	45173-45174	)	_	
212-19	45175-45178	and	_	
212-20	45179-45182	the	_	
212-21	45183-45189	linear	_	
212-22	45190-45194	risk	_	
212-23	45195-45203	contrast	_	
212-24	45204-45205	(	_	
212-25	45205-45206	b	_	
212-26	45206-45207	)	_	
212-27	45207-45208	.	_	

#Text=Panels i-v display the signal change values by group within the regions in panels (a) and (b) showing group differences (significant differences are denoted by * for each ROI).
213-1	45209-45215	Panels	_	
213-2	45216-45219	i-v	_	
213-3	45220-45227	display	_	
213-4	45228-45231	the	_	
213-5	45232-45238	signal	_	
213-6	45239-45245	change	_	
213-7	45246-45252	values	_	
213-8	45253-45255	by	_	
213-9	45256-45261	group	_	
213-10	45262-45268	within	_	
213-11	45269-45272	the	_	
213-12	45273-45280	regions	_	
213-13	45281-45283	in	_	
213-14	45284-45290	panels	_	
213-15	45291-45292	(	_	
213-16	45292-45293	a	_	
213-17	45293-45294	)	_	
213-18	45295-45298	and	_	
213-19	45299-45300	(	_	
213-20	45300-45301	b	_	
213-21	45301-45302	)	_	
213-22	45303-45310	showing	_	
213-23	45311-45316	group	_	
213-24	45317-45328	differences	_	
213-25	45329-45330	(	_	
213-26	45330-45341	significant	_	
213-27	45342-45353	differences	_	
213-28	45354-45357	are	_	
213-29	45358-45365	denoted	_	
213-30	45366-45368	by	_	
213-31	45369-45370	*	_	
213-32	45371-45374	for	_	
213-33	45375-45379	each	_	
213-34	45380-45383	ROI	_	
213-35	45383-45384	)	_	
213-36	45384-45385	.	_	

#Text=Demographics by group.
214-1	45386-45398	Demographics	_	
214-2	45399-45401	by	_	
214-3	45402-45407	group	_	
214-4	45407-45408	.	_	

#Text=Controls reported infrequent/no use of marijuana and alcohol.
215-1	45409-45417	Controls	_	
215-2	45418-45426	reported	_	
215-3	45427-45437	infrequent	_	
215-4	45437-45438	/	_	
215-5	45438-45440	no	_	
215-6	45441-45444	use	_	
215-7	45445-45447	of	_	
215-8	45448-45457	marijuana	_	
215-9	45458-45461	and	_	
215-10	45462-45469	alcohol	_	
215-11	45469-45470	.	_	

#Text=MJ only reported frequent marijuana use, but infrequent/no alcohol use.
216-1	45471-45473	MJ	_	
216-2	45474-45478	only	_	
216-3	45479-45487	reported	_	
216-4	45488-45496	frequent	_	
216-5	45497-45506	marijuana	_	
216-6	45507-45510	use	_	
216-7	45510-45511	,	_	
216-8	45512-45515	but	_	
216-9	45516-45526	infrequent	_	
216-10	45526-45527	/	_	
216-11	45527-45529	no	_	
216-12	45530-45537	alcohol	_	
216-13	45538-45541	use	_	
216-14	45541-45542	.	_	

#Text=Alc only reported frequent alcohol use, but infrequent/no use of marijuana.
217-1	45543-45546	Alc	_	
217-2	45547-45551	only	_	
217-3	45552-45560	reported	_	
217-4	45561-45569	frequent	_	
217-5	45570-45577	alcohol	_	
217-6	45578-45581	use	_	
217-7	45581-45582	,	_	
217-8	45583-45586	but	_	
217-9	45587-45597	infrequent	_	
217-10	45597-45598	/	_	
217-11	45598-45600	no	_	
217-12	45601-45604	use	_	
217-13	45605-45607	of	_	
217-14	45608-45617	marijuana	_	
217-15	45617-45618	.	_	

#Text=Finally, the MJ + Alc group reported frequent use of both alcohol+marijuana.
218-1	45619-45626	Finally	_	
218-2	45626-45627	,	_	
218-3	45628-45631	the	_	
218-4	45632-45634	MJ	_	
218-5	45635-45636	+	_	
218-6	45637-45640	Alc	_	
218-7	45641-45646	group	_	
218-8	45647-45655	reported	_	
218-9	45656-45664	frequent	_	
218-10	45665-45668	use	_	
218-11	45669-45671	of	_	
218-12	45672-45676	both	_	
218-13	45677-45684	alcohol	_	
218-14	45684-45685	+	_	
218-15	45685-45694	marijuana	_	
218-16	45694-45695	.	_	

#Text=Control\tMJ only\tAlc only\tMJ + Alc\t \tN\t37\t39\t23\t90\t \tProportion male\t.54d\t.72d\t.61d\t.88a,b,c\t \tAge\t16.05 (1.18)\t15.97 (1.06)\t16.35 (1.11)\t16.31 (1.09)\t \tAdjusted Pumps\t5.56 (.60)\t5.49 (.60)\t5.39 (.53)\t5.68 (.60)\t \tProportion Explosions\t.20 (.10)\t.18 (.11)\t.18 (.08)\t.20 (.10)\t \tTotal drinking days (out of 30; from TLFB)\t.11 (.31)c,d\t.23 (.43)c,d\t3.22 (3.63)a,b\t4.98 (5.17)a,b\t \tAverage drinks per drinking day (TLFB)\t0.62 (2.85)c,d\t1.08 (2.39)c,d\t4.66 (4.03)a,b\t6.99 (5.06)a,b\t \tTotal MJ days (out of 30; from TLFB)\t0.05 (.23)b,d\t14.64 (12.49)a,c\t.09 (.29)b,d\t16.74 (11.95)a,c\t \tAlcohol use frequency (Never=0 to Every day=8)\t.32 (.48) c,d\t.49 (.51) c,d\t3.39 (1.85) a,b\t3.92 (2.35) a,b\t \tMJ use frequency (Never=0 to Every day=8)\t.21 (.42)b,d\t4.69 (3.46)a,c\t.13 (.34)b,d\t5.76 (3.00)a,c\t \tHard drug use (last 3 months); possible range 0 to 8\t.24 (.76)d\t.56 (.99)d\t.52 (.95)d\t1.27 (1.47)a,b,c\t \tHard drug use (ever); possible range 0 to 9\t1.16 (1.85)d\t1.74 (1.71)d\t2.22 (2.11)\t2.83 (2.02)a,b\t \tProportion smoked cigarette in last month\t.41d\t.62\t.57\t.69a\t \tIMPSS\t9.46 (3.53)d\t9.92 (4.30)d\t11.09 (4.21)\t11.87 (3.47)a,b\t \tCASS-S\t22.59 (12.04)d\t26.18 (16.03)d\t27.91 (9.56)\t32.66 (14.97)a,b\t \tCBCL\t15.00 (9.79)b,d\t23.46 (16.35)a\t19.70 (12.04)\t24.54 (11.99)a\t \tCDI\t2.59 (3.29)\t3.59 (3.75)\t3.17 (3.41)\t2.83 (2.76)\t \tRCMAS\t48.38 (12.95)\t49.26 (13.23)\t49.04 (10.50)\t49.26 (12.18)\t \t
#Text=Superscripts show significant group differences of the respective cell and other groups that differ (where a = Control; b = MJ only; c = Alc only; d = MJ + Alc).
219-1	45697-45704	Control	_	
219-2	45705-45707	MJ	_	
219-3	45708-45712	only	_	
219-4	45713-45716	Alc	_	
219-5	45717-45721	only	_	
219-6	45722-45724	MJ	_	
219-7	45725-45726	+	_	
219-8	45727-45730	Alc	_	
219-9	45733-45734	N	_	
219-10	45735-45737	37	_	
219-11	45738-45740	39	_	
219-12	45741-45743	23	_	
219-13	45744-45746	90	_	
219-14	45749-45759	Proportion	_	
219-15	45760-45764	male	_	
219-16	45765-45769	.54d	_	
219-17	45770-45774	.72d	_	
219-18	45775-45779	.61d	_	
219-19	45780-45784	.88a	_	
219-20	45784-45785	,	_	
219-21	45785-45786	b	_	
219-22	45786-45787	,	_	
219-23	45787-45788	c	_	
219-24	45791-45794	Age	_	
219-25	45795-45800	16.05	_	
219-26	45801-45802	(	_	
219-27	45802-45806	1.18	_	
219-28	45806-45807	)	_	
219-29	45808-45813	15.97	_	
219-30	45814-45815	(	_	
219-31	45815-45819	1.06	_	
219-32	45819-45820	)	_	
219-33	45821-45826	16.35	_	
219-34	45827-45828	(	_	
219-35	45828-45832	1.11	_	
219-36	45832-45833	)	_	
219-37	45834-45839	16.31	_	
219-38	45840-45841	(	_	
219-39	45841-45845	1.09	_	
219-40	45845-45846	)	_	
219-41	45849-45857	Adjusted	_	
219-42	45858-45863	Pumps	_	
219-43	45864-45868	5.56	_	
219-44	45869-45870	(	_	
219-45	45870-45873	.60	_	
219-46	45873-45874	)	_	
219-47	45875-45879	5.49	_	
219-48	45880-45881	(	_	
219-49	45881-45884	.60	_	
219-50	45884-45885	)	_	
219-51	45886-45890	5.39	_	
219-52	45891-45892	(	_	
219-53	45892-45895	.53	_	
219-54	45895-45896	)	_	
219-55	45897-45901	5.68	_	
219-56	45902-45903	(	_	
219-57	45903-45906	.60	_	
219-58	45906-45907	)	_	
219-59	45910-45920	Proportion	_	
219-60	45921-45931	Explosions	_	
219-61	45932-45935	.20	_	
219-62	45936-45937	(	_	
219-63	45937-45940	.10	_	
219-64	45940-45941	)	_	
219-65	45942-45945	.18	_	
219-66	45946-45947	(	_	
219-67	45947-45950	.11	_	
219-68	45950-45951	)	_	
219-69	45952-45955	.18	_	
219-70	45956-45957	(	_	
219-71	45957-45960	.08	_	
219-72	45960-45961	)	_	
219-73	45962-45965	.20	_	
219-74	45966-45967	(	_	
219-75	45967-45970	.10	_	
219-76	45970-45971	)	_	
219-77	45974-45979	Total	_	
219-78	45980-45988	drinking	_	
219-79	45989-45993	days	_	
219-80	45994-45995	(	_	
219-81	45995-45998	out	_	
219-82	45999-46001	of	_	
219-83	46002-46004	30	_	
219-84	46004-46005	;	_	
219-85	46006-46010	from	_	
219-86	46011-46015	TLFB	_	
219-87	46015-46016	)	_	
219-88	46017-46020	.11	_	
219-89	46021-46022	(	_	
219-90	46022-46025	.31	_	
219-91	46025-46026	)	_	
219-92	46026-46027	c	_	
219-93	46027-46028	,	_	
219-94	46028-46029	d	_	
219-95	46030-46033	.23	_	
219-96	46034-46035	(	_	
219-97	46035-46038	.43	_	
219-98	46038-46039	)	_	
219-99	46039-46040	c	_	
219-100	46040-46041	,	_	
219-101	46041-46042	d	_	
219-102	46043-46047	3.22	_	
219-103	46048-46049	(	_	
219-104	46049-46053	3.63	_	
219-105	46053-46054	)	_	
219-106	46054-46055	a	_	
219-107	46055-46056	,	_	
219-108	46056-46057	b	_	
219-109	46058-46062	4.98	_	
219-110	46063-46064	(	_	
219-111	46064-46068	5.17	_	
219-112	46068-46069	)	_	
219-113	46069-46070	a	_	
219-114	46070-46071	,	_	
219-115	46071-46072	b	_	
219-116	46075-46082	Average	_	
219-117	46083-46089	drinks	_	
219-118	46090-46093	per	_	
219-119	46094-46102	drinking	_	
219-120	46103-46106	day	_	
219-121	46107-46108	(	_	
219-122	46108-46112	TLFB	_	
219-123	46112-46113	)	_	
219-124	46114-46118	0.62	_	
219-125	46119-46120	(	_	
219-126	46120-46124	2.85	_	
219-127	46124-46125	)	_	
219-128	46125-46126	c	_	
219-129	46126-46127	,	_	
219-130	46127-46128	d	_	
219-131	46129-46133	1.08	_	
219-132	46134-46135	(	_	
219-133	46135-46139	2.39	_	
219-134	46139-46140	)	_	
219-135	46140-46141	c	_	
219-136	46141-46142	,	_	
219-137	46142-46143	d	_	
219-138	46144-46148	4.66	_	
219-139	46149-46150	(	_	
219-140	46150-46154	4.03	_	
219-141	46154-46155	)	_	
219-142	46155-46156	a	_	
219-143	46156-46157	,	_	
219-144	46157-46158	b	_	
219-145	46159-46163	6.99	_	
219-146	46164-46165	(	_	
219-147	46165-46169	5.06	_	
219-148	46169-46170	)	_	
219-149	46170-46171	a	_	
219-150	46171-46172	,	_	
219-151	46172-46173	b	_	
219-152	46176-46181	Total	_	
219-153	46182-46184	MJ	_	
219-154	46185-46189	days	_	
219-155	46190-46191	(	_	
219-156	46191-46194	out	_	
219-157	46195-46197	of	_	
219-158	46198-46200	30	_	
219-159	46200-46201	;	_	
219-160	46202-46206	from	_	
219-161	46207-46211	TLFB	_	
219-162	46211-46212	)	_	
219-163	46213-46217	0.05	_	
219-164	46218-46219	(	_	
219-165	46219-46222	.23	_	
219-166	46222-46223	)	_	
219-167	46223-46224	b	_	
219-168	46224-46225	,	_	
219-169	46225-46226	d	_	
219-170	46227-46232	14.64	_	
219-171	46233-46234	(	_	
219-172	46234-46239	12.49	_	
219-173	46239-46240	)	_	
219-174	46240-46241	a	_	
219-175	46241-46242	,	_	
219-176	46242-46243	c	_	
219-177	46244-46247	.09	_	
219-178	46248-46249	(	_	
219-179	46249-46252	.29	_	
219-180	46252-46253	)	_	
219-181	46253-46254	b	_	
219-182	46254-46255	,	_	
219-183	46255-46256	d	_	
219-184	46257-46262	16.74	_	
219-185	46263-46264	(	_	
219-186	46264-46269	11.95	_	
219-187	46269-46270	)	_	
219-188	46270-46271	a	_	
219-189	46271-46272	,	_	
219-190	46272-46273	c	_	
219-191	46276-46283	Alcohol	_	
219-192	46284-46287	use	_	
219-193	46288-46297	frequency	_	
219-194	46298-46299	(	_	
219-195	46299-46304	Never	_	
219-196	46304-46305	=	_	
219-197	46305-46306	0	_	
219-198	46307-46309	to	_	
219-199	46310-46315	Every	_	
219-200	46316-46319	day	_	
219-201	46319-46320	=	_	
219-202	46320-46321	8	_	
219-203	46321-46322	)	_	
219-204	46323-46326	.32	_	
219-205	46327-46328	(	_	
219-206	46328-46331	.48	_	
219-207	46331-46332	)	_	
219-208	46333-46334	c	_	
219-209	46334-46335	,	_	
219-210	46335-46336	d	_	
219-211	46337-46340	.49	_	
219-212	46341-46342	(	_	
219-213	46342-46345	.51	_	
219-214	46345-46346	)	_	
219-215	46347-46348	c	_	
219-216	46348-46349	,	_	
219-217	46349-46350	d	_	
219-218	46351-46355	3.39	_	
219-219	46356-46357	(	_	
219-220	46357-46361	1.85	_	
219-221	46361-46362	)	_	
219-222	46363-46364	a	_	
219-223	46364-46365	,	_	
219-224	46365-46366	b	_	
219-225	46367-46371	3.92	_	
219-226	46372-46373	(	_	
219-227	46373-46377	2.35	_	
219-228	46377-46378	)	_	
219-229	46379-46380	a	_	
219-230	46380-46381	,	_	
219-231	46381-46382	b	_	
219-232	46385-46387	MJ	_	
219-233	46388-46391	use	_	
219-234	46392-46401	frequency	_	
219-235	46402-46403	(	_	
219-236	46403-46408	Never	_	
219-237	46408-46409	=	_	
219-238	46409-46410	0	_	
219-239	46411-46413	to	_	
219-240	46414-46419	Every	_	
219-241	46420-46423	day	_	
219-242	46423-46424	=	_	
219-243	46424-46425	8	_	
219-244	46425-46426	)	_	
219-245	46427-46430	.21	_	
219-246	46431-46432	(	_	
219-247	46432-46435	.42	_	
219-248	46435-46436	)	_	
219-249	46436-46437	b	_	
219-250	46437-46438	,	_	
219-251	46438-46439	d	_	
219-252	46440-46444	4.69	_	
219-253	46445-46446	(	_	
219-254	46446-46450	3.46	_	
219-255	46450-46451	)	_	
219-256	46451-46452	a	_	
219-257	46452-46453	,	_	
219-258	46453-46454	c	_	
219-259	46455-46458	.13	_	
219-260	46459-46460	(	_	
219-261	46460-46463	.34	_	
219-262	46463-46464	)	_	
219-263	46464-46465	b	_	
219-264	46465-46466	,	_	
219-265	46466-46467	d	_	
219-266	46468-46472	5.76	_	
219-267	46473-46474	(	_	
219-268	46474-46478	3.00	_	
219-269	46478-46479	)	_	
219-270	46479-46480	a	_	
219-271	46480-46481	,	_	
219-272	46481-46482	c	_	
219-273	46485-46489	Hard	_	
219-274	46490-46494	drug	_	
219-275	46495-46498	use	_	
219-276	46499-46500	(	_	
219-277	46500-46504	last	_	
219-278	46505-46506	3	_	
219-279	46507-46513	months	_	
219-280	46513-46514	)	_	
219-281	46514-46515	;	_	
219-282	46516-46524	possible	_	
219-283	46525-46530	range	_	
219-284	46531-46532	0	_	
219-285	46533-46535	to	_	
219-286	46536-46537	8	_	
219-287	46538-46541	.24	_	
219-288	46542-46543	(	_	
219-289	46543-46546	.76	_	
219-290	46546-46547	)	_	
219-291	46547-46548	d	_	
219-292	46549-46552	.56	_	
219-293	46553-46554	(	_	
219-294	46554-46557	.99	_	
219-295	46557-46558	)	_	
219-296	46558-46559	d	_	
219-297	46560-46563	.52	_	
219-298	46564-46565	(	_	
219-299	46565-46568	.95	_	
219-300	46568-46569	)	_	
219-301	46569-46570	d	_	
219-302	46571-46575	1.27	_	
219-303	46576-46577	(	_	
219-304	46577-46581	1.47	_	
219-305	46581-46582	)	_	
219-306	46582-46583	a	_	
219-307	46583-46584	,	_	
219-308	46584-46585	b	_	
219-309	46585-46586	,	_	
219-310	46586-46587	c	_	
219-311	46590-46594	Hard	_	
219-312	46595-46599	drug	_	
219-313	46600-46603	use	_	
219-314	46604-46605	(	_	
219-315	46605-46609	ever	_	
219-316	46609-46610	)	_	
219-317	46610-46611	;	_	
219-318	46612-46620	possible	_	
219-319	46621-46626	range	_	
219-320	46627-46628	0	_	
219-321	46629-46631	to	_	
219-322	46632-46633	9	_	
219-323	46634-46638	1.16	_	
219-324	46639-46640	(	_	
219-325	46640-46644	1.85	_	
219-326	46644-46645	)	_	
219-327	46645-46646	d	_	
219-328	46647-46651	1.74	_	
219-329	46652-46653	(	_	
219-330	46653-46657	1.71	_	
219-331	46657-46658	)	_	
219-332	46658-46659	d	_	
219-333	46660-46664	2.22	_	
219-334	46665-46666	(	_	
219-335	46666-46670	2.11	_	
219-336	46670-46671	)	_	
219-337	46672-46676	2.83	_	
219-338	46677-46678	(	_	
219-339	46678-46682	2.02	_	
219-340	46682-46683	)	_	
219-341	46683-46684	a	_	
219-342	46684-46685	,	_	
219-343	46685-46686	b	_	
219-344	46689-46699	Proportion	_	
219-345	46700-46706	smoked	_	
219-346	46707-46716	cigarette	_	
219-347	46717-46719	in	_	
219-348	46720-46724	last	_	
219-349	46725-46730	month	_	
219-350	46731-46735	.41d	_	
219-351	46736-46739	.62	_	
219-352	46740-46743	.57	_	
219-353	46744-46748	.69a	_	
219-354	46751-46756	IMPSS	_	
219-355	46757-46761	9.46	_	
219-356	46762-46763	(	_	
219-357	46763-46767	3.53	_	
219-358	46767-46768	)	_	
219-359	46768-46769	d	_	
219-360	46770-46774	9.92	_	
219-361	46775-46776	(	_	
219-362	46776-46780	4.30	_	
219-363	46780-46781	)	_	
219-364	46781-46782	d	_	
219-365	46783-46788	11.09	_	
219-366	46789-46790	(	_	
219-367	46790-46794	4.21	_	
219-368	46794-46795	)	_	
219-369	46796-46801	11.87	_	
219-370	46802-46803	(	_	
219-371	46803-46807	3.47	_	
219-372	46807-46808	)	_	
219-373	46808-46809	a	_	
219-374	46809-46810	,	_	
219-375	46810-46811	b	_	
219-376	46814-46820	CASS-S	_	
219-377	46821-46826	22.59	_	
219-378	46827-46828	(	_	
219-379	46828-46833	12.04	_	
219-380	46833-46834	)	_	
219-381	46834-46835	d	_	
219-382	46836-46841	26.18	_	
219-383	46842-46843	(	_	
219-384	46843-46848	16.03	_	
219-385	46848-46849	)	_	
219-386	46849-46850	d	_	
219-387	46851-46856	27.91	_	
219-388	46857-46858	(	_	
219-389	46858-46862	9.56	_	
219-390	46862-46863	)	_	
219-391	46864-46869	32.66	_	
219-392	46870-46871	(	_	
219-393	46871-46876	14.97	_	
219-394	46876-46877	)	_	
219-395	46877-46878	a	_	
219-396	46878-46879	,	_	
219-397	46879-46880	b	_	
219-398	46883-46887	CBCL	_	
219-399	46888-46893	15.00	_	
219-400	46894-46895	(	_	
219-401	46895-46899	9.79	_	
219-402	46899-46900	)	_	
219-403	46900-46901	b	_	
219-404	46901-46902	,	_	
219-405	46902-46903	d	_	
219-406	46904-46909	23.46	_	
219-407	46910-46911	(	_	
219-408	46911-46916	16.35	_	
219-409	46916-46917	)	_	
219-410	46917-46918	a	_	
219-411	46919-46924	19.70	_	
219-412	46925-46926	(	_	
219-413	46926-46931	12.04	_	
219-414	46931-46932	)	_	
219-415	46933-46938	24.54	_	
219-416	46939-46940	(	_	
219-417	46940-46945	11.99	_	
219-418	46945-46946	)	_	
219-419	46946-46947	a	_	
219-420	46950-46953	CDI	_	
219-421	46954-46958	2.59	_	
219-422	46959-46960	(	_	
219-423	46960-46964	3.29	_	
219-424	46964-46965	)	_	
219-425	46966-46970	3.59	_	
219-426	46971-46972	(	_	
219-427	46972-46976	3.75	_	
219-428	46976-46977	)	_	
219-429	46978-46982	3.17	_	
219-430	46983-46984	(	_	
219-431	46984-46988	3.41	_	
219-432	46988-46989	)	_	
219-433	46990-46994	2.83	_	
219-434	46995-46996	(	_	
219-435	46996-47000	2.76	_	
219-436	47000-47001	)	_	
219-437	47004-47009	RCMAS	_	
219-438	47010-47015	48.38	_	
219-439	47016-47017	(	_	
219-440	47017-47022	12.95	_	
219-441	47022-47023	)	_	
219-442	47024-47029	49.26	_	
219-443	47030-47031	(	_	
219-444	47031-47036	13.23	_	
219-445	47036-47037	)	_	
219-446	47038-47043	49.04	_	
219-447	47044-47045	(	_	
219-448	47045-47050	10.50	_	
219-449	47050-47051	)	_	
219-450	47052-47057	49.26	_	
219-451	47058-47059	(	_	
219-452	47059-47064	12.18	_	
219-453	47064-47065	)	_	
219-454	47069-47081	Superscripts	_	
219-455	47082-47086	show	_	
219-456	47087-47098	significant	_	
219-457	47099-47104	group	_	
219-458	47105-47116	differences	_	
219-459	47117-47119	of	_	
219-460	47120-47123	the	_	
219-461	47124-47134	respective	_	
219-462	47135-47139	cell	_	
219-463	47140-47143	and	_	
219-464	47144-47149	other	_	
219-465	47150-47156	groups	_	
219-466	47157-47161	that	_	
219-467	47162-47168	differ	_	
219-468	47169-47170	(	_	
219-469	47170-47175	where	_	
219-470	47176-47177	a	_	
219-471	47178-47179	=	_	
219-472	47180-47187	Control	_	
219-473	47187-47188	;	_	
219-474	47189-47190	b	_	
219-475	47191-47192	=	_	
219-476	47193-47195	MJ	_	
219-477	47196-47200	only	_	
219-478	47200-47201	;	_	
219-479	47202-47203	c	_	
219-480	47204-47205	=	_	
219-481	47206-47209	Alc	_	
219-482	47210-47214	only	_	
219-483	47214-47215	;	_	
219-484	47216-47217	d	_	
219-485	47218-47219	=	_	
219-486	47220-47222	MJ	_	
219-487	47223-47224	+	_	
219-488	47225-47228	Alc	_	
219-489	47228-47229	)	_	
219-490	47229-47230	.	_	

#Text=Main effects of risky decision making vs. non-risky decision making for mean pump actvity and linear pump activity.
220-1	47231-47235	Main	_	
220-2	47236-47243	effects	_	
220-3	47244-47246	of	_	
220-4	47247-47252	risky	_	
220-5	47253-47261	decision	_	
220-6	47262-47268	making	_	
220-7	47269-47271	vs	_	
220-8	47271-47272	.	_	
220-9	47273-47282	non-risky	_	
220-10	47283-47291	decision	_	
220-11	47292-47298	making	_	
220-12	47299-47302	for	_	
220-13	47303-47307	mean	_	
220-14	47308-47312	pump	_	
220-15	47313-47320	actvity	_	
220-16	47321-47324	and	_	
220-17	47325-47331	linear	_	
220-18	47332-47336	pump	_	
220-19	47337-47345	activity	_	
220-20	47345-47346	.	_	

#Text=Contrast\tRegion\tVoxels\tMax Z\tX\tY\tZ\t \tMean Risk > Mean Control\tDACC/RACC/DMPFC/Pre/Post-central gyrus\t9223\t12.3\t−6\t6\t50\t \t\tBrainstem/Thalamus/Striatum/R Insula\t3242\t11.5\t8\t−26\t−12\t \t\tL STG/ Posterior insula\t1246\t10.7\t−38\t−32\t12\t \t\tR STG/ Posterior insula\t865\t8.85\t44\t−22\t6\t \t\tR Occipital pole\t658\t6.07\t14\t−100\t6\t \t\tR anterior insula\t500\t9.37\t32\t22\t6\t \t\tL anterior insula\t471\t8.93\t−30\t24\t4\t \t\tL Occipital pole\t343\t5.67\t−12\t−102\t8\t \t\tL SPL\t175\t5.37\t−26\t−52\t50\t \t\tR SPL\t153\t5.26\t30\t−50\t50\t \tMean Control > Mean Risk\tLingual Gyrus / Intracalcerine Cortex / PCC\t7728\t13\t12\t−76\t−2\t \t\tL IPL/MTG\t4943\t14.4\t−48\t−64\t40\t \t\tR IPL/MTG\t4742\t15.2\t56\t−56\t24\t \t\tL MFG/SFG\t1921\t12.7\t−42\t14\t46\t \t\tL OFC/IFG\t1849\t12.8\t−48\t34\t−2\t \t\tR OFC/IFG\t1492\t12.5\t50\t38\t−8\t \t\tR MFG/SFG\t1089\t11.8\t14\t56\t30\t \t\tPCC\t867\t12.4\t6\t−46\t34\t \t\tCerebellum\t15\t9.98\t−6\t−54\t−46\t \t\tL ITG\t4\t9.22\t−52\t−8\t−32\t \t\tSFG\t1\t9.03\t4\t44\t50\t \t\tL MTG\t1\t9.02\t−64\t−14\t−22\t \tLinear Risk > Linear Control\tLingual Gyrus / Intracalcerine Cortex / Caudate / Thalamus\t16744\t9.34\t6\t−82\t20\t \t\tRMPFC/DMPFC\t2176\t5.49\t6\t44\t52\t \t\tR IPL\t1455\t6.57\t56\t−56\t26\t \t\tL IPL\t1040\t5.68\t−52\t−62\t32\t \t\tR OFC\t860\t5.53\t50\t36\t−12\t \t\tR MTG\t856\t6.72\t60\t−36\t−8\t \t\tL MTG\t279\t4.74\t−54\t−36\t−8\t \t\tCerebellum\t133\t4.68\t44\t−62\t−42\t \t\tL MFG\t117\t4.35\t−32\t20\t50\t \t\tL OFC\t114\t4.54\t−46\t32\t−8\t \tLinear Control > Linear Risk\tL Pre/Post Central\t1783\t7.49\t−40\t−26\t50\t \t\tDACC/SMA\t266\t4.93\t−4\t0\t54\t \t\tL Parietal Operculum\t191\t5.29\t−44\t−34\t16\t \t\tR Occipital Fusiform\t132\t4.59\t28\t−88\t−6\t \t\tR Post central gyrus\t77\t4.52\t58\t−20\t38\t \t
#Text=DACC = dorsal anterior cingulate cortex; RACC = rostral anterior cingulate cortex; DMPFC = dorsomedial prefrontal cortex; SPL = superior parietal lobe; STG = superior temporal gyrus; IPL = inferior parietal lobe; OFC = orbitofrontal cortex; MFG = middle frontal gyrus.
221-1	47347-47355	Contrast	_	
221-2	47356-47362	Region	_	
221-3	47363-47369	Voxels	_	
221-4	47370-47373	Max	_	
221-5	47374-47375	Z	_	
221-6	47376-47377	X	_	
221-7	47378-47379	Y	_	
221-8	47380-47381	Z	_	
221-9	47384-47388	Mean	_	
221-10	47389-47393	Risk	_	
221-11	47394-47395	>	_	
221-12	47396-47400	Mean	_	
221-13	47401-47408	Control	_	
221-14	47409-47413	DACC	_	
221-15	47413-47414	/	_	
221-16	47414-47418	RACC	_	
221-17	47418-47419	/	_	
221-18	47419-47424	DMPFC	_	
221-19	47424-47425	/	_	
221-20	47425-47428	Pre	_	
221-21	47428-47429	/	_	
221-22	47429-47441	Post-central	_	
221-23	47442-47447	gyrus	_	
221-24	47448-47452	9223	_	
221-25	47453-47457	12.3	_	
221-26	47458-47459	−	_	
221-27	47459-47460	6	_	
221-28	47461-47462	6	_	
221-29	47463-47465	50	_	
221-30	47469-47478	Brainstem	_	
221-31	47478-47479	/	_	
221-32	47479-47487	Thalamus	_	
221-33	47487-47488	/	_	
221-34	47488-47496	Striatum	_	
221-35	47496-47497	/	_	
221-36	47497-47498	R	_	
221-37	47499-47505	Insula	_	
221-38	47506-47510	3242	_	
221-39	47511-47515	11.5	_	
221-40	47516-47517	8	_	
221-41	47518-47519	−	_	
221-42	47519-47521	26	_	
221-43	47522-47523	−	_	
221-44	47523-47525	12	_	
221-45	47529-47530	L	_	
221-46	47531-47534	STG	_	
221-47	47534-47535	/	_	
221-48	47536-47545	Posterior	_	
221-49	47546-47552	insula	_	
221-50	47553-47557	1246	_	
221-51	47558-47562	10.7	_	
221-52	47563-47564	−	_	
221-53	47564-47566	38	_	
221-54	47567-47568	−	_	
221-55	47568-47570	32	_	
221-56	47571-47573	12	_	
221-57	47577-47578	R	_	
221-58	47579-47582	STG	_	
221-59	47582-47583	/	_	
221-60	47584-47593	Posterior	_	
221-61	47594-47600	insula	_	
221-62	47601-47604	865	_	
221-63	47605-47609	8.85	_	
221-64	47610-47612	44	_	
221-65	47613-47614	−	_	
221-66	47614-47616	22	_	
221-67	47617-47618	6	_	
221-68	47622-47623	R	_	
221-69	47624-47633	Occipital	_	
221-70	47634-47638	pole	_	
221-71	47639-47642	658	_	
221-72	47643-47647	6.07	_	
221-73	47648-47650	14	_	
221-74	47651-47652	−	_	
221-75	47652-47655	100	_	
221-76	47656-47657	6	_	
221-77	47661-47662	R	_	
221-78	47663-47671	anterior	_	
221-79	47672-47678	insula	_	
221-80	47679-47682	500	_	
221-81	47683-47687	9.37	_	
221-82	47688-47690	32	_	
221-83	47691-47693	22	_	
221-84	47694-47695	6	_	
221-85	47699-47700	L	_	
221-86	47701-47709	anterior	_	
221-87	47710-47716	insula	_	
221-88	47717-47720	471	_	
221-89	47721-47725	8.93	_	
221-90	47726-47727	−	_	
221-91	47727-47729	30	_	
221-92	47730-47732	24	_	
221-93	47733-47734	4	_	
221-94	47738-47739	L	_	
221-95	47740-47749	Occipital	_	
221-96	47750-47754	pole	_	
221-97	47755-47758	343	_	
221-98	47759-47763	5.67	_	
221-99	47764-47765	−	_	
221-100	47765-47767	12	_	
221-101	47768-47769	−	_	
221-102	47769-47772	102	_	
221-103	47773-47774	8	_	
221-104	47778-47779	L	_	
221-105	47780-47783	SPL	_	
221-106	47784-47787	175	_	
221-107	47788-47792	5.37	_	
221-108	47793-47794	−	_	
221-109	47794-47796	26	_	
221-110	47797-47798	−	_	
221-111	47798-47800	52	_	
221-112	47801-47803	50	_	
221-113	47807-47808	R	_	
221-114	47809-47812	SPL	_	
221-115	47813-47816	153	_	
221-116	47817-47821	5.26	_	
221-117	47822-47824	30	_	
221-118	47825-47826	−	_	
221-119	47826-47828	50	_	
221-120	47829-47831	50	_	
221-121	47834-47838	Mean	_	
221-122	47839-47846	Control	_	
221-123	47847-47848	>	_	
221-124	47849-47853	Mean	_	
221-125	47854-47858	Risk	_	
221-126	47859-47866	Lingual	_	
221-127	47867-47872	Gyrus	_	
221-128	47873-47874	/	_	
221-129	47875-47889	Intracalcerine	_	
221-130	47890-47896	Cortex	_	
221-131	47897-47898	/	_	
221-132	47899-47902	PCC	_	
221-133	47903-47907	7728	_	
221-134	47908-47910	13	_	
221-135	47911-47913	12	_	
221-136	47914-47915	−	_	
221-137	47915-47917	76	_	
221-138	47918-47919	−	_	
221-139	47919-47920	2	_	
221-140	47924-47925	L	_	
221-141	47926-47929	IPL	_	
221-142	47929-47930	/	_	
221-143	47930-47933	MTG	_	
221-144	47934-47938	4943	_	
221-145	47939-47943	14.4	_	
221-146	47944-47945	−	_	
221-147	47945-47947	48	_	
221-148	47948-47949	−	_	
221-149	47949-47951	64	_	
221-150	47952-47954	40	_	
221-151	47958-47959	R	_	
221-152	47960-47963	IPL	_	
221-153	47963-47964	/	_	
221-154	47964-47967	MTG	_	
221-155	47968-47972	4742	_	
221-156	47973-47977	15.2	_	
221-157	47978-47980	56	_	
221-158	47981-47982	−	_	
221-159	47982-47984	56	_	
221-160	47985-47987	24	_	
221-161	47991-47992	L	_	
221-162	47993-47996	MFG	_	
221-163	47996-47997	/	_	
221-164	47997-48000	SFG	_	
221-165	48001-48005	1921	_	
221-166	48006-48010	12.7	_	
221-167	48011-48012	−	_	
221-168	48012-48014	42	_	
221-169	48015-48017	14	_	
221-170	48018-48020	46	_	
221-171	48024-48025	L	_	
221-172	48026-48029	OFC	_	
221-173	48029-48030	/	_	
221-174	48030-48033	IFG	_	
221-175	48034-48038	1849	_	
221-176	48039-48043	12.8	_	
221-177	48044-48045	−	_	
221-178	48045-48047	48	_	
221-179	48048-48050	34	_	
221-180	48051-48052	−	_	
221-181	48052-48053	2	_	
221-182	48057-48058	R	_	
221-183	48059-48062	OFC	_	
221-184	48062-48063	/	_	
221-185	48063-48066	IFG	_	
221-186	48067-48071	1492	_	
221-187	48072-48076	12.5	_	
221-188	48077-48079	50	_	
221-189	48080-48082	38	_	
221-190	48083-48084	−	_	
221-191	48084-48085	8	_	
221-192	48089-48090	R	_	
221-193	48091-48094	MFG	_	
221-194	48094-48095	/	_	
221-195	48095-48098	SFG	_	
221-196	48099-48103	1089	_	
221-197	48104-48108	11.8	_	
221-198	48109-48111	14	_	
221-199	48112-48114	56	_	
221-200	48115-48117	30	_	
221-201	48121-48124	PCC	_	
221-202	48125-48128	867	_	
221-203	48129-48133	12.4	_	
221-204	48134-48135	6	_	
221-205	48136-48137	−	_	
221-206	48137-48139	46	_	
221-207	48140-48142	34	_	
221-208	48146-48156	Cerebellum	_	
221-209	48157-48159	15	_	
221-210	48160-48164	9.98	_	
221-211	48165-48166	−	_	
221-212	48166-48167	6	_	
221-213	48168-48169	−	_	
221-214	48169-48171	54	_	
221-215	48172-48173	−	_	
221-216	48173-48175	46	_	
221-217	48179-48180	L	_	
221-218	48181-48184	ITG	_	
221-219	48185-48186	4	_	
221-220	48187-48191	9.22	_	
221-221	48192-48193	−	_	
221-222	48193-48195	52	_	
221-223	48196-48197	−	_	
221-224	48197-48198	8	_	
221-225	48199-48200	−	_	
221-226	48200-48202	32	_	
221-227	48206-48209	SFG	_	
221-228	48210-48211	1	_	
221-229	48212-48216	9.03	_	
221-230	48217-48218	4	_	
221-231	48219-48221	44	_	
221-232	48222-48224	50	_	
221-233	48228-48229	L	_	
221-234	48230-48233	MTG	_	
221-235	48234-48235	1	_	
221-236	48236-48240	9.02	_	
221-237	48241-48242	−	_	
221-238	48242-48244	64	_	
221-239	48245-48246	−	_	
221-240	48246-48248	14	_	
221-241	48249-48250	−	_	
221-242	48250-48252	22	_	
221-243	48255-48261	Linear	_	
221-244	48262-48266	Risk	_	
221-245	48267-48268	>	_	
221-246	48269-48275	Linear	_	
221-247	48276-48283	Control	_	
221-248	48284-48291	Lingual	_	
221-249	48292-48297	Gyrus	_	
221-250	48298-48299	/	_	
221-251	48300-48314	Intracalcerine	_	
221-252	48315-48321	Cortex	_	
221-253	48322-48323	/	_	
221-254	48324-48331	Caudate	_	
221-255	48332-48333	/	_	
221-256	48334-48342	Thalamus	_	
221-257	48343-48348	16744	_	
221-258	48349-48353	9.34	_	
221-259	48354-48355	6	_	
221-260	48356-48357	−	_	
221-261	48357-48359	82	_	
221-262	48360-48362	20	_	
221-263	48366-48371	RMPFC	_	
221-264	48371-48372	/	_	
221-265	48372-48377	DMPFC	_	
221-266	48378-48382	2176	_	
221-267	48383-48387	5.49	_	
221-268	48388-48389	6	_	
221-269	48390-48392	44	_	
221-270	48393-48395	52	_	
221-271	48399-48400	R	_	
221-272	48401-48404	IPL	_	
221-273	48405-48409	1455	_	
221-274	48410-48414	6.57	_	
221-275	48415-48417	56	_	
221-276	48418-48419	−	_	
221-277	48419-48421	56	_	
221-278	48422-48424	26	_	
221-279	48428-48429	L	_	
221-280	48430-48433	IPL	_	
221-281	48434-48438	1040	_	
221-282	48439-48443	5.68	_	
221-283	48444-48445	−	_	
221-284	48445-48447	52	_	
221-285	48448-48449	−	_	
221-286	48449-48451	62	_	
221-287	48452-48454	32	_	
221-288	48458-48459	R	_	
221-289	48460-48463	OFC	_	
221-290	48464-48467	860	_	
221-291	48468-48472	5.53	_	
221-292	48473-48475	50	_	
221-293	48476-48478	36	_	
221-294	48479-48480	−	_	
221-295	48480-48482	12	_	
221-296	48486-48487	R	_	
221-297	48488-48491	MTG	_	
221-298	48492-48495	856	_	
221-299	48496-48500	6.72	_	
221-300	48501-48503	60	_	
221-301	48504-48505	−	_	
221-302	48505-48507	36	_	
221-303	48508-48509	−	_	
221-304	48509-48510	8	_	
221-305	48514-48515	L	_	
221-306	48516-48519	MTG	_	
221-307	48520-48523	279	_	
221-308	48524-48528	4.74	_	
221-309	48529-48530	−	_	
221-310	48530-48532	54	_	
221-311	48533-48534	−	_	
221-312	48534-48536	36	_	
221-313	48537-48538	−	_	
221-314	48538-48539	8	_	
221-315	48543-48553	Cerebellum	_	
221-316	48554-48557	133	_	
221-317	48558-48562	4.68	_	
221-318	48563-48565	44	_	
221-319	48566-48567	−	_	
221-320	48567-48569	62	_	
221-321	48570-48571	−	_	
221-322	48571-48573	42	_	
221-323	48577-48578	L	_	
221-324	48579-48582	MFG	_	
221-325	48583-48586	117	_	
221-326	48587-48591	4.35	_	
221-327	48592-48593	−	_	
221-328	48593-48595	32	_	
221-329	48596-48598	20	_	
221-330	48599-48601	50	_	
221-331	48605-48606	L	_	
221-332	48607-48610	OFC	_	
221-333	48611-48614	114	_	
221-334	48615-48619	4.54	_	
221-335	48620-48621	−	_	
221-336	48621-48623	46	_	
221-337	48624-48626	32	_	
221-338	48627-48628	−	_	
221-339	48628-48629	8	_	
221-340	48632-48638	Linear	_	
221-341	48639-48646	Control	_	
221-342	48647-48648	>	_	
221-343	48649-48655	Linear	_	
221-344	48656-48660	Risk	_	
221-345	48661-48662	L	_	
221-346	48663-48666	Pre	_	
221-347	48666-48667	/	_	
221-348	48667-48671	Post	_	
221-349	48672-48679	Central	_	
221-350	48680-48684	1783	_	
221-351	48685-48689	7.49	_	
221-352	48690-48691	−	_	
221-353	48691-48693	40	_	
221-354	48694-48695	−	_	
221-355	48695-48697	26	_	
221-356	48698-48700	50	_	
221-357	48704-48708	DACC	_	
221-358	48708-48709	/	_	
221-359	48709-48712	SMA	_	
221-360	48713-48716	266	_	
221-361	48717-48721	4.93	_	
221-362	48722-48723	−	_	
221-363	48723-48724	4	_	
221-364	48725-48726	0	_	
221-365	48727-48729	54	_	
221-366	48733-48734	L	_	
221-367	48735-48743	Parietal	_	
221-368	48744-48753	Operculum	_	
221-369	48754-48757	191	_	
221-370	48758-48762	5.29	_	
221-371	48763-48764	−	_	
221-372	48764-48766	44	_	
221-373	48767-48768	−	_	
221-374	48768-48770	34	_	
221-375	48771-48773	16	_	
221-376	48777-48778	R	_	
221-377	48779-48788	Occipital	_	
221-378	48789-48797	Fusiform	_	
221-379	48798-48801	132	_	
221-380	48802-48806	4.59	_	
221-381	48807-48809	28	_	
221-382	48810-48811	−	_	
221-383	48811-48813	88	_	
221-384	48814-48815	−	_	
221-385	48815-48816	6	_	
221-386	48820-48821	R	_	
221-387	48822-48826	Post	_	
221-388	48827-48834	central	_	
221-389	48835-48840	gyrus	_	
221-390	48841-48843	77	_	
221-391	48844-48848	4.52	_	
221-392	48849-48851	58	_	
221-393	48852-48853	−	_	
221-394	48853-48855	20	_	
221-395	48856-48858	38	_	
221-396	48862-48866	DACC	_	
221-397	48867-48868	=	_	
221-398	48869-48875	dorsal	_	
221-399	48876-48884	anterior	_	
221-400	48885-48894	cingulate	_	
221-401	48895-48901	cortex	_	
221-402	48901-48902	;	_	
221-403	48903-48907	RACC	_	
221-404	48908-48909	=	_	
221-405	48910-48917	rostral	_	
221-406	48918-48926	anterior	_	
221-407	48927-48936	cingulate	_	
221-408	48937-48943	cortex	_	
221-409	48943-48944	;	_	
221-410	48945-48950	DMPFC	_	
221-411	48951-48952	=	_	
221-412	48953-48964	dorsomedial	_	
221-413	48965-48975	prefrontal	_	
221-414	48976-48982	cortex	_	
221-415	48982-48983	;	_	
221-416	48984-48987	SPL	_	
221-417	48988-48989	=	_	
221-418	48990-48998	superior	_	
221-419	48999-49007	parietal	_	
221-420	49008-49012	lobe	_	
221-421	49012-49013	;	_	
221-422	49014-49017	STG	_	
221-423	49018-49019	=	_	
221-424	49020-49028	superior	_	
221-425	49029-49037	temporal	_	
221-426	49038-49043	gyrus	_	
221-427	49043-49044	;	_	
221-428	49045-49048	IPL	_	
221-429	49049-49050	=	_	
221-430	49051-49059	inferior	_	
221-431	49060-49068	parietal	_	
221-432	49069-49073	lobe	_	
221-433	49073-49074	;	_	
221-434	49075-49078	OFC	_	
221-435	49079-49080	=	_	
221-436	49081-49094	orbitofrontal	_	
221-437	49095-49101	cortex	_	
221-438	49101-49102	;	_	
221-439	49103-49106	MFG	_	
221-440	49107-49108	=	_	
221-441	49109-49115	middle	_	
221-442	49116-49123	frontal	_	
221-443	49124-49129	gyrus	_	
221-444	49129-49130	.	_	

#Text=Group differences in the mean and linear risk contrasts.
222-1	49131-49136	Group	_	
222-2	49137-49148	differences	_	
222-3	49149-49151	in	_	
222-4	49152-49155	the	_	
222-5	49156-49160	mean	_	
222-6	49161-49164	and	_	
222-7	49165-49171	linear	_	
222-8	49172-49176	risk	_	
222-9	49177-49186	contrasts	_	
222-10	49186-49187	.	_	

#Text=An omnibus test was used to test for group differences across all four groups, which was followed by individual comparisons (see Figure 2).
223-1	49188-49190	An	_	
223-2	49191-49198	omnibus	_	
223-3	49199-49203	test	_	
223-4	49204-49207	was	_	
223-5	49208-49212	used	_	
223-6	49213-49215	to	_	
223-7	49216-49220	test	_	
223-8	49221-49224	for	_	
223-9	49225-49230	group	_	
223-10	49231-49242	differences	_	
223-11	49243-49249	across	_	
223-12	49250-49253	all	_	
223-13	49254-49258	four	_	
223-14	49259-49265	groups	_	
223-15	49265-49266	,	_	
223-16	49267-49272	which	_	
223-17	49273-49276	was	_	
223-18	49277-49285	followed	_	
223-19	49286-49288	by	_	
223-20	49289-49299	individual	_	
223-21	49300-49311	comparisons	_	
223-22	49312-49313	(	_	
223-23	49313-49316	see	_	
223-24	49317-49323	Figure	_	
223-25	49324-49325	2	_	
223-26	49325-49326	)	_	
223-27	49326-49327	.	_	

#Text=In addition cluster sizes are reported for analyses that controlled for hard drug use (last 3 month use and lifetime use) and gender.
224-1	49328-49330	In	_	
224-2	49331-49339	addition	_	
224-3	49340-49347	cluster	_	
224-4	49348-49353	sizes	_	
224-5	49354-49357	are	_	
224-6	49358-49366	reported	_	
224-7	49367-49370	for	_	
224-8	49371-49379	analyses	_	
224-9	49380-49384	that	_	
224-10	49385-49395	controlled	_	
224-11	49396-49399	for	_	
224-12	49400-49404	hard	_	
224-13	49405-49409	drug	_	
224-14	49410-49413	use	_	
224-15	49414-49415	(	_	
224-16	49415-49419	last	_	
224-17	49420-49421	3	_	
224-18	49422-49427	month	_	
224-19	49428-49431	use	_	
224-20	49432-49435	and	_	
224-21	49436-49444	lifetime	_	
224-22	49445-49448	use	_	
224-23	49448-49449	)	_	
224-24	49450-49453	and	_	
224-25	49454-49460	gender	_	
224-26	49460-49461	.	_	

#Text=Contrast\tRegion\tClustersize\tMax Z\tx\ty\tz\tAge\tCBCL\tCDI\tCASS-S\tGender\tIMPSS\tRCMAS\tHarddrugs(3 mo)\tHarddrugs(ever)\t \tLinear risk > Linear control\tL Pre/Post-central gyrus/SPL\t1495\t4.27\t−36\t−30\t50\t1463\t1107\t1457\t1073\t968\t4852\t1471\t1638\t1858\t \t\tR Putamen/Caudate/Insula\t1338\t3.43\t48\t12\t−4\t970\t507\t1282\t707\t1021\t3048\t1222\t1646\t1531\t \t\tDACC/SMA\t1234\t4.09\t10\t−8\t60\t1164\t580\t1229\t713\t816\t1982\t1222\t1401\t905\t \t\tL Putamen/Thalamus/Insula\t812\t3.53\t−46\t20\t−6\t37\t32\t826\t44\t77\t4852*\t641\t910\t699\t \tMean risk > Mean control\tBilateral VS/Thalamus/Brainstem L Putamen, Insula/IFG\t3355\t4.06\t−14\t12\t−12\t3221\t3588\t3301\t2455\t625\t7702*\t3319\t3799\t5094\t \t
#Text=SPL = superior parietal lobe; DACC = dorsal anterior cingulate cortex; VS = ventral striatum; IFG = inferior frontal gyrus.
225-1	49462-49470	Contrast	_	
225-2	49471-49477	Region	_	
225-3	49478-49489	Clustersize	_	
225-4	49490-49493	Max	_	
225-5	49494-49495	Z	_	
225-6	49496-49497	x	_	
225-7	49498-49499	y	_	
225-8	49500-49501	z	_	
225-9	49502-49505	Age	_	
225-10	49506-49510	CBCL	_	
225-11	49511-49514	CDI	_	
225-12	49515-49521	CASS-S	_	
225-13	49522-49528	Gender	_	
225-14	49529-49534	IMPSS	_	
225-15	49535-49540	RCMAS	_	
225-16	49541-49550	Harddrugs	_	
225-17	49550-49551	(	_	
225-18	49551-49552	3	_	
225-19	49553-49555	mo	_	
225-20	49555-49556	)	_	
225-21	49557-49566	Harddrugs	_	
225-22	49566-49567	(	_	
225-23	49567-49571	ever	_	
225-24	49571-49572	)	_	
225-25	49575-49581	Linear	_	
225-26	49582-49586	risk	_	
225-27	49587-49588	>	_	
225-28	49589-49595	Linear	_	
225-29	49596-49603	control	_	
225-30	49604-49605	L	_	
225-31	49606-49609	Pre	_	
225-32	49609-49610	/	_	
225-33	49610-49622	Post-central	_	
225-34	49623-49628	gyrus	_	
225-35	49628-49629	/	_	
225-36	49629-49632	SPL	_	
225-37	49633-49637	1495	_	
225-38	49638-49642	4.27	_	
225-39	49643-49644	−	_	
225-40	49644-49646	36	_	
225-41	49647-49648	−	_	
225-42	49648-49650	30	_	
225-43	49651-49653	50	_	
225-44	49654-49658	1463	_	
225-45	49659-49663	1107	_	
225-46	49664-49668	1457	_	
225-47	49669-49673	1073	_	
225-48	49674-49677	968	_	
225-49	49678-49682	4852	_	
225-50	49683-49687	1471	_	
225-51	49688-49692	1638	_	
225-52	49693-49697	1858	_	
225-53	49701-49702	R	_	
225-54	49703-49710	Putamen	_	
225-55	49710-49711	/	_	
225-56	49711-49718	Caudate	_	
225-57	49718-49719	/	_	
225-58	49719-49725	Insula	_	
225-59	49726-49730	1338	_	
225-60	49731-49735	3.43	_	
225-61	49736-49738	48	_	
225-62	49739-49741	12	_	
225-63	49742-49743	−	_	
225-64	49743-49744	4	_	
225-65	49745-49748	970	_	
225-66	49749-49752	507	_	
225-67	49753-49757	1282	_	
225-68	49758-49761	707	_	
225-69	49762-49766	1021	_	
225-70	49767-49771	3048	_	
225-71	49772-49776	1222	_	
225-72	49777-49781	1646	_	
225-73	49782-49786	1531	_	
225-74	49790-49794	DACC	_	
225-75	49794-49795	/	_	
225-76	49795-49798	SMA	_	
225-77	49799-49803	1234	_	
225-78	49804-49808	4.09	_	
225-79	49809-49811	10	_	
225-80	49812-49813	−	_	
225-81	49813-49814	8	_	
225-82	49815-49817	60	_	
225-83	49818-49822	1164	_	
225-84	49823-49826	580	_	
225-85	49827-49831	1229	_	
225-86	49832-49835	713	_	
225-87	49836-49839	816	_	
225-88	49840-49844	1982	_	
225-89	49845-49849	1222	_	
225-90	49850-49854	1401	_	
225-91	49855-49858	905	_	
225-92	49862-49863	L	_	
225-93	49864-49871	Putamen	_	
225-94	49871-49872	/	_	
225-95	49872-49880	Thalamus	_	
225-96	49880-49881	/	_	
225-97	49881-49887	Insula	_	
225-98	49888-49891	812	_	
225-99	49892-49896	3.53	_	
225-100	49897-49898	−	_	
225-101	49898-49900	46	_	
225-102	49901-49903	20	_	
225-103	49904-49905	−	_	
225-104	49905-49906	6	_	
225-105	49907-49909	37	_	
225-106	49910-49912	32	_	
225-107	49913-49916	826	_	
225-108	49917-49919	44	_	
225-109	49920-49922	77	_	
225-110	49923-49927	4852	_	
225-111	49927-49928	*	_	
225-112	49929-49932	641	_	
225-113	49933-49936	910	_	
225-114	49937-49940	699	_	
225-115	49943-49947	Mean	_	
225-116	49948-49952	risk	_	
225-117	49953-49954	>	_	
225-118	49955-49959	Mean	_	
225-119	49960-49967	control	_	
225-120	49968-49977	Bilateral	_	
225-121	49978-49980	VS	_	
225-122	49980-49981	/	_	
225-123	49981-49989	Thalamus	_	
225-124	49989-49990	/	_	
225-125	49990-49999	Brainstem	_	
225-126	50000-50001	L	_	
225-127	50002-50009	Putamen	_	
225-128	50009-50010	,	_	
225-129	50011-50017	Insula	_	
225-130	50017-50018	/	_	
225-131	50018-50021	IFG	_	
225-132	50022-50026	3355	_	
225-133	50027-50031	4.06	_	
225-134	50032-50033	−	_	
225-135	50033-50035	14	_	
225-136	50036-50038	12	_	
225-137	50039-50040	−	_	
225-138	50040-50042	12	_	
225-139	50043-50047	3221	_	
225-140	50048-50052	3588	_	
225-141	50053-50057	3301	_	
225-142	50058-50062	2455	_	
225-143	50063-50066	625	_	
225-144	50067-50071	7702	_	
225-145	50071-50072	*	_	
225-146	50073-50077	3319	_	
225-147	50078-50082	3799	_	
225-148	50083-50087	5094	_	
225-149	50091-50094	SPL	_	
225-150	50095-50096	=	_	
225-151	50097-50105	superior	_	
225-152	50106-50114	parietal	_	
225-153	50115-50119	lobe	_	
225-154	50119-50120	;	_	
225-155	50121-50125	DACC	_	
225-156	50126-50127	=	_	
225-157	50128-50134	dorsal	_	
225-158	50135-50143	anterior	_	
225-159	50144-50153	cingulate	_	
225-160	50154-50160	cortex	_	
225-161	50160-50161	;	_	
225-162	50162-50164	VS	_	
225-163	50165-50166	=	_	
225-164	50167-50174	ventral	_	
225-165	50175-50183	striatum	_	
225-166	50183-50184	;	_	
225-167	50185-50188	IFG	_	
225-168	50189-50190	=	_	
225-169	50191-50199	inferior	_	
225-170	50200-50207	frontal	_	
225-171	50208-50213	gyrus	_	
225-172	50213-50214	.	_	
